-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, Oz8O8Ld/PH59NJhp2j7zMTGhnFFFvE1XMB7PsC98i7zfVdpSQJ6rAmJEGXUXgz8b rCBd5wVI7pbuXscvKGhXUw== 0000910680-06-001138.txt : 20061130 0000910680-06-001138.hdr.sgml : 20061130 20061130161232 ACCESSION NUMBER: 0000910680-06-001138 CONFORMED SUBMISSION TYPE: S-8 POS PUBLIC DOCUMENT COUNT: 4 FILED AS OF DATE: 20061130 DATE AS OF CHANGE: 20061130 EFFECTIVENESS DATE: 20061130 FILER: COMPANY DATA: COMPANY CONFORMED NAME: OPHTHALMIC IMAGING SYSTEMS CENTRAL INDEX KEY: 0000885317 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 943035367 STATE OF INCORPORATION: CA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: S-8 POS SEC ACT: 1933 Act SEC FILE NUMBER: 333-134368 FILM NUMBER: 061248449 BUSINESS ADDRESS: STREET 1: 221 LATHROP WAY STREET 2: SUITE 1 CITY: SACRAMENTO STATE: CA ZIP: 95815 BUSINESS PHONE: 9166462020 MAIL ADDRESS: STREET 1: 221 LATHROP WAY STREET 2: SUITE 1 CITY: SACRAMENTO STATE: CA ZIP: 95815 FORMER COMPANY: FORMER CONFORMED NAME: OPHTHALMIC IMAGING SYSTEMS INC DATE OF NAME CHANGE: 19930328 S-8 POS 1 s8pos333134368.htm FILE NOS. 333-134368 AND 333-83636 Reoffer Prospectus

As filed with the Securities and Exchange Commission on November 30, 2006
Registration File Nos. 333-134368 and 333-83636

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Post-Effective Amendment No. 1

to

FORM S-8

REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

_________________

OPHTHALMIC IMAGING SYSTEMS
(Exact name of registrant as specified in its charter)

California		94-3035367
(State or other jurisdiction of incorporation or organization)		(IRS Employer Identification No.)
	221 Lathrop Way, Suite I, Sacramento, CA 95815
	(Address of principal executive offices)
	(916) 646-2020
	(Issuer's telephone number)

2000 STOCK OPTION PLAN
2003 STOCK OPTION PLAN
2005 STOCK OPTION PLAN
(Full title of the plans)

Ariel Shenhar, Chief Financial Officer
221 Lathrop Way, Suite I
Sacramento, CA 95815
(Name and address of agent for service)

(916) 646-2020
(Telephone number, including area code, of agent for service)

with a copy to:
Henry I. Rothman, Esq.
Troutman Sanders, LLP
The Chrysler Building
405 Lexington Avenue
New York, New York 10174
(212) 704-6000

As permitted by Rule 429 of the Securities Act of 1933, as amended, the prospectus filed as part of this Post-Effective Amendment No. 1 to Form S-8 is a combined resale prospectus which will be deemed a Post-Effective Amendment to the Registrant’s Registration Statements on Form S-8, registration nos. 333-134368 and 333-83636.

EXPLANATORY NOTE

This Post-Effective Amendment No. 1 to Form S-8 is being filed to include in the registration statements amended hereby a reoffer prospectus prepared in accordance with Part I of Form S-3 under the Securities Act of 1933, as amended (the “Securities Act”). We previously filed registration statements on Form S-8 on March 1, 2002 (registration no. 333-134368) relating to options to be granted under our 2000 Stock Option Plan and on May 22, 2006 (registration no. 333-83636) relating to the options to be granted under our 2003 Stock Option Plan and 2005 Stock Option Plan (together with the 2000 Stock Option Plan and the 2003 Stock Option Plan, the “Plans”). The reoffer prospectus may be utilized for reoffering and resales of shares of our common stock, no par value, deemed “control securities” (as defined in General Instruction C to Form S-8) acquired pursuant to our Plans, in each case by an “affiliate” of us. The inclusion of any individual in the selling shareholder table of the reoffer prospectus should not be deemed a determination or an admission by us that such individual is in fact an affiliate of us.

Reoffer Prospectus

OPHTHALMIC IMAGING SYSTEMS

1,085,000 Shares of Common Stock

This prospectus relates to the reoffer and resale by certain selling shareholders of shares of our common stock, no par value, that have been or may be issued by us to the selling shareholders upon the exercise of stock options granted under the Ophthalmic Imaging Systems 2005 Stock Option Plan (the “2005 Plan”), 2003 Stock Option Plan (the “2003 Plan”), and 2000 Stock Option Plan (the “2000 Plan” and together with the 2005 Plan and the 2003 Plan, the “Plans”).

We will not receive any of the proceeds from sales of the shares by any of the selling shareholders. The shares may be offered from time to time by any or all of the selling shareholders (and their donees and pledgees) through ordinary brokerage transactions, in negotiated transactions or in other transactions at such prices they may determine, which may relate to market prices prevailing at the time of sale or be a negotiated price. See “Plan of Distribution” beginning on page 21. All costs, expenses and fees in connection with the registration of the shares will be borne by us. Brokerage commissions and similar selling expenses, if any, attributable to the offer or sale of the shares will be borne by the selling shareholders (or their donees and pledgees).

Our common stock is traded on the OTC Bulletin Board under the symbol “OISI.OB.” On November 28, 2006, the closing price of our common stock was $3.09 per share.

Investing in our common stock involves a high degree of risk. See “Risk Factors” beginning on page 1 to read about certain risks you should consider before buying shares of our common stock.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense.

Our principal executive offices are located at 221 Lathrop Way, Suite I, Sacramento, California 95815. Our telephone number is (916) 646-2020.

The date of this prospectus is November 30, 2006


Risk Factors	1
Incorporation of Certain Documents by Reference	8
Forward-Looking Statements	9
Our Company	10
Use of Proceeds	18
Dividend Policy	18
Selling Shareholders	18
Plan of Distribution	19
Legal Matters	21
Experts	21
Where You Can Find More Information About Us	21
Disclosure of Commission Position on Indemnification for Securities Act Liabilities	21

You should rely only on the information contained in this prospectus. We have not authorized any other person to provide you with different information. If anyone provides you with different or inconsistent information, you should not rely on it. The selling shareholders are prohibited from making an offer to sell these securities in any jurisdiction where an offer or sale is not permitted. You should assume that the information appearing in this prospectus is accurate as of the date on the front cover of this prospectus only, regardless of the time of delivery of this prospectus or of any sale of our common stock. Our business, financial condition, results of operations and prospects may have changed since that date.

-i-

Risk Factors

An investment in our common stock involves a high degree of risk. In addition to the other information in this prospectus, you should carefully consider the following risk factors before deciding to invest in shares of our common stock. If any of the following risks actually occurs, it is likely that our business, financial condition and operating results would be harmed. As a result, the trading price of our common stock could decline, and you could lose part or all of your investment.

Risks Related to Our Business

If we are unable to obtain additional capital, we would be required to eliminate certain activities that would adversely effect our operations.

We may require substantial funds for various purposes, including continuing research and development, manufacturing and marketing our existing products. We may need to seek additional capital, possibly through public or private sales of our securities, in order to fund our activities on a long-term basis. Adequate funds may not be available when needed or on terms acceptable to us. Insufficient funds may require us to delay, scale back or eliminate certain or all of our research and development programs or to license third parties to commercialize products or technologies that we would otherwise seek to develop ourselves, which may materially adversely affect our continued operations.

If we fail to develop and successfully introduce new and enhanced products that meet the needs of our customers, our business may be harmed.

Our future success depends on our ability to anticipate our customers’ needs and develop products that address those needs. This will require us to design, develop, manufacture, assemble, test market and support new products and enhancements on a timely and cost-effective basis. We cannot assure that we will successfully identify new product opportunities and develop and bring new products to market in a timely and cost effective manner. Our failure to do so could lead to a reduction in sales and our business may be harmed.

Our market is unpredictable and characterized by rapid technological changes and evolving standards, and, if we fail to keep up with such changes, our business and operating results will be harmed.

Our industry is characterized by extensive research and development, rapid technological change, frequent innovations and new product introductions, changes in customer requirements and evolving industry standards. Demand for our products could be significantly diminished by new technologies or products that replace them or render them obsolete, which would have a material adverse effect on our business, financial condition and results of operations.

The markets in which we sell our products are intensely competitive and increased competition could cause reduced sales levels, reduced gross margins or the loss of market share.

The healthcare industry is characterized by extensive research and development efforts and rapid technological change. Competition for products that can diagnose and evaluate eye disease is intense and is expected to increase. With respect to our WinStation products, we are aware of two primary competitors in the United States, which produce and are delivering digital fundus imaging systems in volume, Topcon and Zeiss. In addition, there are a few other small competitors. Both Topcon and Zeiss, however, manufacture fundus cameras and produce angiography products that interface mostly with their own fundus cameras. In contrast, our products interface with different models of fundus cameras

-1-

from a wide variety of manufacturers. Three other companies are known to have systems in primarily the international market, and the U.S. market to a limited extent, each with small market penetration.

We are aware of one competitor for the Ophthalmic PACS, which develops and sells a similar solution. We are aware of a few competitors for the EMR/EPM products, namely Allscripts, GE, and A4, which provide solutions for the multi-specialty medical market, including the ophthalmic market and a few smaller competitors, namely HCIT, Eye Doc and Compulink, which provide the EMR/EPM solutions predominantly to the eye care market.

We are aware of five primary competitors for the DSLI, namely Veatch, MVC, Kowa, Helioasis and Lombart. Additionally, there are approximately four other companies, which manufacture similar systems, but these systems currently have minimal market presence.

Although we will continue to work to develop new and improved products, many companies are engaged in research and development of new devices and alternative methods to diagnose and evaluate eye disease. Introduction of such devices and alternative methods could hinder our ability to compete effectively and could have a material adverse effect on our business, financial condition and results of operations. Many of our competitors and potential competitors have substantially greater financial, manufacturing, marketing, distribution and technical resources than we have.

The NextGen® software products platforms of EPM (Enterprise Practice Management) and EMR (Electronic Medical Records) allows us to broaden our product offerings to the ocular health care industry. Despite this value added reseller, “VAR,” agreement, there is no guarantee that our sales efforts in this new endeavor will be successful in the future. Long sales cycles, new sales training requirements and potential resistance to the initial high cost of the software may be among those factors contributing to us not being successful in reselling these products.

If we do experience any degree of success in reselling these products, our gross margin could be negatively impacted. Our gross margin on the reselling of these products is lower than the majority of the products that we currently market.

Any business combinations or mergers among our competitors, forming larger competitors with greater resources, or the acquisition of a competitor by a major medical or technology corporation seeking to enter this business, could result in increased competition.

We may experience a decline in selling prices of our products as competition increases, which could adversely affect our operating results.

As competing products become more widely available, the average selling price of our products may decrease. Trends toward managed care, health care, cost containment and other changes in government and private sector initiatives in the United States and other countries in which we do business are placing increased emphasis on the delivery of more cost-effective medical therapies which could also adversely affect prices of our products. If we are unable to offset the anticipated decrease in our average selling prices by increasing our sales volumes, our net sales will decline. In addition, to maintain our gross margins, we must continue to reduce the cost of our products. Further, as average selling prices of our current products decline, we must develop and introduce new products and product enhancements with higher margins. If we cannot maintain our net sales and gross margins, our operating results could be seriously harmed, particularly if the average selling prices of our products decrease significantly.

-2-

If we do not spend heavily on research and development and we fail to address rapid technological changes in our markets, it could adversely affect our business.

We have incurred substantial research and development expenditures in the past, and plan to continue to do so in the future. Over the last three fiscal years, our research and development expenses have been in the range of 7% to 9% of our net revenues. We cannot assure that our expenditures for research and development will result in the introduction of new products or, if such products are introduced, that those products will achieve sufficient market acceptance. Our failure to address rapid technological changes in our markets could adversely affect our business and results of operations.

Our products are subject to U.S., E.U. and international medical regulations and controls, which impose substantial financial costs on us and which can prevent or delay the introduction of new products.

Our ability to sell our products is subject to various federal, state and international rules and regulations. In the United States, we are subject to inspection and market surveillance by the FDA, to determine compliance with regulatory requirements. The regulatory process is costly, lengthy and uncertain.

Pursuant to Section 510(k) of the Federal Food, Drug and Cosmetic Act (“FDCA”), we are required to file, and submit, a pre-marketing notification with the FDA which provides certain safety and effectiveness information concerning our diagnostic imaging systems, including our DFI and DSLI. The FDA has approved our pre-marketing notification submittals, thereby granting us permission to market our products, subject to the general controls and provisions of the FDCA. The classification of our products require, among other things, annual registration, listing of devices, good manufacturing practices, labeling and prohibition against misbranding and adulteration. Further, because we are engaged in international sales, our products must satisfy certain manufacturing requirements and may subject us to various filing and other regulatory requirements imposed by foreign governments as a condition to the sale of such products.

We have registered our manufacturing facility with both the FDA and certain California authorities as a medical device manufacturer and operate such facility under FDA and California requirements concerning Quality System Requirements (“QSR”). As a medical device manufacturer, we are required to continuously maintain our QSR compliance status and to demonstrate such compliance during periodic FDA and California inspections. If the facilities do not meet applicable QSR regulatory requirements, we may be required to implement changes necessary to comply with such regulations.

Although the FDA has made findings which permit us to sell our products in the marketplace, such findings do not constitute FDA approval of these devices and we can not predict the effect that future legislation or regulatory developments may have on our operations. Additional regulations, reconsideration of approvals granted under current regulations, or a change in the manner in which existing statutes and regulations are interpreted or applied may have a material adverse impact on our business, financial condition and results of operations. Moreover, new products and services developed by us, if any, also may be subject to the same or other various federal and state regulations, in addition to those of the FDA.

Following clearance or approval, marketed products are subject to continuing regulation. We are required to adhere to the FDA’s Quality System Regulation, or QSR, and similar regulations in other countries, which include design, testing, quality control and documentation requirements. Ongoing compliance with QSR, labeling and other applicable regulatory requirements is monitored through periodic inspections and market surveillance by the FDA and by comparable agencies in other countries.

-3-

The Value Added Reseller (VAR) Agreement signed with NextGen Healthcare Information Systems, Inc. may not generate any significant future revenue for us and may reduce gross margins.

The NextGen® software products platforms of EPM (Enterprise Practice Management) and EMR (Electronic Medical Records) allows us to broaden our product offerings to the ocular health care industry. Despite this VAR agreement, there is no guarantee that our sales efforts in this endeavor will be successful in the future. Long sales cycles, new sales training requirements and potential resistance to the initial high cost of the software may be among those factors contributing to us not being successful in reselling these products.

We depend on skilled personnel to operate our business effectively in a rapidly changing market, and if we are unable to retain existing or hire additional personnel, our ability to develop and sell our products could be harmed.

Our success depends to a significant extent upon the continued service of our key senior management, sales and technical personnel, any of whom could be difficult to replace. Competition for qualified employees is intense, and our business could be adversely affected by the loss of the services of any of our existing key personnel. We cannot assure that we will continue to be successful in hiring and retaining properly trained personnel. Our inability to attract, retain, motivate and train qualified new personnel could have a material adverse effect on our business.

We may not be able to protect our proprietary technology, which could adversely affect our competitive advantage.

We rely on a combination of patent, copyright, trademark and trade secret laws, non-disclosure and confidentiality agreements and other restrictions on disclosure to protect our intellectual property rights. We cannot assure that our patent applications will be approved, that any patents that may be issued will protect our intellectual property, that any issued patents will not be challenged by third parties or that any patents held by us will not be found by a judicial authority to be invalid or unenforceable. Other parties may independently develop similar or competing technology or design around any patents that may be issued to or held by us. We cannot be certain that the steps we have taken will prevent the misappropriation of our intellectual property, particularly in foreign countries where the laws may not protect our proprietary rights as fully as in the United States. Moreover, if we lose any key personnel, we may not be able to prevent the unauthorized disclosure or use of our technical knowledge or other trade secrets by those former employees.

The long sales cycles for our products may cause us to incur significant expenses without offsetting revenues.

Customers typically expend significant effort in evaluating, testing and qualifying our products before making a decision to purchase them, resulting in a lengthy initial sales cycle. While our customers are evaluating our products we may incur substantial sales and marketing and research and development expenses to customize our products to the customer’s needs. We may also expend significant management efforts, increase manufacturing capacity and order long-lead-time components or materials. Even after this evaluation process, a potential customer may not purchase our products. As a result, these long sales cycles may cause us to incur significant expenses without ever receiving revenue to offset those expenses.

-4-

If we fail to accurately forecast component and material requirements for our products, we could incur additional costs and significant delays in shipments, which could result in the loss of customers.

We must accurately predict both the demand for our products and the lead times required to obtain the necessary components and materials. Lead times for components and materials that we order vary significantly and depend on factors including the specific supplier requirements, the size of the order, contract terms and current market demand for components. If we overestimate our component and material requirements, we may have excess inventory, which would increase our costs, impair our available liquidity and could have a material adverse effect on our business, operating results and financial condition. If we underestimate our component and material requirements, we may have inadequate inventory, which could interrupt and delay delivery of our products to our customers. Any of these occurrences would negatively impact our net sales, business and operating results and could have a material adverse effect on our business, operating results and financial condition.

Our dependence on sole source suppliers exposes us to possible supply interruptions that could delay or prevent the manufacture of our systems.

Certain of the components used in our products are purchased from single sources. While we believe that most of these components are available from alternate sources, an interruption of these or other supplies could have a material adverse effect on our ability to manufacture some of our systems.

Some of our medical customers’ willingness to purchase our products depends on their ability to obtain reimbursement for medical procedures using our products and our revenues could suffer from changes in third-party coverage and reimbursement policies.

Our medical segment customers include doctors, clinics, hospitals and other health care providers whose willingness and ability to purchase our products depends in part upon their ability to obtain reimbursement for medical procedures using our products from third-party payers, including private insurance companies, and in the U.S. from health maintenance organizations, and federal, state and local government programs, including Medicare and Medicaid. Third-party payers are increasingly scrutinizing health care costs submitted for reimbursement and may deny coverage and reimbursement for the medical procedures made possible by our products. Failure by our customers to obtain adequate reimbursement from third-party payers for medical procedures that use our products or changes in third-party coverage and reimbursement policies could have a material adverse effect on our sales, results of operations and financial condition.

We have limited product liability insurance and if we are held liable in a products liability lawsuit for amounts in excess of our insurance coverage, we could be rendered insolvent.

There can be no assurance that we will not be named as a defendant in any litigation arising from the use of our products. Although we have our own product liability insurance policy with a limit of $1 million, should such litigation ensue and we are held liable for amounts in excess of such insurance coverage, we could be rendered insolvent. In addition, there can be no assurance that product liability insurance will continue to be available to us or that the premiums therefore will not become prohibitively expensive.

-5-

If our facilities were to experience catastrophic loss, our operations would be seriously harmed.

Our facilities could be subject to a catastrophic loss such as fire, flood or earthquake. A substantial portion of our manufacturing activities and many other critical business operations are located near major earthquake faults in California, an area with a history of seismic events. Any such loss at our

facility could disrupt our operations, delay production, shipments and revenue and result in large expenses to repair or replace the facility. Any such loss could have a material adverse effect on our sales, results of operations and financial condition.

Since a significant portion of our research and development is done in Israel, we are also exposed to terrorism, which could also have a material adverse effect on our business operations.

If MediVision fails to repay amounts guaranteed by us under the Debenture, it could result in a material adverse effect on our business, operating results, or financial condition.

We are a party to the Debenture whereby we guarantee the payment of all of the debts and liabilities of MediVision to United Mizrahi Bank. The Debenture is secured by a first lien on all of our assets. MediVision pledged 2,345,500 of the 9,420,851 shares of our common stock it owns to us in order to secure the Debenture. For a more detailed description of the Debenture, see “Management’s Discussion and Analysis of Financial Condition and Results of Operation— MediVision Transactions” in our annual report on Form 10-KSB, filed with the Commission on March 28, 2006

If MediVision fails to pay the debts and liabilities secured by us under the Debenture we will likely be required to pay these amounts to United Mizrahi Bank. If the shares posted as collateral to secure the Debenture are insufficient in value to pay such amounts, the cash required to pay such amounts will most likely come out of our working capital. Since we rely on our working capital for our day to day operations, any such default by MediVision could have a material adverse effect on our business, operating results, or financial condition to such extent that we are forced to restructure, file for bankruptcy, sell assets or cease operations, any of which could put your investment dollars at significant risk.

Risks Related to This Offering

We may experience volatility in our stock price, which could negatively affect your investment, and you may not be able to resell your shares at or above the offering price.

The offering price of our common stock may vary from the market price of our common stock after the offering. If you purchase shares of common stock, you may not be able to resell those shares at or above the offering price. The market price of our common stock may fluctuate significantly in response to a number of factors, some of which are beyond our control, including: a quarterly variations in operating results; changes in financial estimates by securities analysts; changes in market valuations of other similar companies; announcements by us or our competitors of new products or of significant technical innovations, contracts, acquisitions, strategic partnerships or joint ventures; additions or departures of key personnel; any deviations in net sales or in losses from levels expected by securities analysts; and future sales of common stock.

In addition, the stock market has recently experienced extreme volatility that has often been unrelated to the performance of particular companies. These market fluctuations may cause our stock price to fall regardless of our performance.

-6-

Because our securities trade on the OTC Bulletin Board, your ability to sell your shares in the secondary market may be limited.

The shares of our common stock have been listed and principally quoted on the Nasdaq OTC Bulletin Board under the trading symbol “OISI” since May 28, 1998 and prior thereto on the Nasdaq Small-Cap Market. In May 1998, the NASD notified us that we no longer satisfied Nasdaq Small-Cap Market listing requirements and, in accordance with the terms of the Nasdaq Listing Qualifications

Panel decision, our common stock was delisted therefrom on May 27, 1998. Further, due to our inability to comply with the Boston Stock Exchange listing requirements, our common stock was delisted therefrom on March 3, 1998. As a result, it may be more difficult for an investor to dispose of our securities, or to obtain accurate quotations on their market value. Furthermore, the prices for our securities may be lower than might otherwise be obtained.

Moreover, because our securities currently trade on the OTC Bulletin Board, they are subject to the rules promulgated under the Securities Exchange Act of 1934, as amended, which impose additional sales practice requirements on broker-dealers that sell securities governed by these rules to persons other than established customers and “accredited investors” (generally, individuals with a net worth in excess of $1,000,000 or annual individual income exceeding $200,000 or $300,000 jointly with their spouses). For such transactions, the broker-dealer must determine whether persons that are not established customers or accredited investors qualify under the rule for purchasing such securities and must receive that person’s written consent to the transaction prior to sale. Consequently, these rules may adversely affect the ability of purchasers to sell our securities and otherwise affect the trading market in our securities.

Because our shares are deemed “penny stocks,” you may have difficulty selling them in the secondary trading market.

The Securities and Exchange Commission (the “Commission”) has adopted regulations which generally define a “penny stock” to be any equity security that has a market price (as therein defined) less than $5.00 per share or with an exercise price of less than $5.00 per share, subject to certain exceptions. Additionally, if the equity security is not registered or authorized on a national securities exchange that makes certain reports available, the equity security may also constitute a “penny stock.” As our common stock falls within the definition of penny stock, these regulations require the delivery by the broker-dealer, prior to any transaction involving our common stock, of a risk disclosure schedule explaining the penny stock market and the risks associated with it. The broker-dealer also must provide the customer with bid and offer quotations for the penny stock, the compensation of the broker-dealer and any salesperson in the transaction, and monthly account statements indicating the market value of each penny stock held in the customer’s account. In addition, the penny stock rules require that, prior to a transaction in a penny stock not otherwise exempt from those rules, the broker-dealer must make a special written determination that the penny stock is a suitable investment for the purchaser and receive the purchaser’s written agreement to the transaction. These disclosure requirements may have the effect of reducing the trading activity in the secondary market for our common stock. The ability of broker-dealers to sell our common stock and the ability of shareholders to sell our common stock in the secondary market would be limited. As a result, the market liquidity for our common stock would be severely and adversely affected. We can provide no assurance that trading in our common stock will not be subject to these or other regulations in the future, which would negatively affect the market for our common stock.

We have additional securities available for issuance, including preferred stock, which if issued could adversely affect the rights of the holders of our common stock.

Our articles of incorporation authorize the issuance of 35,000,000 shares of common stock and 20,000,000 shares of preferred stock. The common stock and the preferred stock can be issued by, and the terms of the preferred stock, including dividend rights, voting rights, liquidation preference and conversion rights can generally be determined by, our board of directors without shareholder approval.

Any issuance of preferred stock could adversely affect the rights of the holders of common stock by, among other things, establishing preferential dividends, liquidation rights or voting powers. Accordingly, shareholders, including those purchasing the securities offered hereby, will be dependent

-7-

upon the judgment of our management in connection with the future issuance and sale of shares of our common stock and preferred stock, in the event that buyers can be found therefor. Any future issuances of common stock or preferred stock would further dilute the percentage ownership of our company held by the public shareholders. Furthermore, the issuance of preferred stock could be used to discourage or prevent efforts to acquire control of our company through acquisition of shares of common stock.

Incorporation of Certain Documents by Reference

The following documents, which have been filed by us with the Commission pursuant to the Securities Exchange Act of 1934, as amended (the “Exchange Act”), are incorporated by reference in this prospectus as of their respective dates:

•

our annual report on Form 10-KSB (File No. 001-11140) for the fiscal year ended December 31, 2005 filed with the Commission on March 28, 2006;

•

our current reports on Form 8-K (File No. 001-11140) filed with the Commission on February 7, 2006, February 21, 2006, March 9, 2006, April 5, 2006, May 9, 2006, June 19, 2006, July 25, 2006, August 4, 2006, and November 6, 2006; and

•

the description of our Common Stock contained in our Registration Statement on Form 8-A filed with the Commission on May 13, 1992, including any amendment or report filed for the purpose of updating such description.

All documents filed subsequent to the date of this prospectus pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act prior to the filing of a post-effective amendment which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference in this prospectus and to be a part hereof from the date of the filing of such documents. Any statement contained in a document incorporated or deemed to be incorporated herein by reference shall be deemed to be modified or superseded for purposes of this prospectus to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement.

We will provide without charge to any person to whom this prospectus is delivered, upon written or oral request of such person, a copy of each document incorporated by reference in the registration statement (other than exhibits to such documents unless such exhibits are specifically incorporated by reference into this prospectus). Requests should be directed to Ariel Shenhar, Ophthalmic Imaging Systems, 221 Lathrop Way, Suite I, Sacramento, California 95815. Our telephone number is (916) 646-2020.

-8-

Forward-Looking Statements

We make forward-looking statements in this prospectus, in other materials we file with the Commission or otherwise release to the public, including those incorporated by reference herein, and on our website. In addition, our senior management might make forward-looking statements orally to analysts, investors, the media, and others. Statements concerning our future operations, prospects, strategies, financial condition, future economic performance (including growth and earnings) and demand for our products and services, and other statements of our plans, beliefs, or expectations, including the statements contained in this Item 2, “Management’s Discussion and Analysis or Plan of Operation,” regarding our future plans, strategies, and expectations are forward-looking statements. In some cases these statements are identifiable through the use of words such as “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “project,” “target,” “can,” “could,” “may,” “should,” “will,” “would,” and similar expressions used in this prospectus, supplements to this prospectus or documents incorporated by reference.. We intend such forward-looking statements to be covered by the safe harbor provisions contained in Section 27A of the Securities Act of 1933, as amended, and in Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). You are cautioned not to place undue reliance on these forward-looking statements because these forward-looking statements we make are not guarantees of future performance and are subject to various assumptions, risks, and other factors that could cause actual results to differ materially from those suggested by these forward-looking statements. Thus, our ability to predict results or the actual effect of our future plans or strategies is inherently uncertain. Factors which could have a material adverse effect on our operations and future prospects include, but are not limited to, changes in: economic conditions generally and the medical instruments market specifically, legislative or regulatory changes that affect us, including changes in healthcare regulation, the availability of working capital, and the introduction of competing products. These risks and uncertainties, together with the other risks described from time to time in reports and documents that we file with the SEC should be considered in evaluating forward-looking statements and undue reliance should not be placed on such statements. (There also are other factors that we do not describe because currently, we do not perceive that such factors will cause actual results to differ materially from our expectations.) Indeed, it is likely that some of our assumptions will prove to be incorrect. Our actual results and financial position will vary from those projected or implied in the forward-looking statements and the variances may be material. We expressly disclaim any obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. We do not undertake any responsibility to release publicly any revisions to these forward-looking statements to take into account events or circumstances that occur after the date of this prospectus or supplements to this prospectus. Additionally, we do not undertake any responsibility to update you on the occurrence of any unanticipated events which may cause actual results to differ from those expressed or implied by the forward-looking statements.

-9-

Our Company

(a)

Business Development

Ophthalmic Imaging Systems (the “Company” or “OIS”) was incorporated under the laws of the State of California on July 14, 1986. We are headquartered in Sacramento, California and are engaged in the business of designing, developing, manufacturing and marketing digital imaging systems, image enhancement and analysis software and informatics solutions for use by practitioners in the ocular health field. Our products are used for a variety of standard diagnostic test procedures performed in most eye care practices.

Since our inception, we have developed products that have addressed primarily the needs of the ophthalmic angiography markets, both fluorescein and indocyanine green. The current flagship products in our angiography line are our WinStation digital imaging systems. These WinStation products are targeted primarily at retinal specialists and general ophthalmologists in the diagnosis and treatment of retinal diseases and other ocular pathologies.

We believe, however, that as the U.S. healthcare system moves toward managed care, the needs of managed care providers are changing the nature of demand for medical imaging equipment and services. New opportunities in telemedicine (e.g., the electronic delivery and provision of health care and consultative services to patients through integrated health information systems and telecommunications technologies), combined with lower cost imaging devices and systems, are emerging to allow physicians and managed care organizations to deliver a high quality of patient care while reducing costs. We are applying our technology in the ophthalmic imaging field to the development of new ocular imaging devices and exploring telemedicine/managed care applications targeted at the mass markets of general ophthalmology and optometry.

Our objective is to become a leading provider of a diverse range of complimentary ophthalmic products and services for the ocular health care industry. We are currently focusing our development efforts on related products for the ocular healthcare market, as well as features and enhancements to our existing products.

We entered into the Ophthalmic Picture Archiving and Communications Systems (“PACS”) software market during 2004, enabling medical staff to access new and archived images remotely, improving the environment in which to diagnose patients. The ability to instantaneously share information between locations allows specialists to manage more patients’ in separate locations quickly and efficiently. The Ophthalmic PACS system can be completely integrated with our customers existing infrastructure, including image acquisition, image analysis, short- and long-term storage, archiving, disaster recovery, viewing, and monitoring.

We have also entered into the Electronic Medical Records (“EMR”) and the Enterprise Practice Management (“EPM”) markets. To that end, we signed an agreement on June 30, 2003 with NextGen Healthcare Information Systems, Inc., a subsidiary of Quality Systems Inc. (Nasdaq:QSII), a leading provider of such software platforms to the practitioners market and sale of their products to the ophthalmic market.

This strategic business alliance diversifies our product portfolio, enabling us to offer a wider variety of products and comprehensive solutions to our customer base of ophthalmology departments and practices. The NextGen® EMR system creates and maintains complete medical records with minimal effort while it streamlines workflow, controls utilization, and manages critical data related to patient care outcomes. The NextGen® EPM system is a complete physician management system that provides a common registration system, enterprise-wide appointment scheduling, referral tracking, clinical support, a custom report writer, and patient financial management based on a managed care model.

(b)

Business of Issuer

Products

WinStation Systems

Our WinStation systems and products, delineated by resolution, are primarily used by retina specialists and general ophthalmologists to perform a diagnostic test procedure known as fluorescein angiography. This procedure is used to diagnose and monitor pathology and provide important information in making treatment decisions. Fluorescein angiography is performed by injecting a fluorescent dye into the bloodstream. As the dye circulates through the blood vessels of the eye, the WinStation system, connected to a medical image capture device called a fundus camera, takes detailed images of the patient’s retina. These digital images can provide a “road map” for laser treatment.

Over the past 40 years, fluorescein angiography has been performed using photographic film, which requires special processing and printing. Our WinStation systems allow for immediate diagnosis and treatment of the patient. Images are automatically transferred to a database and permanently stored on CD-ROM or DVD-ROM. We offer a variety of networking and printer options.

Our WinStation systems also are used by ophthalmologists to perform indocyanine green (“ICG”) angiography. ICG angiography is a diagnostic test procedure used in the treatment of patients with Age-related Macular Degeneration (“AMD”), a leading cause of blindness afflicting over 5 million people in the United States. ICG angiography, used for approximately 5% of patient angiography, is a dye procedure that can only be performed using a digital imaging system.

-10-

Ophthalmology Office

We have expanded our offerings in ophthalmic informatics to provide comprehensive solutions for the ophthalmic industry. We provide our own Ophthalmic PACS and recently entered the EMR and EPM markets through a strategic alliance with NextGen Healthcare Information Systems, Inc., a subsidiary of Quality Systems Inc. (Nasdaq:QSII), a leading provider of EMR and EPM software platforms expanding our product portfolio with Ophthalmology Office.

Digital Slit Lamp Imager (DSLI)

The DSLI is intended for use by a majority of eye care practitioners, including most ophthalmologists and optometrists, with an emphasis on imaging the front of the eye. Slit lamps are imaging devices used in virtually all-ophthalmic and optometric practices. The DSLI adapts to most slit lamp models and is capable of real-time video capture, database management and archiving.

Markets

Having reviewed a broad selection of third party sources, including reports by American Medical Information, we believe there are approximately 16,000 ophthalmologists in the United States and 28,000 ophthalmologists practicing medicine in countries outside the United States. This group has been traditionally divided into two major groups: anterior segment (front of the eye) and posterior segment (back of the eye). Within these groups there are several sub-specialties including medical retina, retina and vitreous, glaucoma, neurology, plastics, pediatric, cataract, cornea and refractive surgery. There are approximately 29,000 practicing optometrists (OD) in the United States, with the preponderance of practicing optometrists worldwide located in the United States.

The WinStation market consists of current fundus camera owners and anticipated purchasers of fundus cameras suitable for interfacing with our digital imaging system products. We believe there are now over 9,000 fundus cameras in clinical use in the United States with an equal number in the international market. It is estimated that new fundus camera sales fluctuate between 800 and 1,200 units per year at an average per unit selling price of approximately $24,000. Of total cameras worldwide, including new and previously owned, a significant number are suitable to be interfaced with our digital imaging systems.

We currently know of five manufacturers of fundus cameras. These manufacturers produce a total of 23 models, 7 current and 16 legacy models, for which we have designed optical and electronic interfaces for each of them.

The primary target market for the Ophthalmology Office are the retinal specialists and general ophthalmologists who, combined, number approximately 16,000 in the United States.

The primary target market for digital angiography systems are retinal specialists who number approximately 2,000 in the United States. Our digital imaging system sales have been driven in this segment by both fluorescein and ICG angiography. We expect the demand for digital angiography to continue, as it is becoming a standard of care. We sell digital angiography systems to the general ophthalmologists, but to a lesser extent. The primary target market for the DSLI product is the ophthalmology market which number approximately 16,000 in the United States.

-11-

Sales, Marketing and Distribution

We utilize a direct sales force in marketing our products throughout the United States and Canada. At September 30, 2006, our sales and marketing organization consisted of a national sales manager as well as ten territory sales representatives and twelve product specialists located throughout the United States. These regional representatives and product specialists provide marketing, sales, maintenance, installation and training services. We also utilize our own trained contractors to provide certain installation and training services. Additionally, we subcontract service maintenance in several cities in the United States and Canada for routine component replacement.

Internationally, we utilize ophthalmic distributors that sell our products in various foreign countries. Each country has trained sales and technical service staff for their respective territories. MediVision, our parent and CCS Pawlowski GmbH, an affiliate (“CCS”) serve as the principal distributors of our products in Europe and certain other international markets.

Under the Distribution Agreement with MediVision, dated as of January 1, 2004, we appointed MediVision to be our exclusive distributor of certain products in Europe, Africa, Israel and India (the “MV Territory”). In return, MediVision agreed, among other things (as confined to the MV Territory), (1) to use its best efforts in promoting, marketing and selling those certain products, (2) to service customers who purchased those certain products from MediVision, (3) to diligently advertise the products, (4) to refrain from manufacturing, distributing or marketing any items which will compete directly with the products, and (5) to provide us with a 12 month forecast of their intended purchases every 12 months. Under the agreement, MediVision must purchase the specified quota of the products. If MediVision fails to satisfy its quota obligation, this constitutes a breach and we may terminate the exclusivity provision. The quota for 2005 was $700,000, which shall increase by at least 10% the next year. For the sale of WinStation products, all distributors, including MediVision, receive a tiered volume discount based on the amount ordered. The agreement, as amended on December 9, 2005, and effective October 1, 2005, increased the discount percentages and are summarized in tabular format below. The initial term of the agreement is for two years, which will be automatically renewed in one year periods. Either party may terminate the agreement with at least 6 months prior written notice. Subject to an addendum between the parties dated December 9, 2005, MediVision purchased amounts include amounts purchased from us by CCS, MediVision’s German subsidiary.


Distribution Agreement with MediVision ⁽¹⁾

Purchase Range	Discount

$0 - $249,999	0%

$250,000 - $499,999	10%

$500,000 - $749,999	20%

$750,000 - $999,999	30%

$1,000,000 and above	40%

⁽¹⁾ This same volume discount structure is available to all OIS distributors who deal in WinStation products.

Under the Distribution Agreement with CCS, dated February 14, 2006, we appointed CCS, as our exclusive distributor of certain products in Germany and Austria (the “Territory”). In return, CCS agreed, among other things (as confined to the Territory), (1) to use its best efforts in promoting, marketing and selling the Distribution Products, (2) to service customers who purchased distribution products from CCS, (3) to diligently advertise the Distribution Products, (4) to refrain from manufacturing, distributing or marketing any items which will compete directly with the Distribution Products, and (5) to provide us with a 12 month forecast of their intended purchases every 12 months. Under the agreement, CCS must purchase the specified quota of Distribution Products. If CCS fails to

-12-

satisfy its quota obligation, this constitutes a breach and we may terminate the exclusivity provision. The initial annual quota is Euro 279,000, all subsequent quotas will be agreed upon between the parties at the beginning of each year. If no quota is agreed upon, the preceding year’s quota will carry forward. For the sale of certain products, CCS will receive a tiered volume discount based on the amount ordered. The discounts are summarized in tabular format below. The initial term is for two years, which will be automatically renewed in one year periods. Either party may terminate the agreement with at least 3 months prior written notice.


Distribution Agreement with CCS

Applicable Dates	Description	Discount

October - December 2005	0-4 WinStation Systems	40%
	5 or more WinStation Systems	42.5%

2006 and 2007, numbers based	If CCS purchases less than 50% of its DSN2006 or	35%
on each calendar year	DSN2007, as applicable, from OIS
	If CCS purchases more than 50% but less than 80%	40%
	of its DSN2006 or DSN2007, as applicable, from OIS
	If CCS purchases more than 80% of its DSN2006 or	42.5%
	DSN2007, as applicable, from OIS

On June 28, 2006, we and MediVision entered into a License and Distribution Agreement whereby MediVision appointed us to be its exclusive distributor of a new digital imaging system in the Americas and the Pacific Rim (excluding China and India), for a term of ten years. In return, we paid $273,808, consisting of a cash payment of $200,000, and recognition of $73,808 of research and development advances made in previous periods. Additionally, we are obligated to pay an advance totaling $460,000 based on the completion of certain phases of development of the new digital imaging system and the completion of certain documents. On September 21, 2006, we paid $160,000 based on the completion of the first milestone in the agreement. We also granted MediVision a license to use our OIS WinStation software and any other applicable OIS system and the accompanying intellectual property rights therein and a license to use our patents to develop the new digital imaging system and fulfill its obligations under this Agreement. Our foregoing appointment as an exclusive distributor is conditional upon the payment of the advance and MediVision’s successful completion of the engineering, mass manufacture, and supply of the new digital imaging system, which has specifically dedicated features for the retinal market, in accordance with the technical specifications contained in the agreement.

The advanced funds will be recovered as we purchase new digital imaging systems in accordance with specified quotas. The quotas mandate that we purchase a minimum amount of the new digital imaging system each year. The quotas for 2007, 2008, 2009, and 2010 are 50, 70, 80, and 90 units, respectively, and will be at least 95 units for each year thereafter. If we fail to satisfy our quota obligation, then we may pay MediVision the gross profit on the shortfall units to maintain exclusivity in the agreed upon territory. If no such shortfall payment is made, such failure to meet the quota will constitute a material breach and MediVision may terminate the exclusivity provision or the entire distribution agreement.

Under this Agreement, we may not deal in the new digital imaging system outside the agreed upon territory. Moreover, excluding our current products or products derived from our current products, we may not deal in products that compete directly with the new digital imaging system or represent or provide services to a company which has a product or products that competes with the new digital imaging system. We also agreed to, among other things, as confined to the agreed upon territory, (1) use commercially reasonable efforts in promoting, marketing and selling the new digital imaging system, (2) service customers who purchased the new digital imaging system in the agreed upon territory, (3) diligently advertise the new digital imaging system in the agreed upon territory in relevant journals and by direct mail, (4) cooperate with MediVision in dealing with customer complaints concerning the new digital imaging system, and (5) provide MediVision with a 12 month forecast of our intended purchases

-13-

during such year, including, at least 30 days prior to the beginning of each quota year, providing MediVision with an annual purchase order that includes a breakdown of our purchases by quarter; at least 70% of the applicable annual quota must be ordered in this annual purchase order.

Under this Agreement, excluding intellectual property rights, neither party is entitled to damages as a result of loss of use, sales or profits, or any special, indirect, incidental, or consequential loss or damage. Moreover, MediVision will not be liable to OIS in connection with any patent infringement claim in certain instances whereby (1) the new digital imaging system is combined with another device not manufactured by MediVision, (2) the new digital imaging system is used in way other than for which it was designed, and (3) the new digital imaging system is modified by OIS or a third party.

The initial term of this agreement is for ten years, which will be automatically renewed in one year periods. Cash payments made under this agreement for exclusive distribution rights have been capitalized, and will be amortized over the term of the agreement. Either party may terminate the agreement with at least 6 months prior written notice of the intent to terminate, provided that, we meet the purchase quota.

To promote sales, we prepare brochures, data sheets and application notes on our products, participate in industry trade shows and workshops, and advertise in trade journals, press releases, direct mail solicitations, journal articles, and scientific papers and presentations.

Manufacturing and Production

We are primarily a systems integrator with proprietary software, optical interfaces and electronic fundus camera interfaces. Certain components are subcontracted to outside vendors and assembled at OIS. We inventory and assemble components in a 10,200 square foot facility located in Sacramento, California. For production of certain components of our products, our manufacturing strategy is to use subcontractors to minimize time and reduce capital requirements.

We have been audited by the Food and Drug Administration (the “FDA”) and was deemed to conform to Good Manufacturing Practices (“GMP”). We have 510(k)‘s on file for our digital angiography products.

Components, Raw Materials and Suppliers

As a systems integrator, a significant number of the major hardware components in our products are procured from sole source vendors. Whenever possible, however, we seek multiple vendor sources from which to procure our components. Moreover, we work closely with our principal component suppliers, such as Dell Computer, MegaVision, Lumenera, and the rest of our vendors to maintain dependable working relationships and to continually integrate into the manufacturing of our products, whenever possible, the most current, proven, pertinent technologies. But, as with any manufacturing concern dependent on subcontractors and component suppliers, significant delays in receiving products or unexpected vendor price increases could adversely affect us.

Warranties

We generally provide a 12-month limited warranty for parts, labor and shipping charges in connection with the initial sale of our products. Peripheral products such as monitors, printers and computers also carry the original manufacturer’s warranty.

In the North American market, in order to ensure quality control and the proper functioning of our products on-site at a doctor’s office, we generally install the system and train the doctor and the doctor’s

-14-

staff. We also offer service plans for sale to our customers as a supplement to the original manufacturer’s warranties.

Competition

We are aware of one competitor for the Ophthalmic PACS, which develops and sells a similar solution.

We are aware of a few competitors for the EMR/EPM products, namely Allscripts, GE, and A4, which provide solutions for the multi-specialty medical market, including the ophthalmic market and a few smaller competitors, namely HCIT, Eye Doc and Compulink, which provide the EMR/EPM solutions predominantly to the eye care market.

The NextGen® software products platforms of EPM (Enterprise Practice Management) and EMR (Electronic Medical Records) allows us to broaden our product offerings to the ocular health care industry. Despite this value added reseller, “VAR,” agreement, there is no guarantee that our sales efforts in this endeavor will be successful in the future. Long sales cycles, new sales training requirements and potential resistance to the initial high cost of the software may be among those factors contributing to us not being successful in reselling these products.

Research and Development

Our net research and development expenditures in the years ended December 31, 2005 and 2004 were approximately $1,112,000 and $988,000, respectively. We have focused our recent research and development efforts on new digital image capture products. We expect our research and development expenditures to substantially increase. MediVision Medical Imaging Ltd, our parent company

-15-

(“MediVision”)and other outsourced consultants currently conduct most of the research and development for us.

MediVision performs our research and development pursuant to a Research and Development Services Agreement dated as of January 1, 2004. Under this agreement, MediVision agreed to use its best efforts to develop a WinStation in accordance with our specifications included therein and our, in turn, agreed to pay, in monthly payments, 112% of MediVision’s research and development costs incurred in connection with developing the WinStation. The initial term of the agreement is for two years, to be automatically renewed for additional 12 month periods unless terminated by either party upon 6 months prior written notice. The agreement is exclusive in that during the effective period we may not receive research and development services relating to the WinStation from other parties without MediVision’s prior written consent. Also under the agreement, MediVision must obtain our written approval prior to incur any new research and development expenses in connection thereunder. Moreover, the parties agreed to render to each other, all reasonable assistance in obtaining any regulatory approvals required in connection with the WinStation or any other results of the research and development services performed under the agreement. The parties also agreed that upon termination, (1) for 12 months, each party must maintain insurance reasonable to cover its liabilities, (2) for 24 months, MediVision agrees not to engage or participate in any business, anywhere in the world, that competes directly with the WinStation or us, unless mutually agreed, (3) for 18 months, we agree not to engage or participate in any business, anywhere in the world, that competes directly with MediVision, unless mutually agreed, and (4) for 12 months, generally, neither party may employ any employees, contractors, or directors of the other party or interfere with the other party’s existing business or customer contracts, unless mutually agreed.

Patents, Trademarks and Other Intellectual Property

On June 15, 1993, we were issued United States Letters Patent No. 5,220,360 for “Apparatus and Method for Topographical Analysis of the Retina.” This patent relates to the Glaucoma-Scope(R) apparatus, and methods used by the apparatus for topographically mapping the retina and comparing the mapping to previous mappings.

Further, although we believe that our products do not and will not infringe on patents or violate proprietary rights of others, it is possible that our existing rights may not be valid or that infringement of existing or future patents, trademarks or proprietary rights may occur or be claimed to occur by third parties.

We have registered trademarks for “AutoMontage” and “Ophthalmology Office.”

In the event that any of our products infringe patents, trademarks or proprietary rights of others, we may be required to modify the design of such products, change the names under which the products or services are provided or obtain licenses. There can be no assurance that we will be able to do so in a timely manner, upon acceptable terms and conditions, or at all. The failure to do any of the foregoing could have a material adverse effect on our business. There can be no assurance that our patents or trademarks, if granted, would be upheld if challenged or that competitors might not develop similar or superior processes or products outside the protection of any patents issued to us. In addition, there can be no assurance that we will have the financial or other resources necessary to enforce or defend a patent or trademark infringement or proprietary rights violation action. Moreover, if our products infringe patents, trademarks or proprietary rights of others, we could, under certain circumstances, become liable for damages, which also could have a material adverse effect on our business.

We also rely on trade secrets, know-how, continuing technological innovation and other unpatented proprietary technology to maintain our competitive position. Certain of the proprietary software, optical

-16-

interfaces and synchronization modules of our digital imaging systems are largely proprietary and constitute trade secrets, but the basic computer hardware, software and video components are purchased from third parties. No patent applications have been filed with respect thereto. We anticipate aggressively defending our unpatented proprietary technology, although there is no assurance that others will not independently develop substantially equivalent proprietary information or techniques, or otherwise gain access to our trade secrets or disclose such technology, or that we can meaningfully protect our rights to our unpatented trade secrets and other proprietary technology.

We seek to protect our unpatented proprietary technology, in part, through proprietary confidentiality and nondisclosure agreements with employees, consultants and other parties. Our confidentiality agreements with our employees and consultants generally contain industry standard provisions requiring such individuals to assign to us without additional consideration any inventions conceived or reduced to practice by them while employed or retained by us, subject to customary exceptions. There can be no assurance that proprietary information agreements with employees, consultants and others will not be breached, that we would have adequate remedies for any breach or that our trade secrets will not otherwise become known to or independently developed by competitors.

Government Regulation

The marketing and sale of our products are subject to certain domestic and foreign governmental regulations and approvals. Pursuant to Section 510(k) of the Federal Food, Drug and Cosmetic Act (“FDCA”), we are required to file, and have submitted, a pre-marketing notification with the FDA which provides certain safety and effectiveness information concerning our diagnostic imaging systems, including our DSLI. The FDA has approved our pre-marketing notification submittals, thereby granting us permission to market our products, subject to the general controls and provisions of the FDCA. The classification of our products require, among other things, annual registration, listing of devices, good manufacturing practices, labeling and prohibition against misbranding and adulteration. Further, because we are engaged in international sales, our products must satisfy certain manufacturing requirements and may subject us to various filing and other regulatory requirements imposed by foreign governments as a condition to the sale of such products.

Although the FDA has made findings which permit us to sell our products in the marketplace, such findings do not constitute FDA approval of these devices, and we cannot predict the effect that future legislation or regulatory developments may have on our operations. Additional regulations, reconsideration of approvals granted under current regulations, or a change in the manner in which existing statutes and regulations are interpreted or applied may have a material adverse impact on our business, financial condition and results of operations. Moreover, new products and services developed by us, if any, also may be subject to the same or other various federal and state regulations, in addition to those of the FDA.

Insurance

We maintain general commercial casualty and property insurance coverage for our business operations, as well as directors and officers insurance, flood insurance, and product liability insurance. As of September 30, 2006, we have not received any product liability claims and are unaware of any

-17-

threatened or pending claims. To the extent that product liability claims are made against us in the future, such claims may have a material adverse impact on our business.

Employees

As of November 28, 2006, we had one part-time, 56 full-time, and two seasonal employees. We also engage the services of consultants from time to time to assist us on specific projects in the areas of research and development, software development, regulatory affairs and product services, as well as general corporate administration. Certain of these consultants periodically engage contract engineers as independent consultants for specific projects.

We have no collective bargaining agreements covering any of our employees, have never experienced any material labor disruption, and are unaware of any current efforts or plans to organize our employees. We consider our relationship with our employees to be good.

Use of Proceeds

The selling shareholders are selling all of the shares covered by this prospectus for their own account. Accordingly, we will not receive any of the proceeds from the resale of the shares. We will receive proceeds from the exercise of the options, which results in the issuance of the shares registered under this registration statement. We will use such net proceeds, if any, for general corporate purposes and working capital. We have agreed to bear the expenses relating to the registration of the shares, other than brokerage commissions and expenses, if any, which will be paid by the selling shareholders.

Dividend Policy

We have not paid any cash dividends since our inception and do not anticipate paying any cash dividends on our common stock in the foreseeable future. Future dividend policy will be determined periodically by the Board of Directors based upon conditions then existing, including our earnings and financial condition, capital requirements and other relevant factors.

Selling Shareholders

This prospectus relates to shares of common stock that have been acquired by the selling shareholders pursuant to the 2005 Plan, 2003 Plan, and 2000 Plan.

Executive officers and directors, their family members, trusts for their benefit, or entities that they own, that acquire common stock under the Plans may be added to the selling shareholders list below by a prospectus supplement filed with the Commission. The number of shares to be sold by any selling shareholder under this prospectus also may be increased or decreased by a prospectus supplement. Although a person’s name is included in the table below, neither that person nor we are making an admission that the named person is our “affiliate.”

The following table sets forth (i) the number of shares of our common stock beneficially owned by each selling shareholder at November 28, 2006, (ii) the number of shares of our common stock to be offered for resale by each selling shareholder (i.e. the number of shares underlying all stock options held by the selling shareholder, whether vested or unvested) and (iii) the number and percentage of shares of our common stock to be held by each selling shareholder after completion of the offering:

Unless otherwise specified, the address of each of the persons set forth below is c/o Ophthalmic Imaging Systems, 221 Lathrop Way, Suite I, Sacramento, California 95815.

-18-

			Shares of Common Stock Owned after Offering(2)

Name of Selling Shareholder(1)	Shares of Common Stock Owned Prior to Offering(2)	Shares of Common Stock to be Sold	Number	Percent

Gil Allon	470,000	470,000(3)	—	—
Ariel Shenhar	275,000	275,000(4)	—	—
Michael Benoff	60,000	60,000(5)	—	—
Merle Symes	60,000	60,000(6)	—	—
Noam Allon	220,000	220,000(7)	—	—

_________________
* Less than 1%.

(1)

All individuals named are current or former officers or directors of us.

(2)

Assumes (i) that all shares of common stock registered hereunder are sold, and (ii) total issued and outstanding shares of common stock of (A) 16,503,829, plus (B) for each selling shareholder, the number of shares of common stock registered hereunder.

(3)

Comprised of 360,000 shares of common stock under the 2000 Plan, including 40,000 shares held by wife, Karin Alon; and 110,000 shares of common stock under the 2003 Plan, including 20,000 shares held by wife, Karin Alon.

(4)

Includes 200,000 and 75,000 shares of common stock under the 2000 and 2003 Plans, respectively.

(5)

Includes 20,000 and 40,000 shares of common stock under the 2000 and 2003 Plans, respectively.

(6)

Includes 60,000 shares of common stock under the 2000 Plan.

(7)

Includes 180,000 and 40,000 shares of common stock under the 2000 and 2003 Plans, respectively.

Plan of Distribution

The selling shareholder may, from time to time, sell any or all of his or her shares of common stock on any stock exchange, market or trading facility on which the shares are traded or in private transactions. These sales may be at fixed or negotiated prices. The selling shareholder may use any one or more of the following methods when selling shares:

•

ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers;

-19-

•

block trades in which the broker-dealer will attempt to sell the shares as agent but may position and resell a portion of the block as principal to facilitate the transaction;

•

purchases by a broker-dealer as principal and resale by the broker-dealer for its account;

•

an exchange distribution in accordance with the rules of the applicable exchange;

•

privately negotiated transactions;

•

short sales;

•

broker-dealers may agree with the selling shareholders to sell a specified number of such shares at a stipulated price per share;

•

a combination of any such methods of sale; and

•

any other method permitted pursuant to applicable law.

The selling shareholders may also sell shares under Rule 144 under the Securities Act, if available, rather than under this prospectus.

Broker-dealers engaged by the selling shareholders may arrange for other brokers-dealers to participate in sales. Broker-dealers may receive commissions or discounts from the selling shareholders (or, if any broker-dealer acts as agent for the purchaser of shares, from the purchaser) in amounts to be negotiated. The selling shareholders do not expect these commissions and discounts to exceed what is customary in the types of transactions involved. Any profits on the resale of shares of common stock by a broker-dealer acting as principal might be deemed to be underwriting discounts or commissions under the Securities Act. Discounts, concessions, commissions and similar selling expenses, if any, attributable to the sale of shares will be borne by a selling shareholder. The selling shareholders may agree to indemnify any agent, dealer or broker-dealer that participates in transactions involving sales of the shares if liabilities are imposed on that person under the Securities Act.

The selling shareholders may from time to time pledge or grant a security interest in some or all of the shares of common stock owned by them and, if they default in the performance of their secured obligations, the pledgees or secured parties may offer and sell the shares of common stock from time to time under this prospectus after we have filed an amendment to this prospectus under Rule 424(b)(3) or other applicable provision of the Securities Act amending the list of selling shareholders to include the pledgee, transferee or other successors in interest as selling shareholders under this prospectus.

The selling shareholders also may transfer the shares of common stock in other circumstances, in which case the transferees, pledgees or other successors in interest will be the selling beneficial owners for purposes of this prospectus and may sell the shares of common stock from time to time under this prospectus after we have filed an amendment to this prospectus under Rule 424(b)(3) or other applicable provision of the Securities Act amending the list of selling shareholders to include the pledgee, transferee or other successors in interest as selling shareholders under this prospectus.

The selling shareholder and any broker-dealers or agents that are involved in selling the shares of common stock may be deemed to be “underwriters” within the meaning of the Securities Act in connection with such sales. In such event, any commissions received by such broker-dealers or agents and any profit on the resale of the shares of common stock purchased by them may be deemed to be underwriting commissions or discounts under the Securities Act. The selling shareholders have advised us that they have acquired their securities in the ordinary course of business and they have not entered into any agreements, understandings or arrangements with any underwriters or broker-dealers regarding the sale of their shares of common stock, nor is there an underwriter or coordinating broker acting in connection with a proposed sale of shares of common stock by any selling shareholder. If we are

-20-

notified by any selling shareholder that any material arrangement has been entered into with a broker-dealer for the sale of shares of common stock, if required, we will file a supplement to this prospectus. If the selling shareholders use this prospectus for any sale of the shares of common stock, they will be subject to the prospectus delivery requirements of the Securities Act.

We are required to pay all fees and expenses incident to the registration of the shares of common stock. We have agreed to indemnify the selling shareholders against certain losses, claims, damages and liabilities, including liabilities under the Securities Act.

The anti-manipulation rules of Regulation M under the Exchange Act may apply to sales of our common stock and activities of the selling shareholders.

Legal Matters

The validity of the shares of common stock offered in this prospectus has been passed upon for us by Troutman Sanders LLP, The Chrysler Building, 405 Lexington Avenue, New York, New York 10174.

Experts

Our financial statements for the years ending December 31, 2005 and 2004 incorporated by reference in the Annual Report on Form 10-KSB for the year ended December 31, 2005 have been so incorporated in reliance on a report of the accounting firm of Perry-Smith, LLP, independent registered public accounting firm. Our financial statements are incorporated by reference in this prospectus in reliance upon the said report, given upon such firm’s authority as an expert in auditing and accounting.

Where You Can Find More Information About Us

We have filed with the Commission registration statements on Forms S-8, including exhibits and schedules, under the Securities Act with respect to the shares of our common stock to be sold in this offering. This prospectus does not contain all the information contained in the registration statement. For further information with respect to us and the shares that may be sold pursuant to the prospectus, we refer you to the registration statement and the exhibits and schedules attached to the registration statement. Statements contained in this prospectus as to the contents of any contract, agreement or other document referred to are not necessarily complete. When we make such statements, we refer you to the copies of the contracts or documents that are filed as exhibits to the registration statement because those statements are qualified in all respects by reference to those exhibits.

We are subject to the information and reporting requirements of the Exchange Act and file annual, quarterly, and current reports, proxy statements, and other information with the Commission. You may read and copy all or any portion of the registration statement or any reports, statements or other information that we file at the Commission’s public reference room at 100 F Street, N.E., Washington, D.C. 20549. Please call the Commission at 1-800-SEC-0330 for further information on the operation of the public reference rooms. The registration statement can also be reviewed by accessing the Commission’s Internet site at http://www.sec.gov.

Disclosure of Commission Position on Indemnification for Securities Act Liabilities.

Our bylaws provide that we will indemnify our officers and directors for costs and expenses incurred in connection with the defense of actions, suits, or proceedings against them on account of their being or having been our directors or officers in accordance with Section 317 of the California Corporations Code. Our bylaws also permit us to maintain insurance on behalf of our officers, directors, employees and agents against any liability asserted against and incurred by that person whether or not we have the power to indemnify such person against liability for any of those acts.

Insofar as indemnification for liabilities arising under the Securities Act may be permitted to our directors, officers and controlling persons pursuant to the foregoing provisions, we have been informed that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable.

-21-

PART II.

INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

Item 3. Incorporation of Documents by Reference.

Incorporation of Certain Documents by Reference

•

our annual report on Form 10-KSB (File No. 001-11140) for the fiscal year ended December 31, 2005 filed with the Commission on March 28, 2006;

•

the description of the Common Stock contained in our Registration Statement on Form 8-A filed with the Commission on May 13, 1992, including any amendment or report filed for the purpose of updating such description.

Item 4. Description of Securities.

Not Applicable.

Item 5. Interests of Named Experts and Counsel.

Not Applicable.

Item 6. Indemnification of Directors and Officers.

Section 317 of the California Corporations Code (“Section 317”) states that a corporation shall have the power to indemnify any person who was or is a party or is threatened to be made a party to any proceeding (other than an action by or in the right of the corporation to procure a judgment in its favor) by reason of the fact that the person is or was an agent of the corporation, against expenses, judgments, fines, settlements, and other amounts actually and reasonably incurred in connection with the proceeding if that person acted in good faith and in a manner the person reasonably believed to be in the best interests of the corporation and, in the case of a criminal proceeding, had no reasonable cause to believe the conduct of the person was unlawful. In addition, a corporation shall have the power to indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending, or completed action by or

II-1

in the right of the corporation to procure a judgment in its favor by reason of the fact that the person is or was an agent of the corporation, against expenses actually and reasonably incurred by that person in connection with the defense or settlement of the action if the person acted in good faith, in a manner the person believed to be in the best interests of the corporation and its shareholders.

With regard to a provision authorizing the indemnification of directors or agents in excess of that expressly permitted by Section 317, Section 204 of the California Corporations Code (“Section 204”) stipulates that (A) such a provision may not eliminate or limit the liability of directors or agents, among other things, (i) for acts or omissions that involve intentional misconduct or a knowing and culpable violation of law, (ii) for acts or omissions that a director or agent believes to be contrary to the best interests of the corporation or its shareholders or that involve the absence of good faith on the part of the director or agent, (iii) for any transaction from which a director or agent derived an improper personal benefit, (iv) for acts or omissions that show a reckless disregard for the director’s or agent’s duty to the corporation or its shareholders in circumstances in which the director or agent was aware, or should have been aware, in the ordinary course of performing a director’s or agent’s duties, of a risk of serious injury to the corporation or its shareholders, or (v) for acts or omissions that constitute an unexcused pattern of inattention that amounts to an abdication of the director’s or agent’s duty to the corporation or its shareholders, (B) no such provision shall eliminate or limit the liability of a director or agent for any act or omission occurring prior to the date when the provision becomes effective, and (C) no such provision shall eliminate or limit the liability of an officer for any act or omission as an officer, notwithstanding that the officer is also a director or agent or that his or her actions, if negligent or improper, have been ratified by the directors.

For purposes of Section 317, “agent” means any person who is or was a director, officer, employee or other agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another foreign or domestic corporation, partnership, joint venture, trust or other enterprise, or was a director, officer, employee or agent of a foreign or domestic corporation which was a predecessor corporation of the corporation or of another enterprise at the request of the predecessor corporation; “proceeding” means any threatened, pending or completed action or proceeding, whether civil, criminal, administrative or investigative; and “expenses” includes without limitation attorneys’ fees and any expenses of establishing a right to indemnification.

Our Certificate of Incorporation provides that the liability of the directors for monetary damages shall be eliminated to the fullest extent under California Law. In addition, it provides that we are authorized to provide indemnification to agents (as defined in Section 317) for breach of duty to us, Ophthalmic Imaging Systems, and its shareholders through bylaw provisions or through agreements with agents, or both, in excess of the indemnification permitted by Section 317, subject to the limits on such excess indemnification set forth in Section 204. Our Bylaws indemnify any director, officer, agent or employee as to those liabilities and those terms and conditions as are specified in Section 317, and that we shall have the right to purchase and maintain insurance on behalf of any such person whether or not we would have the power to indemnify such person against the liability insured against.

Item 7. Exemption from Registration Claimed.

Not Applicable.

II-2

Item 8. Exhibits.

Exhibit
Number

Description

4.1

Articles of Incorporation, as amended. (1)

4.2

Amendment to Articles of Incorporation (Certificate of Determination of Preferences of Series A Junior Participating Preferred Stock). (2)

4.3

Amendment to Articles of Incorporation (Certificate of Determination of Preferences of Series B Preferred Stock). (3)

4.4

Amended and Restated Bylaws. (4)

4.5

2000 Stock Option Plan. (5)

5.1

Opinion and consent of Troutman Sanders LLP. (6) (7)

23.1

Consent of Perry-Smith & Company LLP.*

23.2

Consent of Troutman Sanders LLP (contained in Exhibit 5.1).

24.1

Power of Attorney (contained in the signature page to this registration statement).*

___________________

Filed herewith

(1)

Incorporated by reference to Ophthalmic Imaging Systems' Registration Statement on Form S-18, filed on April 6, 1992, file number 33-46864-LA.

(2)

Incorporated by reference to Exhibit A of Exhibit 1 of Ophthalmic Imaging Systems' Form 8-K, filed on January 2, 1998

(3)

Incorporated by reference to Exhibit 3.1 of Ophthalmic Imaging Systems' Form 8-K, filed on November 24, 1999.

(4)

Incorporated by reference to Exhibit 99.1 of Ophthalmic Imaging Systems' Form 8-K filed on May 5, 2005.

(5)

Incorporated by reference to Exhibit 99 of Ophthalmic Imaging Systems' Registration Statement on Form S-8, filed on March 1, 2002, file number 333-83636.

(6)

Incorporated by reference to Exhibit 23(b) of Ophthalmic Imaging Systems' Registration Statement on Form S-8, filed on March 1, 2002, file number 333-83636.

(7)

Incorporated by reference to Exhibit 5 of Ophthalmic Imaging Systems' Registration Statement on Form S-8, filed on May 22, 2006, file number 333-134368.

II-3

Item 9. Undertakings.

A. The undersigned Registrant hereby undertakes:

(1) to file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:

(i) to include any prospectus required by Section 10(a)(3) of the Securities Act;

(ii) to reflect in the prospectus any facts or events arising after the effective date of this Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in this Registration Statement—notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective Registration Statement; and

(iii) to include any material information with respect to the plan of distribution not previously disclosed in this Registration Statement or any material change to such information in this Registration Statement;

provided, however, that paragraphs A(1)(i) and A(1)(ii) of this section do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in this Registration Statement.

(2) that, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof;

(3) to remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

(4) that, for the purpose of determining liability under the Securities Act to any purchaser: each prospectus filed pursuant to Rule 424(b) as part of a registration statement relating to an offering, other than registration statements relying on Rule 430B or other than prospectuses filed in reliance on Rule 430A, shall be deemed to be part of and included in the registration statement as of the date it is first used after effectiveness; provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such first use, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such date of first use; and

(5) that, for the purpose of determining liability of the Registrant under the Securities Act to any purchaser in the initial distribution of the securities: the Registrant undertakes that in a primary

II-4

offering of securities of the Registrant pursuant to this Registration Statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the Registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser:

(i) any preliminary prospectus or prospectus of the Registrant relating to the offering required to be filed pursuant to Rule 424;

(ii) any free writing prospectus relating to the offering prepared by or on behalf of the Registrant or used or referred to by the Registrant;

(iii) the portion of any other free writing prospectus relating to the offering containing material information about the Registrant or its securities provided by or on behalf of the Registrant; and

(iv) any other communication that is an offer in the offering made by the Registrant to the purchaser.

B. The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act that is incorporated by reference into this Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

C. Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers or controlling persons of the Registrant pursuant to the indemnification provisions summarized in Item 6, or otherwise, the Registrant has been advised that, in the opinion of the Commission, such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

II-5

SIGNATURES

Pursuant to the requirements of the Securities Act, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the city of Sacramento, state of California, on November 30, 2006.

OPHTHALMIC IMAGING SYSTEMS

By:  /s/ Gil Allon
        Name: Gil Allon
        Title:   Chief Executive Officer

POWER OF ATTORNEY

KNOW ALL MEN BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Gil Allon his true and lawful attorneys-in-fact and agents, each with full power of substitution and resubstitution, for him and in his name, place and stead, in any and all capacities, to sign any and all amendments, including post-effective amendments, to this Registration Statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that each said attorneys-in-fact and agents or any of them, or their or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

Name	Title	Date

/s/ Gil Allon		November 30, 2006

Gil Allon	Principal Executive Officer
	Director

/s/ Ariel Shenhar		November 30, 2006

Ariel Shenhar	Principal Financial and Accounting Officer
	Director

/s/ Yigal Berman		November 30, 2006

Yigal Berman	Director

/s/ Michael Benoff		November 30, 2006

Michael Benoff	Director

/s/ Merle Symes		November 30, 2006

Merle Symes	Director

II-6

GRAPHIC 2 oislogo.jpg GRAPHIC begin 644 oislogo.jpg M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+ M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$! M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$" M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#S.RT^XOVE M\E0$AC,LLCG"QH.['L*D.ERMI\M_;217-M"P65XFR8]WW=PZ@'L:VK=%'PMU M-XPI>75(8[CGGRPA91]"V?RH\#JDFH:I%-_Q[/I-WYV?01E@?P8*?K7KNI+W MFNAY:A'1/=E!?#DS>'FUP7EE]B240-^]^<2%=P3&.N*CM]$WK:F[OK:R-V-T M`G)^9>FXX^ZN>,FMVV&?@U?$]1K47_HJI=,U#PYXDTNRT?Q!YFG7]JGDVNJ1 M#*%,Y595]`2>1^E1[2;OY,KDB[:;G)ZGIT^D:A+8W6SSHL;MCAEY`(Y'L:U( M]..C6D=SJ#6,-Q<1B2""Y0RR%#T)O#]WX7UT66H21W+;$E$D M3%ED4^A_`C\*F\=([>+[J^+%X-01+FUDQPT14``?0@C':JF,)'TC5-'LM=TRR33KF6=K:]L8CF- M'"E@Z>BD#IVKK],T[0&\*N\C*MPH^51R,?Y_.N"TNRCO?%%OIZAFA>XV[1QC MU_\`U^U)1BFY15K&DF]I:W_`QJ*K_:H_^>R?]]"BJ^L1[,Y^21LZ9JK:?%=6 MTD2SV=V@2>%B1G!RK`CHP/0^YI$U,6VGW-I91&+[6OESRNVYFCSDH.P!(&?7 M&.])KEG%IVOZC90;O*M[F2)-QR<*Q`S5"M.12U&IRCH;Z>(+5/!\WA[[!(5F MNENVG\_D.%VC`QT]J9<:IH]['9/<:7*ES;PK%)Y$N$N`O0L#R#ZD5AT5/L8[ MH;K2:LS2UW6KC7M2-Y<)'$`@CCBCSM11S@9]RQ_&K>FZ[;C3QI.M6C7NFAB\ M11MLUJQZM$WOW4\&L*BG[./+RB]I+FYCHFM--:,'3?$KF(_=AFMY(Y%]!@9S M^%:OA_2I?#.EWOB[4XVA2&)XM+CE0JUS.X*J0#SM&UG6>WFDAE0Y M5XV*L#[$5+J&I:AJTZ3ZGJ%S>RH,(T\A;:/8=!6IW/_V3\_ ` end EX-23 3 ex23-1fors8.htm EXHIBIT 23.1

Exhibit 23.1

GRAPHIC 4 consent.jpg GRAPHIC begin 644 consent.jpg M_]C_X``02D9)1@`!`0$`8`!@``#_[@`.061O8F4`9(`````!_]L`0P`"`@(" M`@("`@("`P("`@,$`P,#`P0%!`0$!`0%!04%!04%!04%!P@("`<%"0H*"@H) M#`P,#`P,#`P,#`P,#`P,_]L`0P$#`P,'!`<-!P<-#PT-#0\/#@X.#@\/#`P, M#`P/#PP.#@X.#`\,$1$1$1$,$1$1$1$1$1$1$1$1$1$1$1$1$1$1_\``$0@" M40+.`P$1``(1`0,1`?_$`!\```$%`0$!`0$!```````````!`@,$!08'"`D* M"__$`+40``(!`P,"!`,%!00$```!?0$"`P`$$042(3%!!A-180'EZ@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>H MJ:JRL[2UMK>XN;K"P\3%QL?(R;GZ.GJ\?+S]/7V M]_CY^O_$`!\!``,!`0$!`0$!`0$````````!`@,$!08'"`D*"__$`+41``(! M`@0$`P0'!00$``$"=P`!`@,1!`4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P M%6)RT0H6)#3A)?$7&!D:)BH*#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6V MM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_:``P# M`0`"$0,1`#\`_?R@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H M`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`" M@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H` M*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@ M`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`* M`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@` MH`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*` M"@`H`*`"@`H`3/)&#@#KVH`6@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@ M`H`*`"@`H`*`"@!`RMG:P;:<'!S@^AH`6@"*:>"WC,MQ,D$0(!>1@JY8X`R2 M!R30`)/#))+#',CS6^WS45@63<,KN`.1D74;6.&1F1)&F0 M*S*<,`2V"0>M`#Q?V)M)+\7L!L84>1[GS%\E4CR79GSM`7!R<\4`9%MXO\)7 MMQ#:6?BC2+N[N6"PPPWL$DDA/0(BR$D_2@!T7BSPM/>KIT'B72IM0:0PBUCO M(&F,@."@C#EMV1TQF@`U'Q;X5TBY-EJWB;2=+O!MS!=WL$$OS#*_))(IY!XX MH`DA\3^&KAM*2W\0Z9.^NM.NFK'=PL;QK4XG%N`Y\PQGA]N=O?%`"7?BCPS8 M2ZG#?>(M,LIM$ACN=1CGNX8VM(9?]7)&6-BKQR127"LK*P(((R#0!TEAXR\'ZK?V.E:7XKT?4M4U/3 M4UFSL[6^MYKBXTV4XCO8HDD9G@8GB0`J>QH`Q]2^*?PQT:WU2[UCXC>%])M- M#U'^R-2FO-8LH([/4!$TWV.X>2=1'-Y:,_EMAMH+8P*`(_#OQ8^%GC#5AH'A M+XE^%/%&NFW:\_L[2-9L;V[^SH0&F\B">1]@+`%L8YH`K>*/C+\(/!&JMH7C M3XK>#O"&MI$D[:?K6NZ?I]T(I,E',%S<1OM;'!Q@T`/U;XP_"30?"FG^/-<^ M*7A#1O`VKW"VMCXBOM;L+?2;J=Q(RQ07TMPL#N1"Y"JY/RMZ&@"#P9\:_@U\ M1]7NM`^'GQ;\%^/-=L;9[VYTWP[KVG:I=PVTA-XD$V<>HZYI0U&V^W:99RIYD=S>V_F^9#$R'<' M=0I'(-`'&>$OV@O@3X]N=7LO!'QC\%^+;S0+66^U-UG]K M+]F+P]J^JZ!KOQ_\`Z1KFAWD^GZC87>OV$-Q:W=M(T4\$T;S!E='0JRD9!&* M`+_B;]IW]G7P9/IMKXL^-_@GP[C3;3Q&NI02:=+>$2-]F6>- MV7S0(GRF=PVG(&*`,'PW^UA^S9XPC\22^%OC5X4U]/"&BW/B/6C8W\VTNQU2! M[JX$8W.(8BX:0A020H)P">@-`'H_Q`^(G@GX5>%=1\DM`EWJ M=\Q6")KF5((0Q56/S22*HXZF@#S;P!^U+^SQ\4Y-;@^'WQ?\-^*;KPY82ZKJ M-M9W8^T06,`S+.?VP?V9?AIXHU'P7X\^,WA[PQXITA;=[ MS3;R6031+=V\5U`6VQL,/#.CC!Z$4`=:_P"T+\%%L_AEJ,?Q(T>[T[XRZ@-* M\%W=G*UU;ZQ>[UC,$$L"2('#MM8.5PV5.""*`.G^(7Q0\!?"G3=%U?XA>(X/ M#.G>(=:M/#VG3SQS2+/J=]YAMK91#'(0S^4V"0!QR:`/*OC!^V!^S;\`_$%C MX4^+/Q5TWPIXDU"*.>/31;WM_*/# MOC3P_I/BOPCK=EXD\-:];K=Z?J>G3)<6MS"_1XY$)4CC!]#P>:`.`U7X\?"/ M1/BWX>^!.J^-K.S^+'BK3VU32_#S1SF:XM52Y/]9YOEXY+X!H`^BF^,GP[3XLZ?\$#K^?B1JOA7 M_A-+335M[AHI=%^U/9_:%NUB-OGS8V&SS-^!NQCF@#R_Q1^V1^SSX-T[XG:K MXC\;S:?8_!WQ%9^%?%LG]E:E*;#4[\N+>+9%:.TBMY;?O(PRH`[GQ)\?_ M`(5^%O$OPV$ZEXD,^L?%W2]6UKPF+"VGO8-1L=%L/[3NYH[BWCDB`%L0Z98 M>9D!,F@#YB_X><_LE-?-ID/B3Q3<:FD7VA[2/PEKAG6'*CS#&;$-MRV,XQF@ M#TS7?VX/V=?#?A7XB>,]7\67UOH'PL\:-X`\23#2;YY+77$:16A6)8"[IF)O MWB@KQUH`]=U'XX?#;3?%OP=\%R:\;O6?CU:ZG?>"6LX);FVU&VTFQBU&YE^T M1(T:+]FG5U+D!@>*`/GCQG_P42_9;\#^)/$GAO4/%FKZP?!=Y_9_B'5M"T+4 MM4TG2[K<5:*XOK:W>+*E2#L+<@K]X$4`?86C>*/#_B+PQIOC+0-4@UCPQK.F MQ:O8:A:-YD-S93Q":*:,CJ&0@B@#XQ\%?\%$OV?_`(A7WAVR\)Z9\0-6B\4W MT6GZ??0^$-4>Q>6286Y8W*0M&$1\AVSA<'/2@#I-=_;N_9^\/>!]3^(-YJ6N MW'A_2?B/<_"F<6>CW-Q M(/%/A'3;KQ'X?\7^$_#]SXHNM#\2Z#?Z/?3Z79IOGGMHKJ)/,V@_=R&/505# M$`&5HG[?'[.OB#X$>,_VBM-UO5G^'?@+6(-"U7S-.>/4%OKEK)8DBM68%PWV M^/Y@<8#?W30!]&?"?XG^%OC1\._"WQ0\$R74OA;QA:M=Z>U[";>%F^'GQ$UCP/X%TSPSKM MSH]EX9MM)16BOA;V[Q+),?,0N[_>9&SU&T`E^(]M\1_%GQ7_`&,OV./$?[16 MO>*/!GBOPSKGB#Q;XY\,3?V/?>,5TR.\EM+4W=K<71*HEGMD(E/F`^8Y:3:0 M`4_$]OXF_9C_`&@O&'[.G@3X@^+/$7PJ^+GP+\6>);/2?$6JSZM/X9UFPM-4 M*7=C=S.;B*)Q9D8W5IP9MTV$ M90#N.2L8!Q?Q4\8V'Q)O/^"-$%X;?4;=5GLYXB9F-P=PB<[WW98`U_P!H/PQ#X2_8A^+USX5^%GQ.^!6J M:GXR\)6N?'WB.ZU2_NP+U0DUJQU*]\F-!=,C!=N[ON*\`$/ACXZ^,/&WQV_8 MO^`_QD^V6?QU^`_CSQ'X5\:PGS0NL64NC!-,U='7'F+D?!VS\4VFBOXAUYA'JTNKVUN]S]I.J?:#F M-BNPR%.?NYH`^F/^"EWB[Q3I'PQ^$/@30?%-_P"!M$^,WQ3T'P5XHU[3IC;7 M%OHU\MPUS$LXQLW^6&8Y&41D;*,PH`\1^,7P<\"?L5?&W]C_`%_]FBTU#P/= M?%#XA67@7Q;X-;Q33W<%Y<7"M);B4L).-K.KGE00`?)OP`^ M#/@SXH>./C[-XF_8KU#]H4I\-+;Q:NAPZ3:27-N?LCV)U"T:7R=[S M%@IW"3;GY<``_0#_`(*Y1F']C/5Q;AD6V\4Z!M*Y^0+,X4Y_+F@#Y)^(/Q#\ M>?`/_@HQ^U!^T#H-K+J?PI\!W'P^T7XHZ7:(SS?V#XD\/V"+J:1+PS6ES:*^ M1\Q+[%?B3\&_P!@SPOKNG)XB\(>*?VD/$VF:A:S>9'#>V-_ MJ<)<`HT<@5HI^N00W%U8:1K,5OJ-I'=QI<33,C.D4:X)_Y;_P!T(``;7[$OP+U)[#]G/QK> M?L+>#K/2QIFBZROQ57QG')J9*VZ30ZO_`&0$W>;(X5S%GY#_@=K MOQI\"_M%^'/`'[*]]X_^*U[\:==L]'^*ZZS;Z7;>'/(NM/GDM94FNH78QIO8 MC9C]\""67%`'T'XO^%'C#Q-^VQX]\(:S\"/#W[6'BKPS\(_!4.MP^(M?&A1) M?6]AIL%SJD-U+&[.\LH8$8!(8D^E`&M^UA\'_B#)?_\`!//X=?"[P-I7[.OQ M3M)OB?K6@>&]%U%=3LM+UG3AIFLVT4=_B-'-R]LN68;4,A#!E4@@'DM[\97^ M/5K^WY\1+[2)_#OB.Z^!7AO3/$FD7$3PR6&NZ7W?$;X1_#GX'?"7_`()Z_&KX*>&;7P7\Z;-+HSRQ7'B&VUO2 MA+JD%U`LF)EFDV!V(Z.5S\XH`Y/X>_"CQI\1OCM^V?=>%OV8_A3\V/[./ASXCP>!M#M_B++J_B32IO$BV,`U9[- M-2D06[7GEB8H!$HVD]`*`/FK]IC1O%.I?\%#/BW=>%/@+X0_:+O]#^"-IK$W MA7QE%'-`MK:W5@)+NPBEC?S+M6(CC52&97D53D[2`>&3>%;4_P#!/KX4:SX7 MU'PSXIN_BQ^T]I?B!?"WDSIX=T&^O;>[M?\`A';BWGW2B",P*)0<@QO\A=2) M'`/M?Q)\.OCY\*_@A^U!XCA^"7[/WPJ\66WPZOH-+U;X'Z=-9>(=DDMN]_'+ M(UO!(L26L+R#:0?-1&`R`0`>&>--%_9Y^'W[#GP#^(WAO]EOPK\7/"I\/:1J MWBSQKIOBNQ$>)],\26YT\S1+?QV=SJ-Q/+=O,LD<+YB5"`H`0J`==XNO_!G MCGXU?MV7OCOQ/=_#;P9XT^`'@B?4-ZUB32H=1L[`H\D5G$T]PBO,HD"J M-Z;L[1D@`Y'X%:"OP>^-_P"R5H7Q6^%OP>^(>C^/=/OM!^'/Q*^&$MSIFIW- ME<:<(3/KNF0FTBOTEAGV2FYMCM\R5B[-D,`?1>@?!CX/I_P5!\6>$D^%/@]? M"MK\`(=9@T4:'8?V=%J(\0:?$+R.T^S^4LVPE?,"AL$C/-`'S)\*?!GQ5\2? M%;]LB[\!^$OV7M>TV#X_>-X9[CXY6-[=:VDYOF+1V3VL;@6FQ@0#_&9*`.L^ M,^B_%63]MW5%^$_PL^%7Q2\5^&_V9=-O;CPKXCL9;OP]+:VNHVZ2)X?M4\L& M7S&1+979%,+.NX$B@#YW71M&_P"'?GPY\1^$_$6A:CK_`,1?VH=+UW6-'O;` MZ?X>\-:W/;7,#:/-8J\@2TB6&-VP!NA<8&`M`'W#K.A_$#1_@!^UG)XYO?V; MIUN/@_XG2S7X,63VNK[A:L7-XTF";?:%R!_'MH`^??B;:_"7_ACS]A>Y^&?\(VVA+9_$"]_Y"&Y%U]E'V@Q"3:9?,X\S9GYL4`?>W_!52)I M/V'/BXZJQ$%WX;=BHR`#KVFIECD8&6'XT`>):'^R9\>_%?QFN_VA?B-X5^%_ MPUC\+?#;Q!X>T;PY\+A<,VNW>JZ;J%K&]\SP0HP5;WY3N/*Q@+P6H`^3=8^( MG@+5?^".7ACX;6'B_2+KXB7.IVNBP>&([N)M7?4%\8O=FW%D&,V[[/\`O!E< M%,'N*`/2_'%OXVMOVW?VJ[#PO\2?A)\,KC_A#/!%OJ-Q\6;>WNK291H-HA6R M^T/Y0*')D)5UP5RI%`'@GPM\6>&+#X+_`/!/TW(@\-:/\./VEK_3]8UV]OE_ MLJ^:">SOKC5;:>6.VCBM"MUM`VJJ[&R2 M^&_'(T+XY^"'OO[`U2TU,6QE35#")_LDLVS?Y3;&34/!4T5PUE!9?:QNGC^S&)7BB MW;OD&TX%`'WA^RCKWP:U3]G_`,)^)?@EX,O?AK\)+N.^O-+TW5[)/$\\-I9#1FL+3^TK2&\N&6*&5KE)"\> M\$D,.IP0#Q[X_>)_@AX[^$WPF^+?P7^&-YX=_9I\%_M,VFK?$UQI"VUAKD4$ MZQ7.N1V\3RF:S>-FB#,J8,@B\M2"J@'VAX[^,7[/'QS^(/B/P7\$M.L?BG\? M#\(O$_\`8/Q`\+0VFHV7AR*\LKF"WM;C5$GS#++-,%5%5BI?:VS><@'QE\/_ M`-H']E_0O^"9'B/X-^(M5TG3?B39>%-?\-7_`("NX#'KLOB^XDNUMIOL3IYK M-]J>*3S@"(L8)5H]@`.C\`ZO_P`,X_M$?L6^)/VBM;C\!V]W^S)'X-N-9UTM M;P1:I:7SW2Z;=7##:DEO!/&K;R`&ZG)&0#P'XFWFB?%+X1?M[?$G0)#K'PV^ M(7QY\$V.C:LBO'%?I9720W3V[,%.W;=H0WHPH`[OP'X<^)7P4_;Z_9)_9J\9 M7-SK?AOX/ZAXWNOA[XDN7WRW_A#Q'HL_V2UDRH^>TDLIXF/09VH`B(2`?<=:`/S*^)^FV4WPT_;\TW4 M66;3[_\`:XL5NLMY8\FZU6^:12RMD860C.1^%`'JGA3PU\5/@W^W'^RG^S!X MKGN-1\+_``HU3QY?_"[Q9-(S37'A7Q-H4ZPV,I``9K.2P:-LG(SM`$7EY`*/ MPB^/&@?`7]D#Q=^SUKWCCPI\'OC_`.`/$VOIXXT+XB>'KS5K;Q+8WLE[NCBA M@A;[7]ICDAB#Y;Y$Y'ELC$`_6#]CO6_$_C7]DCX6:QXL\+:?X.U[6O#]VIT7 M2],71+&VMOM-W%9"WL554AC>V6)UP`I#;AP:`/AO_@F7\+/CAJ7P!^!_CW3/ MVFM0T?X6VNHZQ++\-4\,Z5-;M#;ZWJ*7%M_:SN;H">0-*6VAEW[5X`-`'QGX MFLM0U/\`9\\0:;I.K/H&J:A_P41N[:SU..))WLKB7272*Y6)\*YC8A@IX.,& M@#Z8\,:+XG^'_P"U=\V\.GVL$:QWJ8D++YC``3<',;N`?#/PU^'FLO/\``SX%VFG^;\./VD]"\+?% MW6HR2;8_\(/8>)$U.S="N"+MK2.27)^]LQ][@`_=S_@G5_R95\`?^P'<_P#I MQO:`/M2@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H` M*`"@".63RHI91&\IC1FV1C+M@9PH)')[4`?AA\1M&F\5>+_'OBKX6_!7]L;X M)6?Q?=I/B%H7AKP_HUII^M3ONBGNHUN-5F,$\RM)YDB<-G=M^9MP!I>,O#G@ MO7OA]\*/!7@[]B_]IWX4ZO\``SS7\#>+/"^GZ=!K6FRW+^;=M)-)J;K,+F4F M28,H)8G:4#$$`L_#=;SP=J'Q%\8>,OV;/VJ_B]\5?B3X;N/"-YXR\4:3H\EU M8:/<1LC6FFV\>HK%`A8AR,-EAV!8$`P/&_P\\'_$?X'_``>^"VO?L<_M+LOP M4`3PYXE@TO0+;5MOWKB"=Y+V6$0SD(6'E]40J<@Y`-;XBZ'XQ\<_$#Q?\2_! M7[/W[5OP/U/XG6UM!XRM/!%[H5C;:Z+>,PQSSPW-S*8;@0L5WJ.Y.W^'X;[_B?[#J,]Q<7,MPY MDF/F%RNT'S'&-N``#2O_``G\3/%_PX\9?"[QY\%/VM?BGIWC#4=#U7S_`!9X MA\+^;ISZ'.]S&EA++')%$)FD'G@HQ<(F-A4D@'J?CBP\=_$/XV?#?]HV3]@# MXC6GQ-^&P>*TN8/%_A?3H;^,*Z1)J,4DLSRB(3/Y9!0X;!9E"A0#IK/Q%\=; M#X\ZS^T3;_L'>/V\=ZWX0C\$SPOX\\+?V;_9L5W'>*ZVX.\3>9$HW&0C&0%Y MS0!K?%_QG\9/COX$U7X)O$GA;52DK0MXW\.Q307$63%A*G*LP(!X?\`"WX7_%;X>^/?#OQ%OOV,/C'\6?%_A"S:S\+7?Q'^ M+7AS6H]`@E`A9=.CED@BB.W@;@2HY&.M`'K'P7O_`-I+X'6?CZV\!_\`!/OQ M$(?B+XOU'QIJO]I_%7PI*QU+4A$L_E`I%LCQ"NU<'O\`,:`)/CI=_M)_M'?# M^Z^&'Q)_X)\ZVWA:_O;2^E-A\6/"MM,);.3S(\2JDI`)X.!G!H`K1V_[0D?C M#XW>.'_X)SW&KZM^T%IVFZ1XTM-6^+/AM]/O;+2K$Z9!"D"P2;%:WD(?')Z] M<4`>$3_LZ?%R3X;^"/A3:_\`!/S7M*\,?#CQ!>>)]!GL?COI5M?6VHWW^LE6 MZCTW?\N!MZ%3T/4D`[;P+\+?C5X`\-_%#P]I/_!.2?4[CXR:-<^'_%^O:W\< M--U+6]3TZ[MGM9(#?W%B\D:^7*0!'MY`)R54@`Y;P-^S[\;OA]K/A'6?"_[# MOBNQ;P/?6>HZ9977[0ZSV`DL'66WB-HMJ(3&K1A3&R;&4E2-I-`'OGPG'[4_ MP2TSQ9HWPQ_8,TK0-/\`&?B>^\7ZHFH?%RQU`RZKJ*01W,J,^G`HC+;1@(.! M@^M`'C/Q.^!/Q_\`BU\1=5^*OB?]B,67C;6[.VT^]OM#^-C:2);>T18XD9+. MWB&`$&?4C/6@#J?#?PX_:6\,WGP@U&R_8BLK[5/@;ZS\5-2UC^S%*E#]DAO_M,4;;3@,J97^$CG(!A^,?V/?B[X M_P#%_B/QOK7[$'P\@\0^+]1N-9UFZ_X6SXGB-W?W0PH"S;MJ1J` M.%]``>S^$/AU^UUX%\6>&O&WA;]DWX5Z=XJ\'>"XOASI&HR_$#6[KR/#-O<& M]BLO+N7F5\3DGS9%:8]-^V@#1^%?@7]K[X(MXO/PK_9.^#?@U/'>JMK6M0VG MC/5G@GO6W?/'#.DL<*@,0(X51`.`H%`&W\-=#_;=^#GA"R\"_"_]FOX-^$_# M%O=7%W'9'QCK-XL4UW-Y]Q(SW,V."`4K/PA^W+;?%/4OCA:?L M^_`NQ^)VM:&/"]UK$OBCQ!),VCI/%<);-$I:VQYENC;EC#<=>HH`\EUC]E/] MHS7]"\6^&-5_97^`,WASQSXF3QEK.EQ^+_%\%I-KJ)<1B]CAAN(TARG> M.26$I>2W"?,T2Y.W)QUQ0!R'_#$/QO;Q0/&=O^R!^RK:ZV\PNI(KG4_%4VG& M8OSMTI918JHQG9Y.W'OQ0![@?A/^W*_B?QIXQF^#?[+MSX@^(FB0^&_$DUQ> M>*YH=2TFWC$,=G/:R!H#&(QMP(QD<'-`'GOPQ_9/_:A^#OBUO'/PW_9U_93\ M,>+29?*U1;_QC=2VOGJT&;C7)Y/&DMV^EK,MS]E)C?9Y?G1*V-N>XGDVW*C<\CL3@ M=30![!X7^"G[?/@KQ)IGB_PKX)_9%T3Q+HWA.T\"V6H6X\=B6'P[8M$]MIR[ MG8>4C0(1QGY1DT`BZM\+OV/+C2/'.NKXEUVW%CXU6.[U M9/M*KJ#0B<1^?LNI,L`"2Q!)P#0!D>&_V+_VH_"#>(O^$6^'7[(WAQ?%.C7? MAW5FLM)\69OM*OQ&+JTF#RL/+D\I<@=:`+G@#]CS]J[X7>(;;Q;X`\"?LC>% M_$]D'6UU2TT'Q(;NW$BM&Y@ED+M&61RI*$$@D'B@#U/QW\*/^"A'Q0\+ZEX* M^(5Y^S)XJ\*:MY;76FZAI7B6>"5[>19X&9&;&5EC5@>Q'?I0!TB^%O\`@IOM MVQ_$?X`:=%&L:Q06VD:ZT:J-JE1Y@)``''7/MV`/$+;]C+]J:#QVOQ12P_9< MMOB"M\=2768O!NH>>MZ&WB[7A5$^[Y_,V[]WS;MW-`$OC/\`8U_:G^(OB>^\ M9^/;3]E_Q?XJU)84NM4U;P9J%W7=G9'&JC/0`4`:OB']DK]KGQ M=X8\,^"_$&J?LU3^#_"SMIXVCC9MQR%5<^O)H`RM)_ M8@_:4T*PN=(T?5OV;]-TF[OK#59[:W^&D*1RW^E^?]BN70)@R0"YD\MSRN]\ M8W'(!U?CC]D_]K;XIWNG:C\3_'GP!\=W^CILL;K7?AM%JNS#;CD')H`YF^_8T_:>UOPYH?@C7OB[\$]1\$>'"_]E:'< M_!_1;K3M.\PEG-G8R_N(RS$D[0N3S0!WJ?LZ?MK0^'HO"=A^UMX(T?PS%;&S M72;+X5Z2MBMJ5*&V6U>Z:+RB#]W9CMTH`Y;P1^R#^UM\-8=0M?AU^U)\//A_ M:ZK*)[V+PW\'?#FEI?5(Y(B"CI>22+-N[9W\8XYH`V?%O[)G[7WCZQ.B^-?VVO# MOB?1$F29+35O@QX5U*'>BD!_(O+B:,-D]>ON.E`%4?L??M<1>&[7PC#^W%H2 M^%[`QO:Z&/@GX/7386A<21F.V$IB7:XW*0G!Y'-`&G(-&21;'4)?@UX3FNK,3KMF6WN'G\Q`XX;:1N'6@"Y!^R_P#ME)KH\1R_ MM\VSZRUI]@EU"/X/^$H[]K;<)/(^U&5W$?F*&V'(R/7F@"A??L?_`+4%^E[' M/^W#&R:I>KJ-^G_"I_"2I?"[PM/;_P4'UYD60, MX3X?^'4+*"#@'S&QWZ@CVH`JV7[)G[3>GQ"UL_V]?%-E8IDQVUGX-T"WC1F8 MLY54PJ@LQ.`HH`H?\,<_M%-"(I/VZ/$;C[<=1(_X0GP]L^T[CB?:0?WNWCS, MYSS[4`7KG]D;]H^\GM;J[_;N\675U8EC;33>$/#[R0EQAC&S(2N1P<=:`)O^ M&2/VB5-GY/[=OC.$62>5$$\+:`NR-EVLD>V)=H/8=J`/I_X(_#;Q7\+/"-WX M;\8?%;6?C!J,^IRWT.L:W:VMG-;6\D,$:V445FB1B-&A9QWR[=L4`>PT`%`! M0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4` M%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0 M`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`% M`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0` M4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%` M!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4 M`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`! M0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4` M%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0 M`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`% M`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0` M4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%` M!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4 M`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`! M0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4` M%`!0`4`%`!0`4`%`!0`4`%``<]J`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H M`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`" M@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H` M*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@ M`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`* M`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@` MH`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@#Y,UW]K3PWH/ MP6\8?%J7P=K-YJOA#QE>?#^3P?;-$^J77B&VUG^QH[2W8'8WFLRS(?\`GD](\.Z9[N5.6(9 MKV"$!?XY!G@&@#T_0?B!X"\5:KJ^A^%_&^@>)-;T!BNJ:?I>I6MY=63!BA%S M#!*[QG<,?,!SQ0!-XO\`&_@OX?:,_B+Q[XOT3P1X?CE2!M3U_4+;3;-99<[( MS<74D489L'`W9-`'/Z_\9/A%X5\-Z+XR\3_%/PCX=\(^)-O]D:WJ6MV%KIU_ MO7>OV6ZEG2*7*\C8QXYZ4`-\3_&?X0>"M.T_5O&'Q3\(^%],U>P;5-/NM5UJ MQM(KRR5H4-S;--.@ECW7$:[DR,N@ZL,@%;Q!\,/C/\(?A_HVA^(O'/Q0\* M^$=!\3*K:/J&K:O9VEMJ"LBR!K26695E78X;*$C!!Z&@"CXP^//P3^']GI]_ MXV^+7A'PM9ZO81ZKI\NI:Q9VXO;*4A8[BUWS`S(Q/RM'N![4`)&T"R>6X2!;6.*VEGEO9-P)9%D M$,6`/OS)R*`-&/\`:.^!,WQ';X1Q?%;PY)\1TNVT]M#6\0SB^12S6>X?N_M` M`.8=WF<$;<@T`=%\3/',_@2R\(74!T<'Q+XQT'PR_P#;-Z]BGEZO>1VK?9F2 M"?S+G#_N8B%$CX4NHYH`XG3OVJ/V=]6\;6'PYTWXN:!>^--2U";28-,BF9G_ M`+1@DFB>Q>39Y27&^W<+"[!VP"JD,N0#1'[2/P*/Q(_X5&/B?H;?$3[:=,_L M@3,6_M`)O-CYX7R/M(7K!YGF?[.:`*_AK]IOX"^,/'\WPN\-?$W2=6\<1SW= MK'81><([FXT_)O(+2[>);:XEA`)D2&1V0`E@,&@#C/\`AMW]E81ZU,?C)I*V MOAZ[M[#4+HP7PMH;NZ6X:&V\\VOEM*WV60>6K%@5*D!L"@#KK3]J#X"7OP^U M[XHQ?$G3XO!7A>^72]6N[F*ZMKFSOY"BQV^X%`P-`& M8O[6_P"SM_PK_4OBA-\2[6Q\%Z+J\6@:G=7MEJ%IF\/2R7\ER6%S)IFFS,;9(4A9)(7M>+OVK_`("> M`O%]QX$\6^/%TWQ#IGV!=6>+3=3N=.TF74_+^QQZIJ=O9S6=DTWF*4%Q-&=I M!.`RY`,_QI^V)^SS\/\`Q/XC$>*/&]U9ZUX,O+2R\2>1H>LW=IHK7T-M<6T MNHWUMI\MM;PR)=QXF>01YW#=E)`H!U'[2?Q2UGX-?`3XG?%CPQ8V.L:SX)T. M35;&VU#S&LYG1D`$ODR1.5PV?E<'WH`XNQ_;/_9[OM&\7ZZWBS4M-M/`^D6G MB+5(M2T#6;"Y.B7MQ':PZM:6UU8137-D9)5#3PJ\:CYF(4@T`>WGXC>$/^$_ MT_X8QZH;CQEJ?AZ7Q5%9P0RRQKI$5S%:?:9+A$,*!YI0L89P7PVT$*V`#S[Q M-^TA\+_"GQ8TSX)ZA<:W>_$/4[:PO_L.EZ)J.H0VMAJ,TUO%?7EW;6TD$%ND MD)$LLCJL8(+$+D@`YWPO^UQ\'/&.J+IF@2^)[H:E:ZG=^'+Y_#.L1:?XH31X M7GO%\/7"]6_M<0:<]PTD=LBRWDNH)'!&KSW2QQ11.&C;Y@!0!['JO[8? MP9TOP_X-UV-O%.M7?CS4=5T72?#^D>&M5OO$#:KH9`U+3Y])AM6NH;BW&6=) M$7Y06Y&"0"2]_:\^$.G^(Y]"NHO%2:7INKVWA[5_%0\.:D?#6DZU=/%$FFZA MJPMS!#.LLZ12Y.V*1@DK(V0`"EK7[97P=T'Q)XAT"]MO%KV?@SQ-%X0\3>(H M/#FH2^']$U:XF@@@AOM3$7DJ'>YBP5+;=Z%]H89`-'Q+^UO$?"OB_5O"NHQ M^))[#PUKMAX8U_Q79Z)=W'AG1M9U)K=;>PO]51/*20M=PJ^,K&9%$C*30`[_ M`(:R^&'_``EC>'1IOBQM!3Q,O@T^.!H-V?"7]O-I>-O"VARSG33JGGQ:MJ]I9O:>6)X/ M+,XF,8FR?*W;]CXVD`\NM/VQOA;>>)SX>70O&D&FQ>.I_AK<^)Y]!GBT"V\3 MPW[Z:MA+>LPYDN%54D5#&"Z*[(Q*@`ZK]ISXOZY\$/A?%XW\/>'+KQ+J$OBK MPOH;PV]NERL-MJ^M65E!Z5^VC;^$_$WQ\L M_B=X4\8W/AGX;>/8=.?7=*T))=*\-:#>:/HD\)U>Z2=`/`.N^+M-O?#'C+7O#_PY>WB\:>+=#T?[9H'AQ[B&"Y*7USY MZ2.T4%S'+,+>*8Q(P:3;0!M?M2_$3Q%\,?V,O@S!X/_;*\#_M/7_C[Q?I&AZK M\/M%T+25OH]+U%T6_OXKK1;R>2W^PPEIF:<>6=I#$?=H`^M9_P!KCP%%KVHV ML?@_QI=>`]&\4+X,U'XC0Z;;GPI:ZT;M=.:![AKY;PQI>.('N$M6@63[TH7Y MJ`,3Q7^VGX!\*R>+;\_#SXA>(/`G@CQ$?"6K>.-(TJSFT"+6DNH[&:U5Y=2@ MNV$5S*(7F%OY(DROF$T`9S_M5:)X2U?Q;X=G7Q1\5/&&I?%K5?`'AKPY8Z?H M^ESI'/A9XMT/PU\8=3\46GB.S\1V&GZ=JUDVB6MPGEO#=:G&RK;R1_:97B$BRP M!?L[S.WE$`E\$_MJZ-\1?`ND?$#P?\"?BKJNC^,+^TTSPA&=-TN.77KBX2[: M,M!U-M#:]LY9&MKFXL89AJ\EF[WD%PBPSI,T:Y;>T;`&@#K=%_:A@TN M]\0^%=+TGQE\9_B)K/Q0\:>&=`\.06NC:=/#;>&9+=K_`&W4EW:6J6%FMU&J M3W$@FD9U4J6/`!J']LWPY<6O@RPT?X6^--;^(?B_Q9K/@23P5`FF1:GI7B+0 MK'^T+RUOYKC4HK18A;D2B>.9T,1$@XXH`]G^"OQDT[XSZ#XFU&#PWJO@W7?` M_B;4/!_B30=9-N]UI^KZ:L,DT7G6<]S!*C17,;I)&Y5E84`?GQ\6OB[XY\/? M%KXKV/QB_:+\:_LP?V?K`MOA(;/PW;W'@/4M-%K;M;WFJ:K)H^IK-))<2.+B M*2>'R@!M/(50#Z$LOCY\5M+^.=KX5\0^'/\`A+O!6G_`FV\>:A)X%%OJD6HZ MPLLANKG1H?\`C^N8YG06]I$,%RP=EP0P`$B_;!U74=1\8>`[CX5WO@SXEV_@ M#6O&OAW3;K7-$U)IAI2QK);7ZV%W7,-I`"&)-4DN[N2VMUEOY]SQ6 ML49*?.'\M4S0!V-E^VM:^-1X,@^#7PDUSXG:EXS\&:CXU6W_`+1TW2H]/M]& MU)M*U&UO;BXF>,31W2^6HB,BNW(/EYD`!:\$?MIZ/XJO_AYJ&N?#/7?`?PX^ M+?AO6O$GA'Q1JUU8RM=0^'[)=0U!;NPM)KB2W'V<221,7;S%7.U2<``Q_AQ^ MW9X7\<^(O!&G:CX1@\-:%\5DG/@V]3Q-HVJZA-)'9RZA!#K&DV,\D^GO/;PL M4#&0*^(Y#&Y"T`2?#[]LSQ'XVB^#VLZA\!-5\)>#OC[#<6W@C6+S7+"=[G6( M=.N=0BM;VUMXW>WAN%LY1#/ERIZK/X"^-O@?]H;P7X"^+>BV+F&._M+^WU/ M]_`,#S-.U-42XA.,8!3JF:`/9=(_;!U^^3PIX]U'X*W.D?L\^.?%%OX6T7QX MVO6TM^9+^^.F:?J%WH0M5:&SN+K:JO\`:6=597:,`\`#O@_^V'J'Q?\`B?=^ M"=+^&FG6FB6FNZYH-W*GB[3Y?%.D/HLD\7VG6_"TMO:W%M!.UN0C1S3D%DW+ MR2`#[@H`_,OXY7?Q,^#7Q(\$^++[XQ?$'4=2\9_%#2A)=&R:U^&&@>#[_4EM M!H^K1JD\*SFW_=I<%A*]PZ.6B5A0`?M$7/Q+^#7C'0_'UQ\8/B#>:KXI^(^D M?9KN*T>U^&/ACPCD^)'P9U M=/BYC=7MI)]UVX M\QI&0J(0N:`/ML_%WP)XFU#Q?X$^&?Q,\">)/B[H%GJ*IX;.N6MS<6>H668" MNIV=E-+=Q117+(D_[O'_`-KWP-XM^-+77Q/TKQ[= M:'I/BZ+3!+8Z%)=>'=%N(_[,TB:YV+!;273&.-I/G(WR$NSY`.4^&_CZW^"/ MQV^)GAOQGXY^).C?"SPC\-KC7+R[^+NH76HC7-1T741#?:WX=N+F6\86ZP2* M)H$>/+30^7;@<9D=HL^4B&@#@O%WQ%\;_`++WC7XD MZ=I7BCXFWUKX<^"?BO5X+KXH7]UK6F^+_%VBFTD@U/P^+BYO%MT@$LDEU"KP MJT;+LMRJ^8`#K?@[XCU;X?\`BCPOJ7C+Q'\5OA_+X[^&>NZQ!JGQ)U^#Q%H7 MB:[TVSM+^XU:6Q74[\Z/`=;N/$>I_$+5+_5-#\>Z["EE>VMWX9M[FXN!9;;<7-PJ/#9M]FP MGDN5+``^UOVF_CGKGP1TOPCW-M>>(_B!KHTG2=.%O$LD<4=I M;K-?WMQ.6(CCMXB%"LTKH-NX`$\(_MC?$KXF^%?@TOPZ\#^$K[QS\3_`!=X MN\&W,VH:GJ,'A^VF\*P7%TVI6TAT];R2WG@M]Z1O!')E@C;<%J`-K3/VH_B[ MXD7P[\,M"\$>$[?X_7_COQ3X+U1KZ^O6$VT/A"VMKZ_U*&2.$7DBS0ZA;"& M$JK;W;>P$9R`>A?L>:K\0-6\.?&A_B;Y<7B^R^+WBBUNK6UO9[^QM%3[&R0V M$URD&%\-WQ^",^M+\?;C4Q`XTL^)8]%7PLFG&XV;#/]H07QBW9X#XH`X?X2 M?!CXK17G[2/@ZVT/4?"]U\&_A]XC^%/P=UF[5[:&\M_$NH:OK-G=VD[JB[;: MV_LJV+HV%:)AD$4`<)^R]\.=8M_B]^SZVGZ7\0=,N_AEHVJV_B:UO_AQI?@G M2M%CFTUK26PO-8BTZU;5?.N]AC6&6;>R"Y9AL+4`?8/[2.DW.F?%[X!?%;7O M`&L_$WX9>!;7Q3I^KZ7H6D/X@N].U76(M.73-4&DPI+-,JK:SPEXXW:+S0E0^!O'_`(6^+OB#]DSQ%HOPDO?"?B/0?#'A/0-#D\2ZGX?N[WQ# M/J!O;O08(&DL)-7M95:1(T98-@AD=0V``2_`3X$^+](^(G[-]_X\^&4UGX=T M#1?BYJ^FZ7?VL-U;>#8?$7B#2KO0]+DEC:2&.=;&215C!.P>9&O$9V@'DLOP MD\1^$/#GA6]N?A]\3/!=SX3\9_%K3_#>O^"/#5OXK&EZ5K'B26>STZ^$7>G MWC3:=?6ZF2*>)5"[0I8)*&H`DD^&/QCTF[^!WQ(\<^#O&WP^M8/A+_PAITOX M-^$]"UF71-1@UC4;ORKG0[^PUC[(E_8SVQ*)+#4[K2+K5_%5K>VNGS3V-E8VT< MQLII,111`0Q[X`S*I9@#)^"'@'QU\-]<_9$N-:^'?B&VTOP[<_&OPW?BTL)) MQHR^)?%EM>:%)>)'DPVDEI9$K*1L5=F<;A0!]'_M0Z1XDDUS]FGQAH7A/6/% M]A\/?BI;ZMKEMH5M]LO;?3[C1-:T_P"TB`,K,B37D0?'*@[L8!H`^68/AK\4 MY?A)I'[*9^"VNV/BZP^)<'B.?XG_`/$M_P"$>6RMO%HUYO$D-ZMZ;DWTMJOE MB`PB42-M;]T,D`^POVG?!7BGQQHGP>MO"ND2:Q/X<^,G@#Q)J21/&AM]+TG6 MK>YO;EO,=,K%$I8@9;`X!H`^98?@3\18?V>O#'AA/`[Q>,+/]I*/QW-;*UL) MTTP?$&;4!J32"7'&G$/G=O\`+^7':@#6\">$_BMX.T_3_@)<_L_1>*KJR^*^ ML>,1\2-=;3;CPY'I.H:_>ZU%K\+?:FOEUFWCO%A@B\CQRHTD@4/CS&7YB`#IM?^$?QL\<>/?$W[2=K$[ MG0;NR^(G@/Q)I7PUU;4=,BUC6=-\'Z9KFFW-UR'70]NKW!`%K& M'=^+7C3Q-\8;WX5W'@J'Q5\3?@]?Q>$-4O\`2FU*30O`NIS3 MZGJNJ?9KV>T$CP7S*D*322>7"%VEF5:`-#]HWX5?'KQE\1/C38Z'X(\5:_X6 M^(/A6QTGPE=^#_$VD^%-(6X6PGM[L^+I4GM-6NO+GES$@\Z(PGRE1=TE`'*^ M-?V??CC>^$/'_AK3/ASU\=:3^TQJ^J:IIWCB36] M.M=/T4>)M*L],O5U>TNIEOBU@UNTD!MH9PZ^6/W9!%`'0WW[.7Q&M_AG^W9X M.L-(74]0^+VFV^F^"[BXN[42ZN+7P7I>CI),YEQ"3=V\B_OBG.6^Z0Q`/=_C MW\,/%7Q"_9.\>_"?0+*.Y\9:]X%&BV=K)<)#&U^MO&BHT[,$"[TY).*`/*(_ M!WBSXD^/[SXF_M'?#G1/@O\`#?PC\+M=\`ZC97^OV%]%JP\2SV#:C-)(G\&>*_BQXR\10^--1\17-OX&\)Z[ M$&*7?@GP+YVD:58K]"``#V'4_@MXB\0_'CXX^*=1$>G M^"?B5\(M'\"6FHPRHUTMY'=:\UV1#PR^7'?QL">&)X/!P`?,OP)_9?\`B'X2 M\2?`O1/%/PICTNT^",BRW_C*_P#B3XE\0Z9J,FG:;<:;9S^'O#4NJK;V6'BK4#=)"-/^%VA^+_#_`,0_'M_XFMO'6L>.?$5KI]AI>M:H M=5NX-1\(V5[:Q7-S;M(\<1B=$EQ')(58-N`/=/&_[./Q'U_X'?M:?#^PBTMO M$'QG^)-WXH\.B:Z*0?V?/)H3*UQ((F\MP-/E.W!_AYYH`NQ?#O\`:<^'WB;X MF^#OA1IWA4>#?BO\1)/'\\/0:G)9S:O9RZ%+93"ZEW6TBVS+.J8 MD4OLV4`>':?^Q9XTT;6T\#0_#'PEKOA8>/'\1Q_$;5/%VO23KHDVMMK!MIO" MR>7;R7\:MY*2"41$A9B-^Z@#[N_:#^'.N_%#P3H'A[PZ;)=0TSQUX,\1N]]( MT:+::#X@T[4KLHRQRGS#!;.$&!DG&1F@#PQOV<_'A^%7BCP5')HT6JZS^T*W MQ/MBMQ((1H9\>6_B,+(WD$B<6<1&P+MWX7=_%0![;^TM\/\`Q1\3O@[KOA3P M5'8W'BE=7\-ZYI]OJ=P]I:W,GA[7],UDVTEPD-P8_-73S&'\MMI8$C%`'@^M M_LZ_$KQ)$_VSO"EU_86G^(_VCM2NM5T&U^W37%G92W?AS1M.:.ZN?L43?)= M6,@#+$!?ASXQTGXO7T.I_\`"6>*]2U6 M*_\`#%Q/:6=GJ2'1K:!K;4HA]E,ML&EB.YS'+E%!(!]I_'KX2ZM\1OV;OB'\ M&?"4VGP:QXB\(2^'=*EU#=;622B!8H6D\B&8HHV#[J''84`>??$K]FV]-Q\- M/B;\#K+PUX&^.?PSFL;?[2P?3]+\0:&YBBU30]7GL[2:9[>2-2\+F%VCE5&5 M5RQH`^8V_8(\0Z?XRUC2-(\&?"K4?!&M^.V\6IX\UM+Z[\6V&G7>H_VI=:8- M*DM9;">97+00W#S`+%AVC\Q1@`\;^*>K^,-';XK?LC_#;Q!HES;>,_BHM_8> M%]3T36X_&:QZWK]KK%XML4A?36TP,\LRW\DPQ;!E9/,`-`'UIX\_9.^(>MZ? M\3H;.+X=>/M-\VTUE)+% M+;*P((1R59@H`[P#^RY\7_`T?3=$OKN"[O)O[/A91;K<*@D.0S1KB@"I?_`+)7Q0MOV9/V>O@YIVJ^ M$O%6J_"&XC;Q+X;U^[U2U$>*K;[->P_9[R:QMVNBL,MS'/$K0LC/&/,0C&` M#E?#G[%?Q5$^`O$%CX>OOAMH_BI/C+X9^+_`(+=MLJJS2'YW1"[``'>1?LK_%KPAXHNOBM\./%WA1?B79_$/QYXEL+ M#7H+V31+S0/'36#SZ=>RVP2XCGADTZ*1)8U*Y!4J0QH`W?`G[*OC/0_'GPP^ M*/BSQEI&L^-=.^(?BWXB^-VL+:>WLY[KQ'X;E\.VUCI,:9I%BMO-OZ MNKZ#==^&7Q/O[^]>V^)>F:EK. MK>&TU;B\M=,EAO5AN+9-[M!!<*%CR(_N+R`8-]^QMXFT6U\->%OAM\1H]!\* M6_P/OO@QJFI7L=RVNP+B6>RU73Y8)HXQ(;F3,L;;0(\K$5.TJ`8/PO\`V+?% MOAOQ_H?C?Q#/\*O!UAI_@WQ!X+N?#_PP$RZ)!/%K<5JIU&:[FO)I9KC?;\B M1<*OW269C0!F#]BCXB6_A_X2W[ZK\)?%WQ"^&7@.T^&$L?C'P=+K?A^_\/:0 MQ.D720SWGVFWOH=SM(T)O".OOXUMM9&@_#/5 M_`U_'!HUKIBW6H:QK<6M37\,%B8;>"%'#QI`L9.TJ6D9@S,`8^@_L@0V?A/] MF'P?K_BR+6-*^`OACQ!X9U>..S>'^W(/$&AR:-,8F^T,8-HD+<[\CCCK0!Q_ MPL_8R\6>!_$O@==;\;^"KOP1\+(+F#0GT'P19:3XFU@/9O9V;:_JJS2B0VZ2 M$G[/'$9G"R2'.10!Z7X:_9=N?#_@3]DOP6WC2*[;]F;5K74Y[L6!0:P+;1M3 MTO8D?VEO(RU^'R6?A2.]`'??LX?"3Q)\#OA]-\-]:\4Z?XLT;1];U6Z\.7-I MI\EA^%/%JZ=)?:?+HVM>(8/$S6L3>;;(;FWO;2YMY(S*&1&AF^9 M7&0#V'XW_LF^&?C%\6/@I\8X->E\(>+OA)XCTW5[U[:V,\?B#3]+N#=6^GW: MBX@`,4K,89B',8DD`0[^`#B-'_9#\6V4WACP#JGQD&J?LW^!O%4'BS0_`ZZ% M#%J?F6-^-4T_3+W6?M+B:RMKO#JHMU=E5$9R!R`,MOV.O$5W\8?!WQ!\7_%B MT\5Z#\._$]QXIT!Y/#5K!XR+2?:1;Z7J'BI;EYKFQA6Y*^7Y*F151'.%H`^P MO!>D^*=%T%+#QCXM7QOKBWE],VJII\6EAK:>[FFM+?[-#)(@^SP.D._.9-F\ M@%B*`/E+Q-^R?XS\67_B7PGK?Q]U;4OV??%OB=?%.I>!KW2H;O4V6/3VN8PPB$'F*F8UE5:`%\9_LG^,?&M]XT\+:I\?M8F^`/Q#\0_P#" M0:[X"N]*AO+]_.N8KR[TRU\0371F@L)YH\F%8"R(S1QR*IH`D\J M^.?#Q^/NMV7P(^*6K/K'BOP)<:;!?WDK7)C:]L=-UV>$M&TO7KN.2*?4K2PMX;R6.5UDD62X2-9&#.H9 M@6Y(!/-`'CMM^SIH7V#]HG2K_P`3ZQ)I_P"T1K$NKWQT^3^S[O2))=*LM,S8 MW,19O,7[$LBNPQNP"I`.X`X[PM^RY?:AKP\0?M$?$L_M'RZ;X=O?"FC:?K?A M[3=/TRUT[4Y;.74'N+2'SUN;FX.GP!Y7(`"X5!DF@"HO[#7[/]K\1O$GCS0_ M!&B^$;;Q'X`G\!_V1X;TFQTF.R^V2WIN]6LKBTACEAO9;>]-N94PWEJ%R1Q0 M`N@?LF2WUY$WQN^+NN_'G2-$\,:MX0\/Z9K5AI^FQV6FZ[;K9:C)=2Z?#%+= MW4MJBP^<[#"ER%WN6``>$/V2$M+VQ_X6K\6/$'QJT#PKX8U7P9X3TC6[2PL8 M],T?6H%LKTW,]A##+=W3V<:P?:)&!";SMW.6H`T/AG^R[J'@GQ1X$UGQ;\9_ M$OQ2T/X/6=Q8_#S1-8LM+M$T5+BT?3C/^%?B3JGPM\>_#F+5K+3M8L-/T[54:QUQ+9;V)K35+>YA M#DV<1250&7!'S*Q%`',?#K]E#PY\/=4\%:R/'?B7Q7J7@KQCXI\;17>M-:/< M7NH>+K&2SU#[6\%K`&&Z9Y5VJOS-C[H`H`BUW]E'1[F75]?\(_$+Q#X"^(=Q MX^U;X@Z3XJT^.QN;C3+S7+&VTZ_L1:W=K-;3VDL-JFZ.5&.X*V[*B@#TSX(_ M!RT^"OAO7]#A\8Z]X\U#Q5XBOO%.KZUXC>V>]N-2U)81:XTD'B6/P7-XA30]1?PU M%XEE9431GUI;GZ_?F%;?3+S6(X&M8YB]S$C`OM1Y%1V5CB@"MXE_:M^%' MA7QCJOA+45\1W-MX;UBQ\/>(/$UAH=]=>&]%U;4O(^S66HZK%$T,3DW<(8Y* MQF11(R$T`>]>)?$6B^$/#FO^+?$=^FE^'O"^FW6KZI>R!BEM964+SW$S!0S$ M)'&S'`)XH`\(\,?M4?##7K+Q=>ZS;>)/AQ_PA7A@^-K^#QGHUSI,[^'%\S.J M6R.K^;$#$00OSJVU60%ER`3>"/VGOAWXPE\16^I:;XF^&MWX;\-OXRF@\<:1 M-HSS^'(O];JUMYA';(QB[U*R:3<62$31F1'"2JKJ2F#0`OP[_:I^&WQ#U># M1AIGBCP//J?ANX\8Z+/XPTB71[;6-`M&B%QJ-C+*S*8XQ<1,RR;)`CJ^S;D@ M`7X>?M2>`_B1XD\/^&]-\->,=`;QQI5YKG@W4?$.COIUAXGT^Q$+S3Z9+)*6 M_P!7.DBK.L3-&P<+M.:`/5_AK\1=`^*?A.T\7>'H[NS@DN;S3KW3M11(M0TS M4M.N);2^L+V*.294G@GA='`=EXRK,I5B`=?=:IIEC/9VM[J-M9W.H/Y=K#/, MD-# M!);R%RL.[8I<*10!]C1>,/"DSZ'$GB33!/XFMX[O28'NHDFO8)5#I);Q.RNX M((/`-`%JY\1^'K+5K/0;S7=.M-,OB;X%\,ZC]JU[X3:I;Z1KB,T.TW%Q:07>8`DKNR()Q&[,JXD# M)SMH`\N\=?M#>+M#^,.I?!GX??!'5?BEK^B>%=/\6:A6< M48_M&:'AH`Y?QW^UI>?#6R^'&E^._AK:>"OB5\3-9O-.L/"_B#QA MH5G%;6-E;2W#ZE=ZFD]Q`D3^7Y<8`+-(53[Q`(!TGPA_:M\"_%+0_B#XWO+W MP]X)^&_@[Q#<>'['Q#J7B?3)!?/:W5U://G>`KA$EB\2W.JV<.D.DA*HRW[S+`0Q&`0_-`'G M>K_M)_"+2O&_P@\#Q^,]&U2Z^-D-_<>'-0L]5L)+&>.S$:Q[)?M.93.40748"MM;RVX-`%G5OCY\#M!7PK)K7QB\%:7%XY3S?#LESKVG MQIJL9?R_,LG:X"RIO^72= M/2$^+?/'V)?$\EF^K)X?,'E9\TZ7&;GS/,]$V9.:`/1-8_:!^!GA_P`60^`] M<^+WA#2/&D^H#2DT2\UBSAO_`+:T4,RV[0/*'5V2XC*@@;MR@9)%`%GPM\=/ M@QXWT#Q/XJ\(_%/PMXB\,^"C(-?U6QU6UEL],$2-(SWZE2&!+J3>! M%YCR*%+X!SQ0`OA3]HCX%>.-#\7^)O"/Q;\*Z_X?\`(TOB/4+34[=K?2X@LC M":Z*;J^AN-+634]5O-*DTO4+6>'RT`6&*0F1OF65?DVD,0#J;3]KW]D70O#BO MI?QJ\$V'AO0+B'18K;3KF(16H6,>2L5M;J2MNL8!$JIY(7G=B@#O?B%^T;\# M?A5/H=MX_P#B;HGARX\1V8U+3TEF,QEL"=HOF\A9=EL3QY[[8_\`:H`I^/?V MF_@'\,;JSL?''Q2T71;W4=(MM?M+<2/=37&DW;7"PW\,=K',SVY-I)F5047& M6(#+D`YFT_:F\`:K^T!X+^!>AW$6M?\`"<>`[CQOI_B"S>::TG7S;,V4$!CM MGAD2XM9I9A/YP0>6$Y=Q0!0_:O\`VC[[]FCP]\-_%%MX,G\V<*`^;)!%IY;8<`C(++P:`-35_P!H6PB^*7[/WAKP^=+U M?X=?&_PIXH\4IXH-R46&VT&UTR[ADCSA/+DCU#+E\8`]C0!T?PS_`&E_@;\8 M=>N_#'PX^(5GXDUZTLFU,6BP7=JUQ8I+Y#7=FUW;P+*[G7+/4?&.LPFRL9KK2M&;55M]&5F# MW6,J)9MHB7E%+ONV`'J_QW^*=M\$O@Y\2/BQ=:7/K:^`]"NM4BT^!)G:ZN(T MQ;PN;>&X>.-Y6422["L2;I'PB,0`>6W_`.V7\!_#>A^#]1\9>*;_`$'4/%7A MZ'Q+)8'P]KTMSI^G.S1/>ZC;QZ:\UG;>;&ZK-/VJ_B MW#K^L^%M;^`GAS2;/QAKWAFPTSQ!_;G]KLFCZG<:>CRQP:AL+R^2&&TF*`,&Y_;Q_9SLX-6DNM9\4V]UX>5KG M6=/D\'>(TU#2]-6.*8:M?V;:8)K>Q:.9&6XD54;/!R"``?7]K=6U];6][9SQ MW5I=Q)/!-$P=)(Y%#(ZL,@@@@@B@#\P/AQ^U%^T/\5-0USQ'X/U[X27.I:)X MDO=*N/@+?/-I_CJ*PT_4)+6837]YJ5O''>M%&9%)MC;GA=P.2`#]"/BIXJUK MP+\,_B#XT\.>')O%_B#PGX=U+5]-T2WW&74+JSMI9H;90BLY,C(%PH+<_*"< M"@#Y3_95_:-\;?%[QAKOA;7_`!/X!^*&DV_@[1_%H\4_#>&YAT[2+[5)IXI/ M#VHBXO\`4(/&5U-9^ M'_#GAK3+G6-:U26UB\^Y^RV5JCN4AB&^1VPB#&6RR@@'RA\4/VMM3\3:O^SW MX6^`MYJ6G-\7O%>KZ'K>L7GA.\U&]T230+2ZFO=,FTFYET]XKM98!YRRX,4. MZ8!DVD@'U%^T+\6G^"/PB\5_$2UT<>(=9T[['I^BZ4TGE)>ZOJUY;Z=IT$DG M\,;7-TF]NR;C0!\Q>,_&'[7/[/'AO3?C'\5/'O@3XH>`;"^L!X_\-:1X?GT6 M;0M.O[F"UEN]%U!K^Z:Z%HTP=EN(E+H&P5.-H!ZKJ_[9/PJT3Q3XK\.WNB>, MSIO@'Q'#X5\4^*(-!GF\/:+J-RT"P+>WZ,0J.;F/+JK!-RF38&!(!YIX<_;+ MB\.^+/CSHOQ/\.^)KSP[\.?BG)X7@\3Z+H32Z)HVD7-KHXLO[5O5D4;Q26[N%NII(O+1<1O!C]YF@#Z/A_:U\!)H/CO4M<\'^.?"_B'X>W MVCZ=J'A#4M%W^(+BX\0R&+2!96UG<7<4XNG1E1EEVC:WF%`I-`'G?Q/_`&J[ M\_#3XE77@[P[XB^&OQ+^&GB3X?66J:1XPT^R%PFG^+?$FG6"SQK;W6H6\D4] MLURBLLF593]U@#0!JZI^W/\`#/2-2UJ"X\`_$:?0=`\<:E\-KKQ'::%',/A#X MBTCXQ>'/A]XD\.Z[H>FW6IO-J\*W,%G<*NI3P16UW#*?$5[X5T3Q^-)A?POJ&JV#7$", MR6DJ+.]JL+,AQ)CF@"]^UY\0/%WPN^`WB/QMX%U;^Q/$NFZ[X2M(+LV]O<@0 M:GXFT?3[N,Q7,4T9$EO=R)G;E<[E(8`@`X+QA^W'\/O!.H_$'^U/AS\1+KPC M\*/$\7A'Q=XOL-*L[C1]-U.Y:U6V7"ZE]KF61KR(?N;=V4NF]5WID`Z:T_:T M\-BP^)IU_P"%_P`0O#/BKX6IHD][X1GTRTO];O[?Q++)#I$MA#I>H7T+B9XF M5M\J>2P82[`,T`9,G[9O@O0H?B3:_$/P!XP^'?BWX96&AZA=>&+U-*U+4M23 MQ'=M8:7%IAT?5=0@EFENE$1C>1"K,"V%RP`.$^)O[7HM/!7QIT'6O!/Q(^`G MC[X>^`X_&LES=6'A_4KJ/3KB^6SBN--VZK?6-S)NX*NP53N5B&7!`.O\8_MG M:)X2U/XO)#$/'?B+PO\`]3CL/'GB73TTE;#3HI+6VN_M%O'<:K!<702.YW2 M)%$715+,/F3<`.\>?MFZ%X1A^)NO:!$O&_Q*^'OP;#0^+_%OAQ=+^PV5ZMI M'>O;00WNI6=S<>3'/&;AXHF6'=EC@-@`^O\`2[^+5=-T[5($>.#4K:&ZC63` M=4F174,`2,@-S@T`?D!X%^-WQ2G\0Z+9>//VHM3^%O[2USXC2+4?A3\2?#UM MHO@:\M&U$1-INE:BFCF20-:Y^S7$5X\DS[,KAS0!]UZM^U/X6T?0/BG?W?A? M65\3?"_QY9?#U_#'[@:EJNIZO-8QZ-)8@R[3%>QZC%+&S$80.6`V&@#`^&W[ M6@^*OBF[TKPA$_$6H^%QJNN:%;>(8;_`$F;R=0T)KF-UU?38;U[W38KB6T= M()+B(;B8RRH)%-`'C?PH_;0\4I\&_AIJ_P`1/!TFN_%/XH^)/&%AH%@FK:)I MEK=V'AW4KI;R[GO99K>UM8;)"EMAMTLCJI"N7+4`>CVG[:^D:[I?@B+P;\,- M=\6^.O&7BW6_`;^%[34-)\S3]?T*P.I7,4^H"\>S>W-L/.6>.1@8B&"EODH` MA\*_MHS>(;KPA=:C\$O$GA;PEKGCT?"O5];U#4=+?^S/&/VJ6Q-E':P7$LMS M;BZC$1N5VC)SL^5L`'2_"[]J\_%?XB7_`(3\._#2\;PQI_B'6O#-UK2:UI:6T=(7<$G=$611(,`'L_P`9/BM:_"+PMI^M'P_? M>+M=\2:YIWACP[H.G/#%/J>L:K+Y5K;^?M)V@\.>*MW]KI_@+PM)J^OW.I7TFLWD$ M6GVC7-ZTUZ41[ED$;Y?:-^,A1G%`'@'AO]JCQ1/>>#6^('P0U#X=Z!\5=&U' M5O`VI2ZU9ZBU])8Z=+K"6&IP6\2FQN)K&!Y47=,ORNA;$KF*']I.PGOK6)[M-VDB'PS?>(]DI$1\TE;(Q9`7D[NVT@&G^S5\: M/&?QZ\!V7Q(\0?"M?AGX8\2V-AJ7A@OKD6KW6HVMU&[2R3PQ6=L+<(RC8"SE MU8,0ARM`'T50`4`%`!0`4`%`'Y@?M!_$_P``^+[G2+#P3\0?['^('PU^*^D1 M3_`B^MM-@NO%>MV?B""5;V:Q@3^TW216%[;W*3&W*JLT\;8<*`'[47Q2\`^* M;/6/#/A3QW-H?Q5^'/C_`$Q4^"&H0Z;;MX_UFTU6PN[&2>QCC;4KFVN1''+# M/%.L6`&N(VVE%`%_:Z^)WPZ\4^'_`!UX#TCX@:CX(^+/P]\16\]K$;FVT^, M?$C5HI=/U#2DEL4AEU"]LKMH4C66WN(E&7^T*=FU0#VCXZ7?[3?_``KOX_#4 M/!7PY\0_#R?P;KUMI&E:?-K.HZ]>17$#1!;RT-O:P.!;R2&2*&0LY4+&V7X` M/G+X->+_``5X2^)NO:_\,/B+XE_;(\)>'_@G=-XGU28VVKZOH_\`8]S;R:=H MUA+%%I]MNU%);EWLY`UPS0*S.R?"?XGZ-/ M\3[+4_@1\1/'?[17@>/X<>(=:^)6EZK?W&L/::Q:_8)-%M;..^:&"PU&\?[5 M$UA$8HMJY:)!&&H`\V\<:[I'[0/Q&US5/V>O'&J_%?5OB#\%_B#X9US2-2@1 MH/A\-1TE3ID%MY=M:BQN[G44B@E@E9Y9%0L2!$20#KOV:/%.FW/Q,^!6D_!S MXE>./'LD_AC48OCAH_B:^U&[M?#\MIIL2V$(EOI=ZFI*(([>V2(-")?D M*H&H`^IOV;E)\>_M%)?B](-/'\!OX_#GA]-9,?'3[<)`V.-X?^+=0! M\C?'?3?@[%\3?VI(?VCO",GB7QMXOTS3;;X+/+I%YJ5Y/81Z'"D5GX6G@@G, M%ZFL^>THB9)`SI(Y\L@@`2P^`MMX_P!3_:-U3X_?#VP\>?$C1/@7X#L8]0UF MP6^6+Q`?#VK'5I]->1)%6X-W`A,L)\Q<+AAGD`_0WX`SZI=?`CX*76N274NM M7/@+PW+J#WN_[2UT^EVK3&?S/G\PN3NW'K_`%*\.EPZ%I]OX9A\ M.:I;6CI9"QU%9/."RQ^6VZ27--,^._[7FB_"JYT'X4_$+7_&FA>)K;6=<\(W&J6.H^&[CP]81W(MI8+G M2XV9]2WLY%PQ$BR;HRS%P`>9_$[PTVA?M4W6M_&K6/B_),GA9KUD`21'$,D[!-W!Y%`'JVDZ#X3\9>-?V3+_`,*> M&_B#XL\*^$?&'C2VU#5?B9INOW&JVZW'AK4)HGN[CQ)!]K^S&:X2.!Y#Y>\! M$)9:`/GC6OA'XMT;X?\`[/VMWGAO7?"OA'P=\3/BS>^)8M,\$Q^)[RQFU/Q' MJZ^'=6N?#L]G,;<-0!9\"_#[4?!L/P\^)/BOX;^./& MOP8TOXM>,/$%WHNH^#T6]@&JZ';V6G^(H/!NG6GG6]J;N*X*QF`R1F4S^4F_ M(`/8?"EE8V?Q*_9O\>:'^SIX@^%7@&]\;?$*SM[6+3+VYN(O^$ABLQI^LZGI MT5F9-*BO;B&5O*D58[<;7D9,X`!Y8GPU^.OPZ^`?[,VL?##P-K0^*'BOX8?\ M*0\4VXM)H[K0DU<+<:9KE]"ZH\*:7<).69]H43G=0!E?$KX&>(?AEX[^,?AJ MWT+XE:M\//&W@KPMX7\%6W@?P7HOBRVO=)T31(])DT2^O+_2M1?37%Q$THD= MHH3YOFY+J:`/U2\!65_X'^$?@O3=8M=3O=3\'^$-.MKZW:5=4U.:?3["))HS M+!%"MQ.S1D;D11(_*J,XH`_,ZZ_9E_:*N/@9[EL0+$Q[L?\L\;.*`-;XB?!?Q/\1?A_^W+J,_PFU*74 M_BYXL\":MH-E>:&))8D#J'/D2)<(XR-K"4+ MO&'[2S>!/">H1Z)K?AOX1WMI!H\-G;C6E\*:[J=WJ6GV9O8GLWN8K1$,:3(T M9/E(ZE&Q0!Y7XN^#WQ`^)_AG]H'7]'\&_&3Q*_B?POX*\-1S?%"UT#2+[67L M?$]EJ$UM%H&DZ#ICR)96RR?Z5-+C:[Q)&ZKO`![9^TW\"?'OB_XL?$G5_!/P M_;7/#,OPN^'Q.G0BWM;+Q%<^%/&]UJ][H+/)M3S)=.C5$#?+@HC$(:`/,/C1 MX.^(GQ[U/]ICQ;X4_9Y\8>#['QE\)?"WA2PB\1V%M8:AKVIZ?XE:[N,VD=S, M1Y5LX0%R"4C_`+FR@#Z6\E/:7VBZW#K$,OEPR2SEUFC8IEI`ZD@4`?0O[.'P*\6 M_#SXK>%+GQ%X-ETWP[HG[.'A;P,TMY?0ZPMMJ,&NZU=W>CF]$5OYWDPSPABL M2QD!<9`%`'%_LR_"WXJ?#'Q=^R/?>+?A_K$=II_P&UCX>Z[/`;:9=!U MJPKJ7^D`I$\-BT:-&'_>%5P!D@`^J/V@O!/B'QAXB_9GO-`T:;58?!?Q!Y8H?V M<;SX?_$ZT\)WC2HK^$=4\>:?;VUWH[J9O-:R^U6ZS6X2/Y%EECSA%H`]O\`Z M;\6_'?Q"_9ZU;7O@'J_PDTW]FKPWK=MJDNI7VDO'JVIWFD1:3#I>A_8;VX,E MH<&;SI1$F4C&W(H`^Y?!^LZOXA\+Z#KFO^&+OP5K6J645S>:%?307%SI\SKE MK>66UDEB9E/!*L10!XC\4O`OBOQ!^T!^RUXTT?2&O?#/P^O/&+^(+T30H+)- M4T)[2S8QR2)(XDF^3]VK8SEL#F@#L?VA?!FL?$7X"_&GP#X=A2Y\0^,_`^OZ M-I4,CK$DE]>Z?<0VR-(Y"J&E=06/`ZT`?%WAVR^/OP[?Q+XLT7]FO5O'-Q\9 MOAUX7\/OI-UJNAVMWH6M^&K6_P!*:VUD3:D87L;A)TG62!Y"H9U>,,>`#[1_ M9]^&^H?!_P""'PJ^%^K:FNL:KX%\,Z=I%[=HS-%)>^+/@[\<[CPO\9/V9]+^&*:CX*^,?Q"U3Q0G MQ2_MG3XK73='\0ZQ'K-\;FP>07[W]J2\,`2(HQ$3^8H5A0!Z)KGP+^(E]\+_ M`-J'PQ!H=O+JWQ/^,4'B[0H#=6P6ZTE)_##--([2;4.S3)ODZ5H]O<1_&_X.Z3X0\(2-=0(UUJMKI?BJUF@DW.#"HEU.W^ M=]JG.<_*<`'UAX$T?4-#^'_@WP_J'^B:KI'A[3M/N?+*2>5<6]I%%)M;YE;: MRG!Y!H`_,?XG?!#]I3XL>&[CX:?$3]G?X>>+_B?OCL-._:0M=6T_2KBSBAE# MVVM+I]O9Q:G%=Q1JI,$+B(RCY6$?!`/IOXL_LGW?B[P/\6;7PS\5O'D_C7X@ M>';_`$RWM_$/BW6;GPTMS=A&D3^RA68V\J/\`=QNXC7H*`,+X&_"O MXACXVV_Q5U[X)^&OV;_#_A[P)/X*?P_XVD]O=3C3[:WMUMK. M.U=;;>/._>MD(ORT`>A_';P/\2T^)'PC^.7PJ\-Z?X^U_P"&=GX@T/4/"6H: MDND-J&F^(DL2\]E?2Q311SP2Z=&<2+M=&==RD+0!XWX`_9S^*UC\1OA#\5O% M5EH^GZU=?%CQU\2O&NDZ=>>?!HT?B/PI-H&G65K,T4/VIXUM[<32!5W2,[J- MO-`'U1\?_A,GQN^$WBKX=)J[>'M4U,6E]H^K*@E^P:OI5W!J.FW+1G[Z)7EY8/X^\3:%KUSK%Q MX@L+&X@NY+/1=.>SMVLQ#5=(@;3/#TFJ)!I:64JW+RVS(MLXG39)O\P;0 MIH`]^\0_LV_$#5?A%^V1X&MKK1UUGX\^/]1\3^&WDN91`EE=:?H%M&MXXMRT M0:G&BS0,SGYE8(IS0 M!XIX<_8I^*5KH?QQMH=!^''PZB^+EW\+[VQT/0=4U>_CT]O`WB9M5O?MU_>V M`ENII[5\B;:,R8C*JB^:P![._P"R]X^/A%]"CUG0!?\`_#3I^-:.\UT8?[#_ M`.$I_MP6I(M-WVOR/EV8\O?QYNWYJ`+/B_\`9B\=>(/BAXN\;6FLZ%#I>O?& MWX=?$JWAFFNA<+I?A#1+'3;Z"15M&47$DMJQB4,4*X+.AR``2?"SX.?M+_"Z MY\'_``JT#Q?X+TGX`^!_$UWJMOK-LMS<>+-1T":XNKR+0+FQN;%[*/\`>W/E MR74<^\QJ&14D)P`>T_M,_"K7?C5\&]?^'7AN^L--UC5=6\-7\5QJ;2I;+'HV MOZ7JLZLT,4S[FBL75,+]XC.!D@`\&\:?LJ>-O%'PJ_:=\`V^OZ';:A\;OC!I MWQ"T>YD>Y,-KIUG<>%)GAN]MON$Y&@S`!`R_,F7Y;:`6OCA^S)\2?B#XA^.W MB+P7XRTO0I?B?X>\!Z58VMU<:A:II7FI:?J<]@$GCM+Z"\$+-`Y?:7 M!7'W@#YEU?\`8Z\1_#CP[\5_B=K^E^"_`4;:#X7N=)T3X.Z!?ZI_8NL^%?$" M:M:ZG-;7(MIM40%R]VY5)3"I1$)1"0"A9^%?C#^V/K?[0@F\6>&-4TKQ-\&[ M+P+IWB'1-#UO2/#%MK$NLRW[VD4VK![N[D6*,23ND>V+S(X\%@Q8`^R=8_9J M\3ZC\/OVR/!Z>)M--_\`M*7VI7>D7'=.T<"\55SD36;L?+W#:1W MRM`'PI\=A\0?AUIW[2'[/WPNUZ:U/QDBE9O#&I^"-9U+6-8U?6]'L=/O3X9U M:RG&G-8WA0+++=%7M&\[*8"9`/V5TC29+;PMI>A76[>P^V;8@AO,%R7<7<$0NKBVL]9NY6DB9XPJP98MC`!8TW M]D+Q_+\>O"WQ/\1^(_`?V3P7XIO/$58E&$+,U`'/)^Q'XSA\*>"]+DU3X<>)M5^#OB[QE>^"[;Q5X>F MUG1+[PYXTU`ZE>VFMVP\,>&[70-(=O$'A^[T.+3]-MK3:4BM5F0B2X:660*= MS\J%`-6+]ES45\+/X>D\7VID?]H-OC;YRV3`"W_X2?\`X2!=,($P)DV`1^:3 MC/.T@8H`Y&W_`&2O&=U\=/#/Q)\2>+?!NHZ1X-\5WGBG3_$-CX8&G?$*]BG2 MZ2WT35-'_&.D7NB:G"K;3)9ZA!);7"!L M'!,?LC?$CPSJ'P-M?%GQTL_$O@G]G M6'4M/\):+9>%UT^>YLKW0=0T&%M3O#JEQYD\,-XI5HXT0[7#(3('C`/J'X)? M#4?!SX1?#CX5C6?^$A_X0#0++0SJ?V?[+]K-I$L9F\CS9_+W$9V[VQ_>-`'J M-`!0`4`%`!0`4`9IT;1SJ@ULZ59G6EB\@7Y@C^U"+G]V)MN_;R>,XH`=+I.E MSZA;:M-IMK-JMFC16]X\*-<1(V=RI*5+*#DY`-`$CZ?827L.I26-O)J-O&T4 M5TT2&:-&^\JR$;@#W`-`%R@#FWU[POI7B/3?"!O[*R\3>([6^U>TTU<)<75O M8/:Q7ER$4/-"'B?P;J,>JZ)W&FWJ%)HXGS'` M%`SDJ"`=&R95PI,;/GYE`R#C&>01D>XH`\6TY?AG^S7X)\'>&9K^[L-(U[Q1 M::!:7EX)KZ]U/Q'XJU%B)[R:*,EIKN]NF>25@J`M_"@``!J?&'XW?#7X"^'- M*\6_%/Q`?#7A_6=:M?#]M=_9I[E?MUZLKPHXMXY2BE8')=@%7')%`#OBI\:_ MAO\`!>+P;+\1->.B_P#"?^([/PIH4<=O/=276J7V[R8PD$K4`%`'#^.OB)X7^'%KX;O/%5U+:0>+/$ND>$M.,,+S%]4URZ2SLHV"`[ M5:60`L>%ZF@#N*`/G+X@_M4?"7X:^)?$'AC7I]>OY_!-K:7WC"_T31+_`%33 MO#%K?KYEM-K-U:02I;AXP9`.6$8\Q@$PU`'T1!/#4I&A>5E1B(\8R`8GBK]KKX6^'9=/71M.\5?$BVN/"E MCXZU"[\&Z/+JL&D^&M35Y++4[\AHF5)DC=TCC#S%%9O*VC-`$OC3]K'X;>$] M0MM/TC1_%7Q,8>&;7QIJ<_@C2FU:'2?#U^&:TU&];S82$F2-WCCC$DK(C,(\ M8)`)_&W[4_@#PH=(C\/^'O%GQ:N-5\,6_C62'P'I8U1[+PY>9^R:G=&6>U58 MYPCF)%+2R!'VQG::`/?=#\0:1XB\/:/XJTF\$^@Z[IUOJUE=.K1![2ZB6>*5 MED"LH,;@D,`1WH`63Q%X?AM;J^FUW3XK*QG-KIY> MU6!P0RM9)%NWFX5'8IC:<[@.E`'G M'@'X\^#_`(DZ=X/\1^&X+G_A#/&7@V3QG#X@NYK&&ULX(I;5&LKQ/MC31W`6 MZW-\AC0(P:0-A2`>J:7XC\/:W(93#H'BO1]Y;S+4QBX3$4CG,9E0./X M=PSC(H`Y*?XP^!K;XP:=\#9=2"^/=3\-7'BF&W+PB/[';W$5N8N9A(9F\QI% M14/[M'*]&\17VA2^1J5OIE_;W&`/%`#?%7C;P9X$L(=4\;^+M%\&Z9%/`^BW/B/QKXGTGP?X>LBHN-4UN]@T^RA M+G:HDN+F2.-++_`%_Q[X=T6S\! MM;IXEFO=3M8$T=[N*.:V34#)*OD-+',C1B3:75E*Y#"@#P'PY^UEX7\;>)?% MVE>!H-!\2^'/"OC?PKX13Q+'XHT^'3M1@\3:7;ZD;RQD<;)I8&G,(M8W:25E M.T@@J`#T;X&?'[X?_M!:+XIUWP!JUIJ5EX5\3:KX;G-M>6]V7_LZZE@AO`;> M20"&[2/SH"3\T;*W>@#>'QN^#C>/3\+!\4_"A^)(?RO^$8_M>S_M;S=AD\K[ M)YWF[]@W;-N[;SC%`'E7P$_:5L/V@O&OQ:T_P='X8O?`7PTU3^Q8-6T[Q"NH MZK?W&<+=R:;#9B."SF\N402&Y6Q"@=`#AM2_;N^$=J=3N+/4-)GT?PU\6 M[;X7^(-1NM:M;:'3(;C3[J\_MR8A9E%N9+*:)%=DWF-SO!4K0!]!Z;\>_@GK M'@#5?BKI?Q6\+7WPWT*5H-1\20ZI;-IUI,AC!AGG$FU)"9D`0X8[UP#N7(!T M_@/XC>`_BAH0\3_#KQ?I/C7P_P#:)+0W^CW4=W"EQ#CS(7:-FVNNX$J<$`@X MY%`'RCHW[7D_BWXK>/O"7A*R\$7?@?P!XR\/^!9]3U'Q/)::O>:EJ]UI4%Q+ M;6/]F20&.(W\L42&XWS7$7EJ%#%D`/<[/]I7X`ZCXSMOAY8?%[PM>>-KO4)M M(CT>'4(GN?[1@EFADLF4,0LX>W<")B'..`>*`'O^T?\``E/'J?#`_%3P^?'< MFHC1ETE;I6?^TR"18&108A<\?ZG?YF>-N:`*;_M/_L^Q^-8/AT_Q<\.#QM<: MR_AT:3]J'G)J\<\EM]@E.-L<[2Q,J1NP9R/D#<4`:.I?M$?!#1_B%!\*=3^) MFB6?Q!N;RVTY=&DG/FB^O4\RVM'D"F))Y5(*1,X=LC"G<,@'%6/[4OPST+P9 MH_B3XH>-/#?AS4->UOQ%I.GV6B7-UK!NQH.IW=E*;>&*S6Z=HT@4W&(=L3DK MN(P2`7+']H;1/$WQ2^"_A/P)/IGBWP+\7O"/B?Q/;>([.X9Q_P`2&XTJ!(X5 M`VD,U]()-V&5DVX!!H`ZKXD_M"_!GX0:I9Z)\1O'MCX9U:]L6U1;62.XN)(K M!9#$;RX%M#-Y%OO5E\V7:F0WS?*<`''-^U%\/;;XP^-OAAJ=]#I>D>"/`6F> M.[OQ1<&==-:UOVOGE_TDVXMA%%;6T4HF\XJYD*+\T;B@#%\1?MC_``DIMIIT"&Y2-XHP=[L$ M!-`&_?\`[5_P4\.Z%X.U3Q=XJFT.^\7^'D\2QZ MVME=6`FG2-&VDAB`:`+GC3]J;]G[X<7UKI_B7X@6UM=ZKX?M?&,*Z98:AJPE MT&^>>.'5R^F6EVOV7-J^^)KRYFMKRST^31+2017&IV>H75M!:7=K&Y`>>WEDC7(RW-`%+PW^U7\!_ M%=OXCNM)\:7$,?A7PY<^,+U-4T76=)EDT"S4M<:I90ZCI]K)>6R`%;_P`8Z?:'P]KMF=;TK3ES-<:,]UID M2WZ!B%)M?-QG/2@#C_!G[:_PQOOA7\+/&WC9-+]0T31?"WB34 MY-.LDBC^W7\D4&ERRK813.52[8>3*!NB>1?FH`^NM#UO2?$NBZ1XCT'4(=6T M+7[*WU+3KZV;?#,?%1T2R M^#3:.OBR26SNV^Q?V$3IS($@8SK*9U4-%O`8,K896``/+_VA?VI-$^$&H>% M=,TF]AO[R#QAX0L?%\0TV_U)K;0O%3ZI'`;,60_>7"XD5H`#D[NP!LVG[6/P4O?&NG>"8=;U42:UX@F\(Z9K\FAZG'X:O\` MQ!;O)')I5IKCV@L9;@/"Z!5E(+J44EAB@#R[]G+]L_PK\4_"GPHA\:Q:EH?C MCXC-/IL%^GAW5K'PQ>ZY;"ZEETZPU2YB>W>58K5CM\Y@S*RJS.I4`'TC\3OB M_P"#_A/!X?'B-=6U/6/%UZ^G:#H?A_3;K5]6U.YBA>XE2VM+2.1RL<4;/([; M411EF'%`'E<_[8GP7M_!VC>,9)O$A76_%UUX`BT./P]J*;2WFN'T>?2 MH[9KE+@K!@`KM)9?FPQB>RTR+1S$;B26XA82Q%`4:/+[PJ.5`(S^UI$X?# M&M:]J$/B;2-;T'7;#PO=>#;W0KV+Q2=:U5/-TVQATORS)*UU&"\+H6B90S>9 MA'V@&1>?ME_"32/"7BSQ5XDTWQ?X7N/`WB'2_#.N>'=2T&Z&O6E_K:1R::/L M$/G-(ERLJF-HRP;H.>*`.W^(/Q3FL?V=_&_Q97N$9F7<",D4`>>>)/VS/AGX/OO&^DW^@^-O$1^%$&F7 M/C;6-$\/37&FZ/9:GIEIJD&H7,HEP(6@NMS)'YDJ;'+)M4,P!W/[2OQ@U3X0 M_L\?$;XO^"]-3Q-JGA[P])JFD+Y?VBU+R(##W8VZ;P\FUPVT<4`?/L' M[8FO>'OBU\6-!\5_#CQMKWA;PQX(\&^*[73_``]H<%U?:)%J-MJDVL3:K(+U M4`'DP[(UD=SM?RU8*Y`![7XC_:K\!Z7>6UCX5\+^,OBO.?#>G>+M1/@G21J" MZ5HNK(TMA=7K3W%H`T\<;O'"F^=E4L(L8R`>]^$_%7A_QSX8\/>,_">IQ:UX M9\5:=;:KI=]"&"7%I=QK+#(%<*PRK#(8`CH0#Q0!\3_!']HKXA^,_CKJ5IXJ MFL)?@C\95\0M\'+JW@6.4MX*O%L-0264`/)_:$1>]AW_`/+*-MG%`'=VG[9? M@:[UVSL_^%?>/K7PA<>.9OAQ+XVN=,M(]`M_$<>IRZ1%;._]H&Z:.6ZC"+.E MNT2ET61D;>$`(S^V=X'77=0LV^'GCV/P?H?Q`G^&6K^-GT^Q70;#Q%%JG]CQ MQ2-_:1NGADN2H$T=NR+O0.5;S3RH;K4H-0G@6>Y1&GAM73[Q0N%S M0!V'P$\>^)_'-[\>H?$M^E]'X&^*^M>%]&"PQ0^1I=G9:7-#"3$B;R'N7.YL ML<\G@4`?0=`!0`4`%`!0`4`?DGXP\1_%;P_\,OVD?C3IOQ0\87VOV7Q?U;X= MZ;9W.N+8:!X=\-3>+++3I;J*.:WE@AEAAEE5+R1)?LZMNV[(L``Y'6O'_P`8 M_!/AS]HGP]=?$2^\%:/I'@#0_$5M--X^D\>ZUH%]/K<%M_:<.I_V?:O#;SVK M.3;RRMN,>Z--CO0!UGQ)\?>*?A'J?Q9\-_`SXR>)OB;X8_X5!%XJUS5]5U]O M%<_AB_FUVPL!JUK>SM<>29=,N;VZ$"D1#[.)$B5."`0_%;Q)/\*H/C5X>^!/ MQK\4^.O#=Q^S[XM\8ZW>W?B^\\27/A_7+$VJ:)JEGJLUU"?AS^UO\`LXAO'?C;Q!=ZGX`\;7\&H>)_&FN7DE_J4-YX M6V(D,^HB'9*MQ+));)&(I#AGC;RX]@!WW[0EUX=UOX]_#GP#\5_B;JOPQ^%% MQX)UOQ!I[:?XCN/"46K>)+&]L8MD^J6MU9R,;.UF,R0>8`2QD8,(\``^%?!' MBK0;KX+?L\?#VQ\8:MXJTO5KSXM:\C:G\0W^'/AS6K&Q\:W\4>I:QK]G`^H7 M,ZK>+.EK!PP9II5"H#0!?^$6IQ?$*?\`8-\3>/\`QC<^($\.?%CXH^&+/7H? M%&JR6DUM8V.N2Z-$NIO'$3AD=XV`,SX0>-_BIJFO_!GQ MUK7Q.\*Z'\:/%'Q)ATGQ=IEY\0_%>IZ]!M<^(T M)_V2O$G@+X:ZE+
;XVF\;Z=:ZY=J9``Y.FZ-9RI(I(VWC@8^:@#%^+/Q' MTM_'.K?$CPSXKTS1/'N@_&^UTN'_`(23Q[JMW\0#!8^)K6PN[2'PM90V>G6& MDB#>JQSB0/;D&1C+(I(![S?^%+UO!7[3!TB\P-\RL"!0!S?Q.T#]E[4?#DO@_]G[Q M;K>N>#M4^)OP>_M^3PWKUSJOARPNKSQ$;;?I>I"[GFAU62W7/D!8&;9* M?1OA[9>%_`WB2RT-KNZNK6SU+4GU^"]FM MEN9IC'YZV<1D"G#,H;KG(!YK^V/\2?A'XB\.?&?X.:_\1]<^#'CO2].BN4T= M+6QC_P"%CK=V,;V-K;((KB\U&UDD!M)([>6"8.'1_DVD@'VQ\.O'=CK%IH?@ M_6?LFA?$_3/".AZYXB\+6X93I0U*%D"*,;?+$]O+&N&/W*`/B[]J7]IKP-HO MQ*O?V<;7Q_I/P?U7Q'H<%U\0/'=[9R37MIHUP'2#3=(CC@E\Z_FCE.O@]\-+? MP[%-975VVLZGH&D7VG7_`('_@G. MFD_M,>-_'WP]N/$'P2^'D7@=O"^I:UI;R^(O#^G7]G?Z;&VCLIN+^QFN(A;V M\H9<3,1&V:`/T6^(*_$#5OV`_'B?$"SFE^*&I_`+5U\06B1'[0VMS>&)Q=1& M)!_K#.S`JH^]P.U`'Q/\6?@SX$^&FD_LQ>7I/A+X;?!-_".H7FNWWB;P%<>, MM$?QK=6FB):WNO:;!=Z-$O/!]Q/IMY;Z>^E:=IENFI:I=V-O(;/P;\--3\,:):FY ML-.EM](UC6-6>XDU6X9K=V;SVW*RLS*&EY`,#3/#UT:ZM'7Q5'>>%DO+.:,V\+/=/+;RYX)D*L1NP:`/"-5\7_LY>-M!OG\/V(TJ.[N+:[\.26L-U M9M^YBV>#0!N_"A_@;=?MB?!5_@E\'M2^%L5C\)O%MIK9O/"M[X6$QM[OP\EO M9O%>6MJ9Y[,O(LTRAP3*B^:Y'`!T/[4?A#7[[]H+49?!NBR67CCXA_LZ>.?" MG@[Q!!ITCG_A*!QM8;;0]0N+JSLDOKD:B@GS&9MO MEO)N`DRP!Z-\=],\+Z#^TAX4^)7QD^'>I?$#X21_#B^\.:1-:^';SQ=:Z/XA MGU)9[OS]+L;/4)8VO;011I.8=O[IHV9=W(!X9\,++Q'\"]8_9M^(GC/X=^,- M)\"KH7Q3T.WTS2_#U_K&I>&=/\0^)-/U?PMI%_8:;;WUU&!96OEJ"N(F'E,5 MQR`5_@=\*-3\7_%'X#Z]\2/@UJEOHUI+\=M?>Q\7:(Q72KG6O&-G) MXHYI+>=S$NYHRRC=0!]0_MDP:V^E_""\T[PM-JNEZ/XU^WZGX@M/#%YXU MN_#*QZ7J*V^H6WA^S?-P[2R+"))(I4@\SS/++!2H!\7>!O#'Q%\,>'-;\;:O MX$^(>L:/X5_:@TGXCSI=^$FT[6[[P_/X9CL+G5;;0M.M(%(^T3[I(H(C(@5O M-7S5>@#=U71O&7C'XA_%'XWWWP0\"/%L_A74_#MS%K&M:%I'@U M]"&H6VD7$:3S_9K]X;K[/L,F$^9!(FT`%C1_`_B;Q5XY\<^-?"/P3\5^!/"? MB?\`:2^%WBJPLM4T.XTFXET[3+*W35M7DL9(T>&(SJ\DA=006S(%Q6>(Q"ZL;R>%X+N+(&Y)0"0PX)S0!\D:C\.?&&K>.=4\-WOPUUFZM--_:WT MGXB2W<^F2/I5SX>N]`>./48KIU:"40SVVV4*%+?3Y-5U6QTWPFNF7UWH]OJMO=6=Q<6MU+'* M4DB;>82`/,$9`!]`?LD>$M?T_7_C=X\U:P^(UO9>/]4T<6=]\3AH]CK.JMI= MG)!-?-HVCZ-I2VBGS$B#3%Y9EB5BL04!@#B/%?PR\>7=Y\3%L?!^H21:I^U= M\.?&]I(B+LN-"T^#P*M_J"?-DQPMIMQO./X&QG%`'/Z?\&/'5M\![_18O`]U M;^+I/VGE\]>U'PUX< ME^&WQ'T>]\,?'"P\7:AHWAVQ\,Z1\-++1;?Q:MZ-3LI8`FJ:C*O%G[1#^--&ME6W$]UIP\::+?)J M*,98E`6SM7<,S!MB=&^Z0"SHVD?$SP)J_P`1?@]+^SO/\3)_'WQFN_'VE^+] M7BT^Y\&Q:1J^L0:H+[4)9+I;F.\TV-&CBB6!F,D4)C.PC`!XOHWPW^/?@,># MEG^&_CBVT&:\^)27%]\,8/#"^,A=:QXSO-0TZTNM4UI_,M=*N;1UF)MY%/F! M6D("B@#N/V4?@A\7/`NN_LU2^-O`FI>'O^$"TGXQ66N27NH6VH?9'\0^)=.O M]+C>YBF?SC-&LCB4#Y\$G%`'5_M:_#_X@WGQ0_X37P%\./B#J.KZIX!/AK3O M$_PVU72,S7ZW5[-'I'BK1?$$HL9],S*#;_ M``UT_P`4>.?'G[.?A;PO/J-K;:3<>&;?Q1X=OM'-"G\.>$O&.E^&]1T76?#BWUG]CUE?[0$,MG<+=":*:*9S'F3S(@7P M`#T_P%^SCX^\%VOB?1F\*6GV9_V8-$^'-DEG?BZM6\06]WXHGNM,MYKZ83F) M!J,`624*A4CGY2%`,KXD_LL_$;XC>&?A'X6L;"+PO_9_[.'BCX<:S?/=PB#3 MM;U&T\.1V-G+%#([R1&2RG#M$C*%4Y.2@8`\YT[]GSXU^.)/%5_K?PH\8>&- M1T/X2^-?"]A+X_\`B.WBV:]UWQ-IJV<5GH*Q:G+;06I,0,LUTBEOW6$4HS*` M?3>N?!;XAZCXQ_9-U.TTFRM]*^&OPT\8^%/%+-ZED!``ST(H`^4_^%%_'V/X:?L_P3?L^Z]%XT^&'P\_X0,ZEX,\?V7A?Q3IU M]IS1(EQ)>QZHVGWFDW8C$BPO&\T3*Q*$2;:`/T`^$GB?XFZ9?>#/A#\3=*&O M^+=#^&6CZ]XH\;63JMA/KLUQ+8SV2VZ6\0#,;9Y5D!4,`<1KB@#P_P#:'_9E M\3_&#XY^![B.TM+GX)>-]+AL?BM#)+&LSGPJ-5O/#GE0.P,A>[U=@[`':L:Y MX`H`\L^'G[,'QWM/AQ\,KGXBI8:S\6;?XU^"/%'B>XAO(C''X9\$VEOH]HR2 M%R'+]&TFRFT[4?B_\)_&%O+)= MQ1/_`&9X5B6'6)F0G.](RRHAY?M0!3^$'@C]I_X61>#?@)I'@GPW;?#'P7XP MO]4F^)MWJL5[)J7AFXU*\U,646BF-;B+4I?M8A>9F,2%7D4N2%H`B\,?LZ_$ M_3?@5^QWX`O[33!XC^"_Q*TGQ/XE5+I###IMBVM%V@D"`22;;V(8`Y);GO0! MZA^U9X%^+/C6T^'1^'NGZAXJ\,Z1JUW)XO\`">D>*Y_!5_J]M-:M':-'K=LH ME2.";YI(5D3S01D_+0!\%V?PE^-/[.EG\)+:#P5X8F\8^*OVI=1\8^&_#:>( MKV\TUM.U/P-?6[Z=)K-Y;277VA%M9D$\L3!I=LC#830!U_Q6\&_&GP;K'PV^ M,VL^&?#5G\9?C1^TOX7U.V\&?VK++I-C9Z7X+UW1[+3[C58[,YNI(87,EPD# M(LC)A2B8H`ZWX@?LC_%CXO6_C'XP^,M!T*Q^*.K^/?#_`(LLOAU#K]\FE2Z/ MX;TBZT:/2[C7[!+.:.[N([^>47$<>U'$:$%-]`&?9_LL_'+3/`OCG6?!G@K1 MOACK'CCQ9X8N]6\`Z/X\U]]3UCPKH5OJ$5SI5]XUE:::&:>;4/,4VT2*D:&, ML_F'`!4\%?L:_&&P7XA27'AGPCX$T[QE\2?A7XWTS0M,\0ZEK@TZU\)Z@9-6 MBNM1U"U2>YN6AB63>(/'/A M#6-$TYKV1HK875[:2PQ>:Z)(57:,UU^T+ MX5L]#\+M]HF"1W%OX&M?#C->DV^8T-W"2"H<^7\V,_+0!Z[\5OA%KGQ`_9>\ M7_!.QOK.S\2Z]X`?PU;W,S/]D6_%BL,9=U1G$1E098*2%YVYXH`\^\$_!KXF M3ZY\?O&/B^RT'P[JGQL^&_A+PU!I=EJ4^HI8:IHUCKUM=B>X-C:YBW:G%L9% M8D!_E&!N`/EWQ+^P;XSTZ;0=:T;P1\,?BWK6K?#KPEX0UV'QK?ZQ8Q:+K/AG M2H-)74M+N+&!FN+26-`9()(HI,QJRN"[*`#[8O?A/X]\+_LLR_!CX7ZQH>G? M$&S\%#PSIFKR0R:7I=O>30""XO88+6.X:$)YDDD*!6PP0,<9:@#Q36?V$O!/ M@OPU\.-0_9^M8_#'Q6^$NMZ'JNAZIKFLZS+87,5G)'!JMM<0F>^2)+RR>=6$ M4(^=A]T9(`.EU+]FKQI-\&E^'>GZMH<>M0_&^3XF0S7$MTUJNE-X\D\3I`76 MV5VN!9N$*[`AERN\+^\H`=XD_9M\<:S\%?B/\-K/6]"L]:\7_&-_B'I]V3<& MWM]-?QK:>)?+F/VT4`%`!0`4`%`!0!XM>>,/V=_#Z^)_!NH^ M*_AWHRZS?7TGB+0[K4-*@^U7M^Q-\;^TDE7?),6/F^8I+9^;-`'*Z]^S'\); M_P"#GC'X3?#7PSX?^%WAWX@+;37=SX4LV5CV@LQPIXX MXH`]<\)?#/X<>`;+5]-\#>`?#O@[3M?G>YU.UT33+6PAO9I`0\EPEO%&LC$, M1E@>..E`%/P[\(?A/X0TC7_#_A3X8>$_#&@^*PZZWINDZ+8V5IJ0=71A>000 M(DP*R,#O!X)'0T`;VL^"_!_B/4?#FK^(?"FCZ[JO@^Y:]T&]U"QM[JXTNY90 MK364LL;M"Y"@%HR#P*`*7B3PI\/OB/:S:)XO\-^'O'ECHE\C2V&L6=IJD5I? M+$DT9:&X298Y1'.K#(#;6!Z,*`*NJ_"SX8ZYI.FZ!K?PY\+ZQH6C7$MWI^G7 MVCV5Q:6EQ,[22S0020,D;N[LS,H!)))Y-`%Z[^'_`(#O[./3[[P3H%[80ZJN MO1VT^FVLD*ZJK;UOUC:(J+@-R)<;\\YH`R=>TSX4^!+C6OBWXDTKPOX4OK"U M+:MXPO;:SM+B*VPL9-SJ3HCA,8'S/B@#R[P5\:/V3?B/X^6S\`^/OAQXP^)6 MN)YB_P!D7&G76KW:V"&4-YD>Z5_)2(L.3M`R,4`?1ES9V=YY`O+6&Z%K,EQ# MYR*_ES1\I(FX'#+V(Y%`$3:7IKI/&VG6S1W-PMW,IA0B2X0H5F<;>7!C4ACR M,#T%`&WILX#<7*1[-BS2[-[@>6N`Q.,#T%`&A M)_9>CVE_>R_9=+L8Q+>WL[[((@`NZ6>9SM7[JY9F/0(_"_AGX8:\]IJ>G:L/(M=/O)M0*RVLT`55\R64X9-JESC/:@#LO!'C/ MP/\`$70K7QOX`\0:7XLT'6%,46KZ5+'/%-]F>1&B:1,G,;EP4;E6W`@'-`%> MV\6^`->\3^)]!AU73-0\5?"X6LFM02!3/HPU2V-S;N[R*/+$L";L@]!STH`\ M6O?CE^S-X8MH_CY<>,+=4^)$=OX5T[6H8-4OI];AT::]EBMM(L(H)Y9XHY+N M=R]K"4?.YF8!2`#H)/VI_@''\.]2^*C?$2V;P3HVJPZ%J-TEG?O=V>IW$D<4 M5E MZU&X\6^/7E_LC3-*TK4-5E,$$UK;W%Y=&PM;A;6UBDO8A)<3M'$N[E^M`%/X MJ?&?X;?!;2=-U?XC>)!HD>MW@T_2K2"VN=0U#4KQAN%O96%E#<7,[XZA(SCJ M<"@#,^%WQ]^%OQBO=>T?P3KUR_B3PLL3ZQH&LZ9J&AZQ8QSY\J2;3]4M;.X$ M;XX<(5/3.:`/2/$_B/2/!WAKQ#XN\071LM`\+:9=ZOJ5P$>4PV=C"]Q/((XU M9VVQQDX4$GH!F@!VF^(='U;P[8>*[.\4Z!J6G1:M!=RAHE^QS0B=)6$@5E'E ML"0P!'>@#C/#?Q@^'WB_6O"FA>&]<.J7OC?P9'\0-$9+>=(KOP]-):Q1W8>2 M-`NYKR+"-A\-]W@X`.O\4^&-!\;>&O$'@_Q3IL6L^&O%.G7.E:I8S;A'<6=W M$T,T3%2K#*O!M[-IE[X MLUG5O$,UKX8TF\L8Y[&TN=0GG2WA%Q=0L8UPTA`9BVP8`/JR@#G(/$UI<>*] M1$)I^J)>Z9IEKJLE])8SIICQW-6+*I5F`#"@#HZ`// M?#GQ.\*^*O'GQ(^&^DSW#^)_A4='_M^.6%DA3^W+5KRS\F4\/F)#NQ]T\4`> MA4`%`!0!S.F>)?[3\2^*/#?]@:SIY\,)8/\`VI>VGE:;J'V^.23&GW.\^<8? M+VS#`V,5'.:`-]+FVEB>>.XBD@CW;I%<%%V?>RP.!C'-`"PW$%PH:">.=64. M#&P8%6R`P()X.TX-`'S9XY_:?T'PG\0-;^&?AKX9?$#XO>*O"5C9ZAXFB\#: M7:7D.B1:BCRV:7DM]J&GJ99HXV=(HO,@H`]=^&WQ)$?%CP=H7CGP9? MO>:+X@MY)X$N8GMKN%H)Y;6XAN+:4+)')#<0212*1PZ,.<4`=5+K.D036MM/ MJMG#<7TC0VT3SQJ\TB':R1J6!9@>"!0!QNB?%+P9X@^(/CGX8Z9J8E\6_#NS MTN^UFW;:JQQZLMP\`0ELL56WS)@87U@:XDBCW. M[CDMPH9CPIH`L^&OBEH.H:/X,E\7WNC^`O%GC:U2YLO#=YKFFW=U)YKE8UMI M;:X>.Y#<$-"64YP#0!U-SXT\'6>N6WAF[\6:-:^)+R3R;?29K^W2^ED\M9=D M=LT@D9O+<-@+G:0>AH`\C^(/[2?PY^'?CG4?AMJMV9_&=CX`UKX@K9)/;1K+ M9Z,T(-FIDG63[3.)6>)!&04CD0#K/A9\9O`'Q)=)N=8U;0= M-U^\\/PZC:7.J:7%J5M#<)'>V\$KO&R^>JG(`S0!U&@_$#P'XIU76-!\,>-M M`\1ZYX>H2::)XS=I:2R211W#0;MXC9XG57(VEE8`Y!H`X+6/C9\&O#UKHE]K_`,6_ M!>AV7B:XN+31[C4-?TZVBU"XM)C;7$-H\MRBRO%,#&ZH25?Y3@\4`6O&OQ>^ M$_PUDTR'XB_$[PGX"FUL%M/3Q%K-CI;7:J0&:`7<\1<`L,ERL%R0:`+_CGXB^`/ACHR^(?B-XUT/P)H4DZ6J7^OW]OI]N\\@9EB22XDC5G M(4D*#G`)Z`T`<_KWQQ^#'A;0=$\4^)/BQX0T/PUXELY=0T?5;[6K*&RU&UA, M*R36<[S!)E4W,8)0G[Z^HH`AU3X\?!71/`FF?$_5?BOX3L?AUK4H@T_Q))JU MI_9EW,2Z^5;W(E*2.#$X*J2PVMD?*<`'FW@#]K#X7>*_`GCWXF^)/$GA[P/X M`\'>/-7\%6?B"ZUNVGTS5ETZ1$MKVWNBD$9^U*^Y(T+\='<BWWQ\^">F M_#^P^*M]\5?"]O\`#C59EMK+Q&=3MSI]S<,SJ((9@Y#RYC8&-O^'8K&3P_X.\<:GX2TW4]-OTU"UU:UL8+.>+4(I8XT4+*+ MOA06`Q]XYX`/GK2OVH/VC_%M]\5-3^'G[,NC>./!/PM\>^)?!,SP>-%LM;OS MX;NWMYI[:QGTCRM\BJ&2,S\L=F[^*@#W"T_:S^`)^&OP]^*NN_$72_!WAGXG M637NB1Z[,EK>2&%3]KA:W#.V^V962?;E48T3PUXRC$V@7[WD29#,@C=6+H"H4@D@$4`4/%7[2GP$\ M%:)X4\1^)?BQX)-`M]=F\+QS/,]K>BU M26^MK2XEBC2:6V$S"58R9$7.]5YH`](\+?M(?`SQMXTN/AYX5^)FCZWXO@GN M[5;&!WVW%Q89-W#:7#(L%P\(4F1874#,\21LQ,3@JK$J5(8`B@#P/Q_\`M'_%_P"'WC%= M0UKX0:5I_P`'W\>Z7\/[%[W6GC\8:W+J5S;68UC2-*CM989[5);D8B\X3/&C MR811P`=SXL_:+NM#_:+^%GP&TWX?:W<67C34-1L=7\77]K+9Z1!+:^';W78+ M739I`/MDS+;*)3&#'$#M9O,^50#Z@H`^)?C=\?/CW\-O^%I^.M!^$_AW_A3? MP4CAGU:\\4:K=:?K'B:(6T-U>/X?2&TFMU6(3^4C3,?-E5D4`B@#+\+SK=]=6>N:M+OVHOBWK&K?%76/@5X$\,>+?AO\"=#TK6_$=QKM]>6^J:\ M^I:5'KSV.AK;0R0QR16$T;%YBP:1U0+U8`'&_$/]M[56^)VF^#_AAXR^#?A7 MPW>^"?"WBF+4_BOK%[I,M]/XJ^USVL%DEGO#*EK'`\C,`%,J@GYER`?H[I;7 M[Z9ISZJ;4ZH]K"UX;(NUM]H*+YOD%P&,>[.TGG&,T`7J`"@`H`*`"@`H`*`" M@`H`*`"@#\3V?QGH,O[9/C31OV/_`(??M#^'M#^+WB^34-4U^\M3K,$:6>FM M/#'I\VC7DDT$*`2%8Y][Y94CW#+`':^"O&/Q"^'7@[]F']G?X/\`C#Q'XL\. MW_PUU7Q[=^,?AQI6C:K?WL$NJQ+::=I<7BVY6WAL[3^T"CF2.2<(D$>R(ERH M!WGA3XM_M$_$WQ!^SM\/+OXCS?"?4?%,WQ1M/%&IVVE>';G6-4B\&WNCPZ8Z M6LAUNRLKUHKQOM,(\Q483#9A8RH!+X-^+WQL^)OC7PE\`[OXIW'A2XT_Q-\2 M](UCXBZ+I6E1ZGXDM_`]QI,%G%80W=I?:?!,XU@FZ*6[8-NXC5,G`!D:?\6O MC[XW\:?#/X)0?&&Z\.7'_"T?B/\`#_7O'&DZ/H[7^N:?X3TFVU6SNHH;JQN; M2"Y#3&VF,403>DA"?="@'NG[(>BZIHOCK]L*VU/QKKGB^2'XO&%I-7734#RC MPWX?D:ZV6&G6(65UD6-L8CV1Q[8U;S&D`/,/%OQ)^,&I>%?VLOCCI_QFN_`B M_L[>)M=T?P_X)6PTF30[NW\+VMO<^7J[75C<7TDFJF7"-%/$8Q)'Y8)Z@&?X MY\:_&_6;/]M?XBZ+\9?$G@>V_9XMK;6O"?A2VT_1'LXY[7P5I?B"\M-5>YTN M>XGB>:9TV"9-F6.YCMV@'M_[=-W_`&A^Q)\=+_"C[;X,\_"G*_O'MVX/IS0! MD^*-=_:F^%/PM^-?Q'\::;\);V;P7X`US5_#\7@?3=62]_M>T@\Z"2Y_M"=T M:V1$=I$4;FP,'&<@'F_B_P`0?$7X,:_X-T30/CQXD^,-G\6/AEX[US4Y]7?3 M)VL;K0M&CO[#Q!I#65E;"WADN)O*$9+0GS(]OS+D@'.:#8?%F]U+]C+POJ7[ M1OQ"N#^T-X6U_P`3>,[^"YTR._P#A)J6D:B-/32+OP]9WGB#28Y); M:VL(&:[SI<"KA=&WE_D\TL)A#GG>?E^;%`'HOPZ\;>-_"?Q'_:TU7X+ M?""[^,_@W5OBQ:QQ6V@:SH^DP6NJQ>%M#&NW`EU6[M89"U\"D@C8L)0^X9S0 M!\S_`!/\%?'3XE_'3]M*+P%96K^'=-@^%>N^.?AX\TL>J^+[:#1!+<>%XM2L MYU6&.6`7"R,F[SG$<6?*=\@'T=\1_&WP,^*L'[+WC#X?_&;_`(4%XD^P:W4RH+LZK%^V;X$;6?CSX6_:;U7Q#\./$>F"Z\,V%GILO@ZSM; MS3+QIKF/3;Z_C>*_E"1AIBKJZ`1_*S@@'H7QCN=!\3_M)R>!/C!\4-7^&/PQ MT;X:0>(/#,6G>*[SP=%JFLS:C?6^K7[L+::-)790P1TSS0!\_\`[1_Q!\*? M$KQS\2/%WP)\66>N7GPG_9O^*,'C/QAX6O!<6ML=3LK6;P_IQU&R,BFYCN+. MXN45'W1[6;JU`'GESJ7PVT_0VM_@?\5=2^*%EX[_`&??'VK_`!:%QXIO?$RN MMOHMN=/U2^BNKZX2SNVO)I80B^42K2)LPGR@'<:!\+?#_@Q?V=M$\*ZIXFU# M3_C_`/!/Q7;>,;+4O$.M:@=;EM=#T:]LK@0W%Y(L$D3S2(AA$6U)/*4!2%H` MXC]GKX2_"/XL:M^R;X:NYKG6_"EG^R\NH:C::-X@U"WCDULZEH::A#=S6%[' M*3#=3RDVY<+%(HPBF-0H!Q5]X_TOQ9X`_9^\*?$SQ-8W=WI/@[Q;WGB"U_97^+-K#K"W-T+O=IGBC2+2+;/,QN0T<=N%^=MXV_,6&OS>)->=M7_9B^!^H>--4TV:X_M--#N_%6KI MXFU&$V^9!,=-$S22H-X0,P.5%`'W/^RY)^S=:^-_B;I/[,VMZIKGA9-,T.ZU MVEIKWQ/_9QTRYEL+B:SN?L]Y+;03"*X@9)$8K(0&5@0>0LW>AIJ%YJ6DP+<*D,\TT* M&609+;<9PS`@'!?MC:SX5\0^+OVC9M4B\*Z3\3?#VAV"Z&?&+:WK'C*XEBT* MTO8;KP3IMC)9VVG6OFEBUPK2[95FEF79\@`.V^-[?!O5O#/[4/B;]HBTU35O MB_K/@ZWU/X2:H8=2E=O#W_"(6$UK)H$ULIAB"ZH+QK_!4;2QN/W).0!_BS0( M_$L_Q+T'5+*^NM+\0:W^RY8SI;"9'FM;DI!=K%-%M93Y3N"RL",]10!U7Q`^ M&'A[P!\1/VA/`/ASP5=Z-^S=I_B3X.^(O'/A?PW:7?V%M!NHO$46MS1V-@#( M\+2V=D]XD2G,4;%E/-`'NG[&<'PAA_:*_:X/P,T.30/AU+H_PW>S@CL;G3=- M>X:/Q,;B33+6YB@*6[,1]Q`AD\QEX.:`.>^.6L?!71/CUXWU?X@>+_B-^R=\ M28;;38=(\<^$KF]ETGQWI<5JCP/<6RZ9?V,\UG*\L#6\L1E`565F4J$`//M< M\;?'?P-\+/@_^V'JOA>[U_XI6UIXC^&.IVO]F#2+SQ%HGB"]N4\%:E>Z6WEB MVD;58K)VB`!"W4A"C=M`!XS\'=8M=+\7>,;'X9:+82:!X[\* MZGJ4'C'5TN]1U&_;P1XGT2<7VG:I<:C=R&5-JDR2PR'<@RH!ZG\8_"=WJ7BO M]KN#0O`-[:VGMWMI;MUM8UCN8%G22 MX954'<59`#RN]\$V6K_#[]J&]^%.OQ>,O".L?#+2]'O[3X>_#&[\!>%YM7BU MJT>U"QS:Q=RSZG!:F59/*M?EB=1+*'14(!]`?$O]F/X36_Q/_:FTG1_@GHP\ M-Z1^SM9WGAZPL]%1K*#7Y?\`A([8W5C`D1B^WF*QMU$J#S_E&&Y.0#QOXPZ' M';OHOBO5O"USXF^)?B'X3^`E/@_QMX&U/7[?Q9=Z?9B06OACQ+I#17^E7T=U M-LF5RA\TQRLNWF@#]$_VSO#USXX_99\76EUX0.JZW.?#UY%I'V==2GMKK^U= M/\U8@B/N:-'D4N@^[N_A)H`^2_C#X0^'&AZO^UMX3^(OP5O_`!E\3?B7#!:_ M!R;3?"MWJ<4^DQ^'-/L=(T_1=1MK*:WTU[#5$G>;+P^666<[EPU`'N_[/?P< MD@^/WQA\=_%7P;::]\1]&\/?#?3K/Q=J6G+,YOK7PYY6K2Z5=S1L%+7!82M" MV3\JL>!0!S_[2?A1S^T5+X@;P3?:LOBW]G7Q_P"$M%U.QT6XU$-XD>>QN;:T M>XMK:?R)GM$G$32%`P+1HQ+;2`>4ZC\!_$WA[P+^R+8?!KX<-X'^(5_\%/&G MAS5]5T[33IT]EJ^I>"8GLQK%VL2-'(=756!G;=YVX_>W4`8'[,/@&XB^*G[- M\6BZ9XNTW5?A3H^I6?BVT?X:0>#;71$DTF2TFL-6UR2*!=2\^\VO$MNTY=U\ M]F7:ST`?2/[:\WCCX9:G\.?CS\*;-+[QW.FH?"66R\T1->)XT18]$ER,M<\.O9^-M6\"3_"WPSX2\)W?AGX>6GC MU+W^S(M0BU72[IY["^>QGO+RZ^TEF\N&8S$L^Z/Y0"KXB\"?$GPWINE>"]1\ M$>-M*U27X&>'?"=AJ.E>"K;QSKFORQ0ZBMQH>I:[+!=Z5IJV;21HVZ%/,WF5 MIGVI@`]W_9=^$^O)XX^"/B3XA_#N\CN_!O[,O@KPZE_XATMUETW7K+4[U[BT M1[J(-'BW,O@/P M]IWBO5=(U;5)-.>WO?[(U#3]4+Q30VLL+RP0&2,[GV-IIK74OFRQ6H M0F)F9=V1M4`RO#OPY\;?"KXEZ5\5-8^#_B3Q/\._!/Q?^+SP:!H.E?;;ZPMO M%4VF/H^NZ=I2[7F@_P!$GCW1*619BZC:6H`X*R^$WQ3M(/"/Q6TWX;?$3X9^ M%/#'QM^(WBB7POX6TG1;WQ1IMEXHM;*/2-7M=&U6SU6SE$#1RJ\<4;R1+,WD M?./B[X@\3Z/H.K016]R--U"TTORKAXH'DC0RO&[,JL=K[ESD4`>%_"_Q_P#% M/X%+^T3X6MOV8OB;XW\2^*OC'XZ\3^%[G3;&PCT&^M]:U!I-.EFU&XU&$PPO M@,[F([$.<$\4`>3Z3^SQ\5?V>KKX/ZOJ!^)NMV]K\,+SPSK5[\&[30=5O=.\ M2:CX@U/Q'J$$VEP^J>6DT*J`8$$H",N`#N_A7\.O'O[.)^!GCS4_@ MQXU\::!I_@'Q1X5O/#FG76E^)?$GAB\UGQ"-;MVD%O#HULZ7$)\F7[,@2`HD M>6C`<@'+WGPS^+?A7QOX:^*M[\,OB'\.-!\5?#M/#T7A+X#KX=FN/#-U!K>K M:D--OK748)XO+NXK^*626!@BW(D63Y/+>@#VK]FSX&>+?`?CKX+7OB#P1>:1 MHWASX)Z_HMQ_:E]:ZO-IFI:QXGM-3CTR6[AMK-&D6V9E81PK&H4QJ64`L`9G MPI^"/C[P]X$_8"TJ_P#!4VEWOPLT7Q%;^+K=/LZMILVI^&-0MMLVV4+NENYE M#%2?G.6/)-`'!?"SX<_%WQKX'_9"^#6L_!3Q!\$-1_9U>WUCQ)XPOY-.>S8V M>B7NFI;Z-+8W\\L\NH2Z@)+D,L:Q[9`Q9PN0#EO@Q\"?BGI^J?LY?#7Q'X&^ M*R7/P+\166HZOJVO>(-)7X?V\>AP3PK?:`+.%[ZX:\$N([>1(RJR.LS?*6(! M]^_LD>!=>^&G[.7PJ\#^*=$_X1WQ'H.ERIJ.G[HF,-Q-=7$\FYH'="S&7<2& M.2?6@#Y9^/\`X4^,GQ:UG6/!-Y^STH^*^B>*$F^%?QLT26SM=*\.^'VOX+B& M]NKN;4CJ4=Y!$C)<6T<#1W##*J(W``!]9_%7P=XE\0_%O]F'Q'HVE-?:-X!\ M7:]J6OW0EB065I>>$]>TV"0J[J[[[F\B3"*Q^;)PH)`!V'@7XEIXW\5_%CPO M'X>O-*_X57X@MM`EOYI(I;;4);C3;/4M\#1,VTHEZBNC?,IQGKB@#XE^+$_Q M_P#&_P`<-3MO&W[-/B[X@?`CX=ZG8W?@S1/#VM>'+6PU_4[0B8:OKOV[5[6: M:.*4*;:U*B($;YE=PH4`L^.O"/Q\\*:E^TOX3^'GP?G\7Z=^U7!%JFCZX=5T MZVL_"NK:CH5MH6JQZZL]PLK1P"T6XC-LDWF9,:\\T`4M5^%'QQ^"K?&WP%\( MOAC_`,+*\-_'3PWHFF:'X@75K#3X?#6K6/AZT\+W$NL07DJ3/;B*SCNE-NDK M$AXMH)4T`:&O?##XK_"[0?%'PF\!_LX>%/BUX<\8?#?P_P"`]+\7VD^F:->* M-*T<:.\?B][Z;S[J"+RQ+`;='(C/D[-X#$`^L_@[H_C'P%H7A3X1ZWHT^I:) M\./`OAO3(?',E[`ZZWJ-M;M9WD0LLFXB,?V5)"\G#B4`$E6H`]JH`*`"@`H` M*`"@`H`*`"@`H`*`./\`"?@+PGX&;Q6_A;21I;>-]?N_%&MGSIIOM6JWR0QW M%P1-)($W+`@VIM08X49.0#QO4?V1/V?M0\-:9X37P1-I.DZ#K>I^(-';2-8U M;3;O2KW67,FHC3KRTOH9[6"%TA_Z9T`:E8ZC]J\0?V6\%U::A9W,5RLJR6^%_A9>_#NS@\$^"I3<:#::?))+ MYS^:XFW2%F,A;)H`Z3PU\#OA-X/@^'EMX8\#Z?HL/PI&H?\`"*K;>8O]GMJL M30W\@)D)DDG5V\QY=[,Q+$[B30!M:#\,O`_A?QIXU^(.@:)_9GBSXB_8CXBN MXKFY\J^?3X1!;RM:-,UNLBQ@*9$C5W`&]FP*`.(\5?LT?`GQOXZA^)/BOX:Z M7K7C&.2TFEO)S,(KJ6P_X]);VS25;:Y>'`$;S1.R``*0`*`.WO?ACX"U&S^) M&GWOAJVN+/XOQR1>,8V,G_$V273HM(=9R'!`-G`D7RE?E'KDT`:/B?P-X1\9 M^$-2\`>*-!M=8\&ZO9#3KS29E(MY;50H$)5"I"C:,8/:@#IIX(+J":UNH8[F MVN8VBEBE4.DB."K*RL"""#@@T`>*^"/V:_@+\-W\52>!OA1X=\-/XVM)=.UD MV=HH^TV,^?-LANW>7;L3DPQ[8\\["KVW\+Z=!=?#BQFTSP MO(D*J=)L[B"&VE@M,<1JT,"(0/X5`H`J0?"[X=6NGZ-I-OX*T>'3/#NOR^*M M,MEM8Q'::W--<7$FH1+C"SM+=RL7'.7;UH`[>:&&YAEM[B))X)T:.2-P&5T8 M$,K`\$$'!%`'`ZM\)/AAKWP_M?A5K?@+0]5^&]C9VUA;>&[JRBETZ&WLPJVR M1P,I5?*V#81@J1D'-`&[X/\`!GA+X?>'=-\(^!O#>G>$O#&CH8[+2]*MH[6U MA#,78K'$JC+,Q9CU8DDDDT`6K#PSXW,4MPY4%I74N<>M`%[PC\-?AU\/\`[7_P@?@'PYX) M_M#:+K^P-*L]-\_;]WS/LL,6[&>,T`2^+_AYX`^(4.G6WC[P-X?\<6^CW/VR MPB\0:9:ZFEK<;2GG0+=12A'VDC%_'6AZKHEU%X=LK6Q6 M%=6M)+.:>*&*)8O,"29!*G)`SD4`;'A+X;^"_!>B'1-$\-Z7:Q75E!9:G-%8 MVT,NIB&$0^9>F*)!*S+G<6SU-`'6+ING*]C*MA;+)ID;16;B)`UO&ZJK)"<9 M0%5`(7'`%`%33/#WA_12#H^AZ?I)`E`^QVT4&!.XEE_U:+]]QN;U/)YH`AN_ M"OA?4%TU+_PWI=ZFBS&YT];BS@D%I,3DR0!D/EMGG*X-`%XZ3I30R6S:9:-; MRK.CQ&%"C+<[,XSC/:@` MCM[>(`101QA8UB&U0,1IG:G`Z#)P*`*^G:7INCVD=AI&G6VEV,19DMK.%((E M+DLQ"1JJC)))XH`NA5!8A0"YRQ`ZG`&3^`H`,#);`W$`$]\#./YT`,,,32I, MT2&:-2JR%1N56QD`]0#@9H`^:_B5^RYX3^*&M^*=0U?Q[X^T;0/'\5I!XN\* M:-K0M]#UV&TA2V$=S#);33PK+!&L4PM9H/,0?/DDF@#Z2MK>"SMX+2UA2WM; M6-888HP%2.-`%554<``#`%`'#_$KX=:-\4?"TWA?6M1U?15%U:ZA9:IH%])I MVIZ??64JS6]U:W,>=KHZ]&5E895U9210!@_"KX,^&OA-_P`)1>Z;JVN^+/%' MC>[M[WQ#XE\3WOV_5M2DLX%MK59I5CAC6.&)=L<<<:(N6(7+$D`])M6U^:/X3UH`6@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H M`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`" M@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H` M*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@ M`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`* M`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`^=/B=X^^,.H:C=^"_V= MO"OAS6_$VF.J:WXF\97(=.\&6WQ!T+7_!D%S91#3Y;U;">QO[6YEF*2 MK)(K1X;F/YB6W#:`?=%`!0`4`%`!0`4`?+'[6_QC\?$3 MXN>/-#^&_ARYUH2MIVG7^O?:/+OKI(1N9(A;M@=-Q7.1E2`>67'PW_;[\`PQ M^*M'_:5\-_'RYT\BZO?!'B#P;IWAB'4(D!:2TL-5TZ5WBE?[L33`J&VEV"[J M`/M3P7XFC\9^$_#OBN+2M1T$>(-/@O6TS5[=[6_LGE0,]M'?AU^T-?^#_!VA_L__'/P3I7PC\2:!;ZUJ7Q/NM.NO$7C M/Q!KFIM)-J&IQ13S0Z>B2AE,6XN8^$`"(J@`]X^`?[,WP_\`V?8O%&H:!=:M MXL\=^/KI;[Q9XS\2W(O-:UBX4L5\V54C1(T+MLCC55&>=QYH`^B:`"@`H`*` M"@`H`^3OVTOAMK'Q!^!>JZGX25F^(7PAU2P^)G@X*`Q;6_"[M>0Q!21DS1"6 M(U`'M_PF^).@_&'X:>!_BAX8<-HGCG1[75K=-X=H#.@,MO(P`&^&3=& M_'WE-`'H5`!0`4`?&M_XZ^(=[^WUH7PPT[Q%):_#+0O@E<>+-7T@1KY=SJ=] MKQT^WD9F0L65(`4*M\H60?QX(!]`^/OB[\._AAJ7@#1_''B2'1-4^*'B"W\+ M^&;5HY9I;_4[GB.)5A20JN2H:1L(I90S#<,@'I-`!0!Y'J7QT^&&E_%_PW\" M)_$J3_%+Q1IUWJMMHMI#+>_";XL^!?C=X'TSXC?#?59- M;$:Q-=P6=[);3VGFM97$MK,5CN(XG*^9"P#8P>QH`ZKQ1XH\/>"O#NL^+?% MNLVOA_PUX>M)+[4M1O9!%!;6\*[GD=CZ#MU)X'-`'Y&^+/VHOVB?C;K,5QX9 M^#WQQ\%?`G5([>]\.7?PUT&U_M[Q/IMTH>#49]?U-VM["%T*ND,$+2LI^>9! M@T`><:%^S5^UUXV^(_@[6_AYX>^(W[._AW0-(K/3+`&8QS13Z?!< MZS;7,*JKEFCN]-MP`1@EE7()!H`](\5?$'0OV&/V*?#6KZQ9+XW.Y_A0,1T`H`^0_A1_P4&^+V@_!2Z\>?%CPG M8_%KQM\1?&@T#X0Z#X0AFTJ3Q4D2Q1ZI]C#6]W*;6SN"8Q<-"3(_R\]0`?27 MA'_@I+^SQXAT+]GJZU*^O-'\4_M!7::?:>'H%2^GT6Y-W+IS/J+J8BMNU[$8 M8I0F9/O[`JR%`#[EM_%7AJZ\2:CX.MM?T^X\6:18V^I7VCQW$;7MO9W;R1P3 MRP!MZH[0L%8C!Q0!OT`%`$4T\-M$\]Q,EO!&,O)(P15'J6)`%`%/2-8TC7]. MM=8T+5+/6M)OE+VU[83QW-M,H8J3'+$S(P!4C@]10`_4]1TW2-.OM5UF_MM+ MTG3H)+B\O+V5(+>""-2TDDTLA5%15!)+$`#K0!^.7[(_[:?P,^$'@_XI_"N] MUO6_$^A^`_BEXRC$/X4\/:CK5HGA&XOVO;&Y-SI]M)`(V:>=A@C"CA=NTL` M?H9X6_:\_9G\7>!M*^(UC\:O"FE^%=88Q0W&NZC!HTRS(VQX9+?4'MI5=6!! M!7W!*\T`>E_$WXA>$OAY\-?%'Q"\4>+[;PAX4T?2VNI?$3Q->PVHGVQ6\Z0P MAVF)DE38B@ER0HZT`&O@SH!^.?C33/B1XYL+2XNKS7?#EE*L5[9 M!GDM&6%8(7EF-OM+;84W,=H5C\S`'Y;:-^UKK/B#]M;XA?$[X8_LN_%CQ[=1 M?"W0O!B:1/H\>CW=K)<:E/JD-WJ#3&06]M<1L/)DE.6"DXV`8`/G3XR_&C7/ MA3^W/\-OBI^VI'>:K>^"/"UQXHT3P'X0$.H6'A^\O9;J+2=.CFN);6*::((M MQ<708;I50+N6-10!_0UX"\:Z'\2/!'A#X@^&)99O#OC?1K+7-->=/+E-K?P) M<1>8F3M<+(`PR<'B@#>U0ZBNF:B=(6%]6%K,;);C/DFXV-Y0DP0=N_&<=J`/ MP[_91_:'^$O[,UQXPU3]K?PWX_\`!?[5WQ$UJ\?Q=XH\3>';^]74(#.186ND MW%I%<-]D$<<2JD:!6?&TM$D6P`^NO'W[0FJ_M2^!?'_P<^`'P@\>:S!X[\-: MOX>U/QOX@L)/"FA:*=4TN[BB<2ZDJ7%S(LSQK)%%#]QBV_&W(!YC^SS^V#H? M[//PK\`_`_\`:#^!WQ$^"WB'X::1::!<:@GAV\U70K];-!$^I07E@DY<32*7 MDV(Z[V.UF'0`YO\`X*#?&O2_CQ^P;\0/%WPFDU^#PII7C/2-+UR75=*OM'-[ M:0W40;RH[R")Y(A=2V^3@892&P5(H`_2']FWP]_PB?[//P+\--`;:71/`/AR MTFC)R5FCTVV$N2<\E\DT`>U4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4` M%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0 M`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`? M)W[4_P"RWI_[3(^#AO/$?_"/_P#"J?'-AXJEBDM?M<6HV4#+]KL6430E&E5! MMDRP7!RISP`*8/B9XS\;ZY\;OBW96;Z9IOB+ MQ)MBMM%L6W`VVBZ9&TD-FA5BORL<`LJ;%9E(!Y1IO_!*/]E[2?!?CCPK9-XG M&L>,-4M]3M?%DE]`^NZ(;.8SV]OIMQ]D6-(@Y.\-&S2<%W+)&R`'%V/_``37 M\=_"GQ^GQ"_9I_:I\1_#[Q'XDT>31O&6L^+M+LO%FI:F);J*Z>X22X%N@9FA MC&"H;Y/];\S@@'=?#K7?VB?A!^UWX!^`?COX_/\`M$>%?'_@K6?$E_'>>'K# M2-1\.#3W5+6\EDL=[-%<2H84+M@L2-NX!B`?H/XQ\/2>+?"?B;PM#KVJ>%I? M$>EW>F+K&B3+;ZE8&ZA>+[39S,D@2:/?N1MIPP!H`^1O#7_!/C]F_2;[3M8\ M5Z7XE^+NN:<\<_VSQ]XCU/6TGN(]Q\ZXLI+A+.4DL3AX"H/(`/-`'V5HVBZ/ MX=TRST3P_I-GH6C:='Y5I8:?!':VL"9)VQ0Q*B*,DG``H`_+[]O;X?\`[4GQ M,^)WPU\-_#GX92_%;X&1Z,]QJ_A^378-%T:\\2"YF:W;Q`//AN+BSMTB@D\E M659#N7>&H`^KOV//V>9?V:?@Q8^!=3U"TU3Q7K6J7GB;Q-<:;"EMI_\`:VI> M7YT5C#''$J01)$D<8"KPN0J@[0`?.7CO_@E#^ROXH\/^/K7P_H^I>%/&/C6X M^U6_B62]NM2ETF1KQ+N46MI/<)"5?:8SN!?82`XYR`>T>/?V.='^(W[+_@W] MF3Q+\2/$6H:=X7?0VN?$ESLN-0U!-)N$FECD25F4))'NCB!+"(>7_K/+PP!] ME*JHJJJA54```8``Z`"@#YD^$/PI\9^#OCU^U1\2O$KZ=+HGQ=U3PK+X=>UD M9KG['HFC+92)0#V3X@_#CP;\4?"?B3P7XVT6+5M"\6: M7/HVHJ"T4[6=Q]]$N(RLB<@,"K##`&@#<\,^'-&\'>&_#_A'P[9_V?X?\+:; M::1IEKO>3R+.QA2WMXM\C.[;8XU&6))[DF@#.0,K#(Z$4`6D1(T6.-0B(`JJHP`!P``*`'4`%` M!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4 M`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`! M0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`'!_%#QG>?#SX>>,/&VG M>%M4\;ZGX;TN>\LO#^BP2W-]J5TJX@M88X8Y7S)(54L%.T98C`-`'SQ^R[\# MO&GA/4O'/QU^.%Y:ZK^T#\9VMWUF.Q+-I_A[1[48L-!T_>,A(EP9FS\\@Y+% M=[@'V'0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`% M`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0` M4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%` M!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4 M`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0!\A>)_ MVE?'[>/_`!_X-^$'[/NJ_%_3OA/<6UAXLU>'7]+T9HM0N+2#4/L>G6=X3+=2 M+;W"$DF-"YV!B>:`/6?^%_\`PDT_P3X+\>>-O&^D?"K2/'=A%?:9;^/+VU\. M7G[R-9&@D@U":$B6/=AU!.#W(P:`-WQ7\8?A-X$T#1O%?C3XF>%O"OAGQ&(S MI.K:KJ]G:65^)4$B&UGEF5)04(8%"?EYZ4`5M3^-OP;T74_#&BZM\5O".G:Q MXU33Y?#]C/K5BEQJD6JO+%I\MG$9]TJ7#PNL3H"KLI"DD4`4_"_Q^^!WC?Q3 MJ'@CP=\7?"'BCQ=I22RW6D:7K-G=W<:6YQ.WE13,2(SQ)C.S^+%`'/P_M4_L MTW":K);_`!\\`7$>B:;'K%^T7B'3W6"QE**D[E9S\I,J#URRC&67(!TFH_'? MX+Z1X"TKXI:G\5/"UC\.===8M-\1S:I;+IUY*S.@BMYS)MD?=$X*+EAM;(^4 MX`*^H_M!?`S2/"F@>.M4^+WA&P\&>*EG.C:W-J]HEA?FV5FF2VN#+LD=-I#( MI+`C;C/%`'G'B[]L'X+^'E^#%WHWB[2/&&C?&GQ5)X8T[5--U"%[2V^SP7$E MS=!&H0_:_M MJ*':T`W;3.%.3$#O']V@#V.@#XRU3X[_`!O\?>-_'WAO]F[X9>%O$_AOX3ZK M+X>\0^)O&NMW.DVM]KUM'%+>:5I,-E8WTC/;B94DFE"1^82H^[N(!VNE?M1^ M`]+\!^#O$_QFBN/@9XK\527]F?!_B19&U5+W29F@OA:QPPE[JW0J'2XB0QO& MR/QNQ0!@>,_VH=,LO$/POM_`%SX=\5^#/B?X$\=>+[/Q-+?2BRB;PE;V$T6] MH(I3Y+M=LLQ`+IL.%W`@@',>'?VK;KQ-\:)/`UO?>$-)\!^!/`6E^,?'>OWK M:H`7U2UO[@_V5*](\8:[H7Q M,T^\TWP%HS>(]<=X;NWDMM'168Z@L,]O%++;X0XDB5U)X!R10!CK^V-^S=+9 M:7J%M\2XKZ#7I;Z#24L],U6ZGU)]-%HUV+"WAL9);D(M]$V8E8%267*JY4`M MG]HKP+J>J_"K6_#OQ$\)/\,/'?AWQ;X@GO[_`.W17MK75-"UK1?M MNEK+%"U]8R:KI]DEU`'GC'F0,Z_.ISAA0![?0`4`%`!0`4`%`!0`4`%`!0`4 M`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`! M0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4` M%`!0`4`%`!0`4`%`!0`4`?EC\9](^'UW\5/B%KGQ+^!WQC\#?%6SNEM_"WQ& M^"-IK\TGB725BC_LX27>D&2V^VQX,3Q7L05=J[6,9X`.&N;']H(7WPGU7XT> M#M?L?'TWPEATO4O&GA'P#!XXU[4;^XU34'?0+AY(KW2M,9+4P/-)+;".6623 M,VR/``(_@)X0\:?"+1OV=/&OQ@^"_C/QAX>T7X/:QX`ET6Q\/3Z_J?AW7!XA MFN&\_2EC:9(KRR2.)9XXRFV-0Q6)U:@#VOX3?"K5XOB/=^,9OV=;'P$-,_9Z MT/1_"_AN\*WMCI>H_P!O^*[W^QEU!D15F,4EJ]PJ',6\#=@*Q`/GSX6>$?BO M??$W]CK4+SP+\1[#2/AC-K-IXDTJ?P78>%?"WA;^T?#M_:-8:6(H/M]U&\^( MS?V'\0-#T#X??$WXR.] MMX$T?2-5U[2X/%&LM)HNK6>D:Q8:E#/;-%"ZDQ0^:B2AHCM9J`.V^$GP1\9_ M\)U^SYXIU3P%XR/AP_&?Q]XWU!_&Z:2;^VM[[PI-::?JMYIVDZ9IEMIIN+^! M72W".R2D2%P\FU0"Y?\`PO\`B+X9\9S^,4^'6O7VAZ+^V%>^.&MM'M!-=2^' MM2\'P:;_`&K;VZLOF0?;96$I7YOOM@X8T`95C\./BBOPLT']E#_A2OB*'QII M'Q;@\5W'Q0,=D/#JV%MXO_X2-O$4&I&X:=KR2S_T<0F/S@S%&^0<@'Z1_#SX MEZ7\1[GXBVVF:7?Z:?AOXPO?!MX]Z(?+N[JQM[.XDN+1H)I@T)%X$^;:X=75 ME4KB@#Y$\-7OQ1_9;\;?&S0(_@=XN^,?@#XH^-M5^(OA76O`XT^XFM[[Q!MF MU'2M6@OK^Q:`1W*%HIEWHR..C*5`!P7C&U_:HN==^''BWXA>!O$EI>:UX?\` M$*ZA+\%;+PM=>*-%GO=5BN-,\-7>MZX#LLDLU7SI[8J)+A,EMBJY`/(O`W[. MWQYL/A]\'=&UOX<:E8ZIX,^'GQ_T35(KB_M+V:.^\6W[7.C0M/'<%9FN5D^6 M11@D$MMH`]8U?]FKXL>+?AU\?O!2Z.-%U+QQ\#/A/X6.*1B-NV7()&:`*WQJ\'_`!C_`&E-,\:>(;#X!>)/A9/X4^"O MC;P59Z5KEWHZ7WB#7?$_]F"*PM?L.H7*-96G]FF1)96C#NZ[$'S4`?5$7PX\ M2Q?'C]G[Q4OA]4\,^!?A5XG\/ZA=*T'EV.I7MQX6^RVZH'W9>.RG`**5`4C( MR,@'RA8_L\_M#Z9HWA)/#'AK2],US0[;]H/8VL3V%W8Q7?C+5X[GPP+BV,LZ M2Q7*+O*F-U0`"91]P@&M\!?A!\;K?]H;X:_$[QE\/O'/A_PYX>\&>(-`U2\\ M=^.=/\2W@U&_.ER(UII]C=O:VEJ39LJ_9HU9SS)&B+&:`/T_H`*`"@`H`*`" M@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H` M*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@ M`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`/&/!'Q]^&GQ`^)OQ.^#^@:PX^(/ MPEFMX]=TJZC\F0PW,44B75KECYL(,RHS#[K$!@-R%@#I/AK\3O#/Q6TC7-:\ M*_:_L?A_Q'K'A:[%Y$(7%_H=W)97>T!GRGF1':V>1S@=*`/0Z`(+BYMK2/SK MNXBM800N^5PBY8X`RQ`R2<"@!MU>V=C')->W<-G#$AD>2>18U5`0"Q+$`#+` M9H`:;ZT\Z2U2>.:]CA^T&U1T,QC/`;86!P3P">,]Z`/./@]\7_"/QM\`>$_B M'X2:XM-.\8:7'J]KINI^1'J<%M*S(IN8()[A5)*GH[#WH`]%CU+3I;Z?2XM0 MMI-3MHQ+-:+*AGC1L89X@=P!W#!([T`1VNL:1?7,MG9:I9WEW`@DE@@GCDD1 M&)4,R*Q(!*D9(ZB@#Y9\=?M?^$_!.O\`CBUC^'OC+Q7X*^%-[!IOCWQMHUM8 MOHWAZ[FCMYWBF6XO[>ZG^SPW4"01*PSDY``(/&/[6GA+P-X@\=6&E?# M3Q9XJ\"_"J\CB^(?C70+:P_L;P]=7<<=Y-YJ37D%U=&&&Y2>Z-M#)Y2MELME M0`?744L4\4HFS4+^SENIQ:+Y[16Z.P0KW;``,_Q MI^USI.BZK?VO@'X8^*OC!HOA7PMIOC3Q;K/APV$-MHNBZM#+=6;A-0N[26YG M>VA:?R(59_+P>IVT`2>,OVL;+3=4EL_AC\+_`!)\;M.T3PEIOCKQ)J7AJ;3X M(=,T/6$EFT]XUU"ZM7N;B>"WDF2"(;R@!ZL!0!/XH_:IL_.TJU^#GPR\1?'N M[NO"&G^/=13PU-8VB:?X?U99'TV9VU&YMO,N;I89##;1AI&",2%^7<`?2_AO M7+;Q/X=T#Q+9VM[8V?B'3K74X+;4K=[2\ACNX4F2.YMI0'BE4.`Z,,JV0>10 M!M4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4` M%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0 M`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`?DU8_"[Q M'K_Q-_:R^+OPKL4B^.OP9^+XU3PTQ?RDUZPG\,:!_:7AJ])`!@O(4Q&2?WWGP@\1/!I]Y!:QW.+B2"&Y(N[/S.D,*8^4T`>2^-OA=K?@Z M\^#VJ?'?5O"'ASPUX]\*ZYXZ\1W'Q$\*:CXI\-#XD^*-2-_J=O<6ECJ-A%%> M0V$D-M:/,6'EPR+#AZ`/3_@O\&=&^(WB[]EKPU\6=%OOB?X'T[X8?$:XTQ/% MFAW.EP-8GQ%HZ:1'-IUY?:C)Y,=K+FS6XE9_+6&3:KHI`!6_9T^%FG^$+#_@ MGK\0]*\+W=A\0_$/B#Q5HOBW79HYY-3O=)&B:]';VNISS;I&@A73[98$D.V( M(OEA:`/.?V;O#7PUE\&_L;:7\"/!MQH'[4?AC6[2_P#B#J)T:_L;ZTT"2SO1 MK1U^\GMXDEM)PT*6L;R-G='Y"@!J`*GP%\'WMKXU_9]L]4UVWL?VD-%\>0ZA MX[L=&^&.H1^.@&FNAKC^)?%EYXDAMI],GB9@TXC=6#QM;0.RA*`/O;_@GM\* M?"'@[X&:3XU@\$0Z%\1?&.I^)5\0:O=V8AU>[CM_$6J16T4TLB++Y*Q0Q^4G MW=H5L9.2`>7?'/X\^"_B3\6/$7P2\>:AXB\#?!'P+J-HGBR*P\(^(]5O_'NH M1.C_`-F0S:9I-VD&F121(EQ)N\RY.(DVQ?.X!PW[16EZM#J_[3GPO^'FO_$7 MPIJ7QVC:2'P+:^#QJ-GXNUC6]%M=/.I:9XB%O<1V-DZVZ1ZBD^'012E3%O4T M`?IAX`\1^&[>]O?@]9:G361/:W$2>>.RGCGDB2*82_P!G MRY\MFVLI#8/%`'Q1^TM\:4\6?$K6OV>/$3^,OAW\&--T^W/CGQ%HWA#Q+K%] MXK6_C\QM`T>ZTG2KZ*WMC"=MY'?^$/- M+^"OPHTWXH7+WGQ%L?"6D0>))I7\R5M22TB6Y\Z0,P>0."'<'#-EAP:`/5Z` M"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H M`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`" M@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`#`YXZ]:`"@`H M`*`"@`H`*`"@`H`*`"@#'LO#^B:=JVM:]8Z7;VNL^(_LW]IWL:`3W0LXS%;B M5^I$:$A1T&3CJ:`-B@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@ M`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`* M`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@` MH`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*` M"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H M`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`" M@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H` M*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@ M`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`* M`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@` MH`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*` M"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H M`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`" M@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H` M*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@ M`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`* M`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@` MH`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*` M"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H M`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`" M@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H` M*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@ M`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`* M`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@` MH`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*` M"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H M`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`" M@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H` M*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@ M`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`* M`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@` MH`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*` M"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H M`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`" M@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H` M*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@ M`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`* M`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@` MH`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*` M"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H M`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`" M@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H` M*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@ M`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`* M`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@` MH`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*` M"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H M`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`" M@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H` M*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@ M`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`* M`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@` MH`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*` M"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H M`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`" M@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H` M*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@ M`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`* M`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@` MH`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*` M"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H M`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`" M@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H` M*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@ M`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`* M`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@` MH`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*` M"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H M`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`" M@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H` M*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@ M`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`* M`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@` MH`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*` M"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H M`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`" M@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H` M*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@ M`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`* M`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@` MH`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*` M"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H M`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`" M@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H` M*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@ M`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`* M`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@` MH`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*` M"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H M`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`" M@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H` M*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@ M`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`* M`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@` MH`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*` M"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H M`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`" M@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H` M*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@ M`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`* M`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@` MH`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*` M"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H M`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`" M@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H` M*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@ M`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`* M`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@` MH`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*` M"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H M`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`" M@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H` M*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@ M`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`* M`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@` MH`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*` M"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H M`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`" M@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H` M*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@ M`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`* M`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@` MH`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*` M"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H M`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`" M@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H` M*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@ M`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`* M`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@` MH`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*` M"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H M`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`" M@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H` M*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@ M`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`* M`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@` MH`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*` M"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H M`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`" M@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H` M*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@ M`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`* M`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@` - -H`*`"@`H`*`"@#__V3\_ ` end ~~-----END PRIVACY-ENHANCED MESSAGE-----~~

As filed with the Securities and Exchange Commission on November 30, 2006Registration File Nos. 333-134368 and 333-83636

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Post-Effective Amendment No. 1

to

FORM S-8

OPHTHALMIC IMAGING SYSTEMS (Exact name of registrant as specified in its charter)

EXPLANATORY NOTE

Reoffer Prospectus

OPHTHALMIC IMAGING SYSTEMS

1,085,000 Shares of Common Stock

The date of this prospectus is November 30, 2006

Table Of Contents

Risks Related to Our Business

Our products are subject to U.S., E.U. and international medical regulations and controls, which impose substantial financial costs on us and which can prevent or delay the introduction of new products.

Risks Related to This Offering

PART II.

INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

Item 3. Incorporation of Documents by Reference.

Incorporation of Certain Documents by Reference

Item 4. Description of Securities.

Item 5. Interests of Named Experts and Counsel.

Item 6. Indemnification of Directors and Officers.

Item 7. Exemption from Registration Claimed.

Item 8. Exhibits.

Item 9. Undertakings.

SIGNATURES

POWER OF ATTORNEY

As filed with the Securities and Exchange Commission on November 30, 2006
Registration File Nos. 333-134368 and 333-83636

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OPHTHALMIC IMAGING SYSTEMS
(Exact name of registrant as specified in its charter)